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Lower respiratory tract infections (LRTIs) are the largest infectious cause of death globally according 
to the WHO. Rapid diagnosis and appropriate management are key to control. The gold standard for 
diagnosis, microbiological culture, is too slow to provide clinicians with the necessary information to 
treat patients appropriately and reduce morbidity and mortality. 
In recent years, there has been growing interest in the application of clinical metagenomics 
(CMg) for the characterisation of pathogens in clinical samples. CMg has the potential to be faster 
and more comprehensive than culture, capable of detecting any pathogen (bacteria, viruses and fungi) 
in a single test within hours. This would transform the field of clinical microbiology, ensuring 
patients received the appropriate antibiotics sooner, while concurrently providing pathogen genomic 
surveillance data. However, the development and implementation of rapid CMg has been 
challenging, mainly due to the high ratio of human:pathogen DNA present in clinical samples, 
resulting in high sequencing cost and long turnaround times. In this study, we developed and 
optimised a rapid CMg pipeline for the diagnosis and characterisation of LRTIs that overcomes these 
challenges.   
The pipeline includes: a simple and highly efficient saponin-based host DNA depletion step, 
automated microbial DNA extraction, rapid library preparation, low-input nanopore sequencing and 
real-time identification of microorganisms and resistance genes. The pipeline was developed, tested 
and optimised using excess respiratory samples from suspected LRTI patients. The optimised 
pipeline was then evaluated in a clinical trial comparing three technologies for the rapid diagnosis of 
hospital acquired (HAP) and ventilator associated (VAP) pneumonia (the INHALE trial). The 
pipeline was also evaluated for the rapid characterisation of Legionella spp. in respiratory samples 
for outbreak investigation applications in collaboration with Public Health England.  
The developed CMg test had a turnaround time of six hours for the identification of bacterial 
pathogens and resistance genes with high specificity and sensitivity. A reduction in sensitivity was 
observed when applying the method for the detection of pathogens in suspected HAP/VAP patients 
and for samples containing Legionella spp. Reduced performance was related to the difference in 
how respiratory samples from the intensive care unit are cultured and testing of old freeze thawed 
samples, respectively.  
CMg demonstrates great potential for replacing culture for the diagnosis of LRTIs, however, 
further optimisation is required to enable concurrent detection of viruses and improved automation is 
required to allow successful clinical implementation. 
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1.1  Overview of Lower Respiratory Tract Infections  
 
Lower respiratory infections (LRTIs) are the cause of three million deaths worldwide and were 
recently characterized by WHO as the deadliest communicable disease 
(https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death). Infections of the 
upper respiratory tract affect the nose, sinuses, pharynx and larynx. LRTIs, on the other hand, are 
infections of the trachea, bronchi, and lung parenchyma. A uniform definition of LRTI does not 
exist, however from an epidemiological point of view, the most important LRTI infections are 
bronchitis, bronchiolitis and pneumonia (1-3).  
Pneumonia is then subdivided into community-acquired pneumonia (CAP) and nosocomial 
pneumonia (4, 5). CAP is considered the most common type of pneumonia and develops in 
individuals who have not previously been hospitalized or were in healthcare facilities and initial 
diagnosis is based on LRTI-related symptoms (cough, chest pain etc.) along with high fever 
(>38ºC) (2). 
Nosocomial pneumonia includes hospital-acquired pneumonia (HAP) and ventilator-associated 
pneumonia (VAP) (6). HAP usually develops after 48-72 hours from initial hospital admission 
and VAP (the least common type of nosocomial pneumonia but with the highest mortality rate) 
is generally associated with the intensive care unit (ICU) (7). VAP develops 48-72 hours after 
patient intubation (early-onset is often defined as after two days of intubation and late-onset VAP 
after six) (8).  
Previously published guidelines (in both the EU and USA) have introduced the term ‘health care-
associated pneumonia’ (HCAP) in order to describe similar but different infections to the ones 
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usually observed in community-related LRTIs. However, the most recent published guidelines 
do not consider this term as clinically relevant, hence HCAP will not be used in this study (5, 7).   
Atypical pneumonias also fall under the umbrella of LRTIs. This term was initially used to 
described viral CAPs but recently has been used to describe LRTIs caused by certain ‘not-as-
common’ respiratory pathogens (9).  
1.1.1 Epidemiology and aetiology of LRTIs  
LRTIs can be caused by various pathogenic agents, bacterial and/or viral as reported by many 
studies (2, 10, 11). Etiology also differs amongst the different types of LRTIs. Bronchitis and 
bronchiolitis (commonly observed in children) are mainly caused by viral agents such as 
Influenza virus and respiratory syncytial virus (RSV) respectively. Infectious agents are also 
dependent on host’s factors (e.g. age, patient’s immune system condition). For example, RSV 
has also been associated with bronchitis cases in elderly patients (6, 12).  
The main causative agent of CAP is Streptococcus pneumoniae (pneumococcus) and this has 
been proven by numerous epidemiological studies carried out in the UK, Europe and the USA (1, 
8, 13-15). This is followed by the Gram-negative bacteria and viruses (see Figure 1.1), although 
with the increase in sensitivity of diagnostic tests more viral CAP cases have been reported (2) 
including influenza, rhinovirus and human coronavirus. Viral aetiologies are mainly associated 
with pediatric cases (>75% vs 25% adults CAP cases). Conversely, S. pneumoniae infections are 




Figure 1.1: Main causative agents of community-acquired pneumonia observed in selected 
European countries (12). 
 
The main aetiologies of HAP are aerobic Gram-negative bacilli (such as Escherichia coli and 
Klebsiella spp.), Pseudomonas aeruginosa, Acinetobacter spp. and Gram-positive cocci such as 
Staphylococcus aureus (5, 16, 17).  Early-onset VAP has been associated with community-
related pathogens such as S. aureus and Haemophilus influenzae. Late-onset VAP conversely is 
associated more, with polymicrobial infections (18, 19) and with multi-drug resistant (MDR) 
HAP pathogens such as methicillin-resistant S. aureus (MRSA) and extended spectrum beta-
lactamase (ESBL) producing Gram-negative bacteria (Enterobacter spp., Klebsiella spp.). These 
pathogens in addition to Enterococcus faecium, are known as the ESKAPE pathogens (20).  
ESKAPE pathogens are responsible for 80% of all VAP and HAP cases (20).  The SENTRY 
Antimicrobial Surveillance Program (21) also reported similar findings, with S. aureus being the 
main HAP and VAP bacterial pathogen reported in the United States (36%) and Europe (23%) 
followed by P. aeruginosa (19.75% cases in the United States and 20.8% in Europe) and the 
other members of the ESKAPE pathogens (22) (Figure 1.2). Other Gram-negative bacteria such 
as Stenotrophomonas maltophilia and Moraxella spp. have also been reported less as cases of 
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Other non-bacterial pathogens of VAP and HAP include respiratory viruses such as, influenza (A 
and B) and parainfluenza (in adult patients), cytomegalovirus (CMV) (reported in ICU patients 
(23), and mimivirus (associated with prolonged ventilated ICU patients (24-26)) and fungal 
organisms such as Aspergillus and Candida spp. It is thought that Candida colonization in 
pneumonia patients suggests the existence of an underlying bacterial infection rather than the 
cause of the pneumonia. Candida is also associated with higher mortality rates and poor patient 
outcomes (27, 28). A small number of aspergillosis cases (3%) have been reported in late-onset 
VAP. Aspergillosis (caused by Aspergillus spp.) is mostly associated with severely ill patients 
(29, 30) (Figure 1.2).  
 
Figure 1.2. Overall frequency of isolated pathogens from patients with nosocomial pneumonia in 
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Atypical pneumonia is mainly caused by bacterial organisms that cannot be identified using the 
standard methods (e.g. culture or Gram stain). Most cases of atypical pneumonia have been 
caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila 
(referred to as Legionnaire’s disease or legionellosis) (31).  
Legionella spp. reside in aquatic habitats and water distribution systems hence, the main 
transmission source is through inhaling contaminated aerosols (32). Many water distribution 
systems, such as hot tubs, industrial/domestic plumbing systems and cooling towers, are 
contaminated with Legionella spp. and have been connected to legionellosis outbreaks. 
Legionellosis or Legionnaires’ disease is also associated with <7% of severe CAP (sCAP) cases 
(33, 34)  and 2-9% CAP cases. The European Legionnaires’ Disease Surveillance Network, 
between 2011 and 2015, reported 30,532 cases (of which 92.3% were confirmed) of 
Legionnaires’ disease from which: 67% were community-acquired associated with reported 
outbreaks such as the 2014 reported in Portugal and the 2012 outbreak reported in Edinburgh, 
24% were travel-associated; and 7% were related with health-care (32, 35). Legionella 
pneumophila is the most commonly detected species of the Legionella genus, with sequence 
types (ST) belonging to Lp1 serogroup associated with the majority of legionellosis cases in the 
US (35), in England and Wales (36). 
Legionnaires disease is less frequently caused by Legionella longbeachae (associated with 
contaminated soil) and other Legionella spp. such as Legionella micdadei and Legionella 





1.1.2 Clinical features and diagnosis of LRTIs 
 
Patients with bronchitis or bronchiolitis are typically presented with a cough and this is the main 
symptom observed in healthy adults. Cough can be persistent for a few weeks (depending on the 
infectious agent) and can be productive/non-productive with the production of mucoid sputum 
(1, 4). In the majority of cases bronchiolitis is viral and is self-limiting and initial antibiotic 
treatment is not necessary. However, the production of purulent sputum is often associated with 
bacterial infections. Additionally, if a clinician suspects that bronchitis has progressed to 
pneumonia, a chest radiograph will be requested to exclude the presence or absence of a 
pulmonary infiltrate (PI). However, in some paediatric cases, when the clinical features are more 
severe, hospital admission and ventilation might be necessary (1).  
The main clinical features of  CAP, HAP and VAP, are cough, dyspnoea/tachypnoea, increased 
pulse (>100), persistent fever (> 4 days) and the presence of a pulmonary infiltrate (5). A 
pulmonary infiltrate can only be confirmed with a chest radiograph and according to the 
guidelines published in 2011 by ESCMID, a chest radiograph should always be performed in 
suspected cases of pneumonia (4, 5, 16). For HAP and VAP cases additional physical 
examination such as lateral or posterior chest radiograph can be requested to determine the 
progress of the infection (29). The infection’s progression is also monitored by routine blood 
counts and chemistry (6, 15). 
In addition to these tests for patients with suspected pneumonia, a C-reactive protein (CRP) test 
can be performed. Pneumonia is likely present if CRP level= >100 mg/L and is highly unlikely if 
CRP levels = <20 mg/L (5). In addition to the CRP test, erythrocyte sedimentation rate (ESR) 
can be performed to determine inflammation levels – this test measures the rate red blood cells 
(RBC) settle in a test tube (higher rate suggests presence of inflammation). However, the 
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diagnostic value of such tests is debated amongst clinicians (5, 37). The diagnostic value of the 
CRP test is also debated - accepted by some studies (38, 39) and rejected by others (40).  
The main symptoms for atypical pneumonia such as Legionnaire’s disease include headache, 
low-grade fever, cough, chills and malaise, meaning it can be easily mistaken as pneumococcal 
pneumonia due to symptoms resembling mild CAP (41). Also, in patients with suspected 
legionellosis and pneumonia (confirmed by a chest radiograph), neurological abnormalities and 
gastrointestinal manifestations (such as diarrhoea and vomiting) caused by persistent headaches 
are observed. Other less common symptoms of legionellosis are myalgia or arthralgia and chest 
pain (observed in <50% of patients) (38-40). 
If the clinician suspects infection, they will request microbiological tests (e.g. culture, gram 
stains) to identify the causative agent (described in 1.1.4). The typical respiratory sample used 
for testing is expectorated sputum, as it is easily collected. The use of expectorated sputum is 
recommended by the UK and European guidelines) for culture testing and investigation 
sensitivity (5, 42).  However, in some cases, such as previous treatment failure or if the patient 
cannot produce sputum, an alternative is required. Bronchoalveolar lavage (BAL), endotracheal 
aspirates (ETA) and protected specimen brush (PSB) can be collected instead. These are 
considered ‘cleaner’ samples, as they are collected invasively, meaning contamination from the 
upper respiratory microbiota is minimised. Invasive techniques are used only is certain cases, 
such as in unresolved pneumonia cases or for severely ill patients as invasive techniques require 





1.1.3 Empiric antibiotic treatment 
The European Respiratory Society and European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) has published guidelines to be followed by clinical routine 
practices for the management of LRTIs (5). The guidelines recommend for all patients with 
confirmed pneumonia (by x-ray) should be given empirical antibiotic therapy (5). The chosen 
treatment is determined by the patient’s history and risk factors (5, 16) (Table 1.1). The UK 
guidelines according to the ‘start smart and then focus’ report published by PHE for 
antimicrobial stewardship, recommends the start of empirical antibiotic treatment as soon as 
possible only in patients with sepsis or severe infections (43). Microbiological cultures should be 
available prior to initiating empirical therapy when possible (in cases where patients will not be 
at risk).  
Table 1.1: Recommended criteria for determining empiric antibiotic therapy according to NICE 
guidelines (42).  
Criteria Additional information 
Severity of patient 
For severely-ill or pregnant patients, advice 
from a specialist is recommended for 
choosing empirical antibiotic therapy 
Co-morbidity 
A co-morbidity may be related with the 
causative agent  
Residence  
Similar microbial patterns are observed by 
patients residing at the same nursing homes  
Patient’s Infection History 
Patient could have been previously infected 
with resistant organisms 
Microbial and resistance patterns locally 
and regionally   
Allows a possible prediction of microbial 
aetiology and (if any) resistance 
Toxicity of antimicrobial agents  Assessed for each patient individually  
Risk factors for an immunosuppressed 
system 
Immunosuppressed patients are at a higher 




ESCMID guidelines, in cases of CAP, recommend for penicillin (amoxicillin) or tetracyclines as 
the first-choice broad spectrum antibiotics. In cases of penicillin allergy, macrolides are 
recommended as a good alternative if macrolide-resistance is low in the country/region. If there 
is high resistance to first choice antibiotics then quinolones such as levofloxacin or moxifloxacin 
are recommended (44-46). For severe cases of hospitalised patients with CAP (sCAP) the 
combination of macrolides with beta-lactams (or with antipseudomonal cephalosporins only if a 
Pseudomonas infection is high) is recommended. If the risk of infection by ESBLs Gram 
negative enterobacteria is high then ertapenem is recommended, only if the risk of a 
Pseudomonas infection is low/excluded (47-49). These recommendations are also in agreement 
with the UK guidelines (published by the National Institute of Health Care and Excellence -
NICE), where the use of amoxicillin or tetracyclines or macrolides are recommended for the 
empirical treatment for suspected CAP cases (42). Although for severe cases of pneumonia, 
quinolones (levofloxacin) are recommended as the initial treatment (42). In CAP cases when 
Legionella infection is suspected then the recommended first line of antibiotic treatment is 
quinolones (levofloxacin) or macrolides (50, 51). 
Treatment of nosocomial pneumonia is determined based on the risk of multi-drug resistant 
(MDR) bacterial infection and if it is a late-onset (i.e. VAP) case according to the NICE 
guidelines (42). If the risk is high or it is a late-onset VAP case then the broad-spectrum 
antibiotics of choice are cephalosporins (ceftazidime for Gram-negative bacteria) or beta-
lactamase inhibitors with penicillins (piperacillin with tazobactam) (active against both Gram-
negative including P. aeruginosa and Gram-positive bacteria (52)). For MRSA suspected 
infections, dual therapy is recommended and the antibiotics of choice are glycopeptides 
(teicoplanin or vancomycin) and oxazolidinones (linezolid) (42). Antibiotics in these cases 
should be administered intravenously instead (42). However, if the patient is at a low risk for 
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MDR bacterial infection or it is an early-onset VAP case, antibiotics should be given orally. 
Penicillin (co-amoxiclav) is the first-choice of antibiotics recommended, followed by 
tetracyclines (doxycycline), or sulfonamides (co-trimoxazole) by the NICE guidelines. 
Quinolones (levofloxacin) are only recommended if the previous options are not suitable (42).  
Recent guidelines published by both the American Thorasic Society and IDSA (Infectious 
Diseases Society of America) also focus on the need for targeted antibiotic therapy and the 
limiting of empiric antibiotic treatment (53). The consequences of inappropriate empirical 
antibiotic therapies have been clearly highlighted throughout the years (54-56). Overuse of 
broad-spectrum antibiotics has resulted in increased levels of antimicrobial resistance and 
consequently higher mortality rates, especially in patients with nosocomial pneumonia (54-58). 
Alvarez-Lerma et al. showed that, in 214 (43.7%) of 490 VAP cases no improvement was 
observed with initial therapy and a change in antibiotic treatment was necessary (59). Other 
studies have observed a reduction in inappropriate initial therapy and drug-related costs when 
utilising computer algorithms based on epidemiological data (such as local antibiotic resistance 
patterns) and patient-information (i.e. the patient’s history and microbiology results) gathered 
from the relevant local microbiology labs and ICU (60, 61). Using a targeted antibiotic treatment 
is not only beneficial for the patient’s health/outcome but also reduces hospital and drug related 
costs. However, a targeted antibiotic treatment can only be chosen once the aetiology is known.  
The antimicrobial stewardship treatment (AMS) algorithm by PHE, states that reviewing 
antibiotic prescription can only happen after 48-72 hrs due to the current choice of diagnostic 
method for LRTIs (43). At the moment in the UK, testing is based on traditional microbiological 
culture, meaning results are only available after 48-96 hours or longer (62). 
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1.1.4 Microbiological diagnosis and targeted antibiotic treatment  
 
The current ‘gold standard’ method for bacterial and fungal identification from respiratory 
samples (sputum and tracheal aspirates) is semi-quantitative culture (42). Other microbiological 
tests include pneumococcal and legionella antigen detection tests (63, 64) (see table 1.2 of all 
diagnostic approaches). Expectorated sputum is the most common respiratory sample collected, 
despite the fact sputum cultures have low sensitivity and specificity due to the carry-over of 
contaminants from the upper respiratory tract (URT) (63). Hence, it is recommended, to collect 
sputum samples early in the morning, which are considered to contain pooled secretions from the 
lower tract concentrated overnight and are more likely to contain pathogenic agents(65).  
Sputum and mucoid samples are firstly sputasol-treated (1:1 ratio of sample to sputasol added) 
and plated (previously sample is diluted with water) on blood agar, chocolate agar, and 
MacConkey agar (media inhibiting the growth of Gram-positive bacteria). For sterile samples 
(e.g. BALs) and samples from ICU and/or immunocompromised patients, 10 µL of undiluted 
primary sample is also plated on Cysteine–lactose–electrolyte-deficient (CLED) agar and 
sabouraud dextrose agar (SAD) agar (65). For Legionella-suspected samples, 100 µL of 
undiluted sputasol-treated primary sample is plated on Legionella-selective media, buffered 
charcoal yeast extract (BCYE) supplemented with anisomycin or cefamandole, which restricts 
the growth of lung microbiota and promotes the growth of Legionella spp. (65). Samples from 
patients with suspected Legionellosis, are plated on Buffered Charcoal Yeast Extract (BCYE), 
Buffered polymyxin anisomycin (BMPA) and Buffered Charcoal Yeast Extract with 
Cefamandole (BCY-C) are incubated for maximum of 10 days to enable the growth of 
Legionella spp. After 4 days of incubation the plates are initially examined for growth followed 
by re-confirmation at 10 days (6, 62, 66-68).  
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Other microbiological tests such as antigen and serological tests are also performed due to their 
rapidity and high sensitivity. Antigen tests are mostly used to identify viral aetiologies but are 
also recommended for bacterial infections such as L. pneumophila serogroup 1 using urine 
samples (63, 69, 70). Also, any Legionella species reported in clinical samples, must be isolated 
and sent for identification and serogrouping (65). Urinary antigen are also recommended for 
rapid identification of S. pneumoniae (5, 6, 16, 42, 63, 71). Antigen tests (targeting 
galactomannan glycoprotein) using BALs or serum samples with PCR-based tests are also 
recommended for screening of patients with high risk of fungal infection (A. fumigatus) (65). 
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*Chocolate agar with bacitracin is used for the isolation of M. catarrhalis and S. pneumoniae 




 The AMS treatment algorithm published by PHE recommends to stop antibiotic treatment when 
appropriate - there is no evidence of bacterial infection (negative culture findings) and patient is 
improving (42, 43). Also, intravenous antibiotics should be changed to oral antibiotics. 
Antibiotic treatment can also be refined when appropriate, following the microbiological 
findings and susceptibility profiles, and narrow-spectrum antibiotics should be chosen (43) (see 
Table 1.3). Targeted therapy can be either combination or monotherapy, although in the UK, 
monotherapy is recommended and combination therapy  should not be used routinely (42, 43). 
ESCMID guidelines however, recommend combination therapy as the initial targeted treatment 
in severe cases, followed by monotherapy after 3-5 days and if the patient is improving (Table 
1.5) (5, 16). When MDR Gram-negative bacteria (GNB) are identified (including ESBL and 
resistant P. aeruginosa) then carbapenems are recommended for refined treatment but when 
there is known/past carbapenem resistance then treatment should be refined following 
susceptibility profiles and national guidelines (72). For example, the use of polymixins (colistin) 
in combination with aminoglycosides or tigecyline for carbapenamase-resistant GNB is 





Table 1.3. Recommended antibiotic treatment based on identified respiratory pathogens and 
susceptibility/resistance (5, 72) 
Identified pathogen Recommended treatment 
Resistant S. pneumoniae 
Levofloxacin or Vancomycin or 
Teicoplanin 
MSSA 
Flucloxacillin or Cephalosporin II or 
Clindamycin or Levofloxacin 
MRSA 
Vancomycin or Teicoplanin or 
Linezolid 
Ampicillin-resistant H. influenzae 
Aminopenicillin and b-lactamase 
inhibitor or Levofloxacin 
Legionella spp. Macrolide or Levofloxacin 
Carbapenem-resistant A. baumannii Ampicillin and sulbactam or Polymixins 
Quinolone- or Carbapenem-resistant P. aeruginosa 
Avibactam and Ceftazimide or 
Polymixins 
MDR-GNB including resistant P. aeruginosa Carbapenems or Ceftazimide/avibactam 
 
Although culture-based tests can successfully isolate pathogens and identify susceptibility 
profiles, various challenges and difficulties still remain. Several studies have highlighted the 
problems that arise form culture-based diagnostics (10, 62, 73, 74). Culture has a slow 
turnaround time (>48 hrs) and has low clinical sensitivity, as >30% of culture tests fail to 
identify the causative agent (10, 75). Failure in identifying the etiology in hospitalized patients 
increases to 50% (76) when infection is polymicrobial. Sub-optimal results and slow diagnosis 
delay the design of tailored treatment which increases the use of broad-spectrum antibiotics, 
promoting the emergence of antibiotic resistance. In 2017, the WHO released a list of 12 
‘priority’ resistant bacteria that are currently the greatest threat to humanity and seven bacteria 
on the list are important respiratory pathogens (https://www.who.int/news-room/detail/27-02-
2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed). In fact, in 
the north-western hemisphere, the majority of prescribed antibiotics are for the treatment of 
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LRTIs (77).  For example, in the UK, 60% of all antibiotics prescribed are for respiratory 
infections (63). Additionally, according to CDC, in the US, 46% prescribed antibiotics are for 
respiratory illnesses in urgent care centres and 25% in emergency departments (78). These 
numbers demonstrate the significant overuse of empirical antibiotics in respiratory infection and 
the likely contribution this has on the emergence of antibiotic resistance (79). Delayed 
appropriate antibiotic treatment leads to poor patient outcomes, meaning hospitalisation is 
prolonged therefore increasing hospital-related costs (80). In Europe, the annual hospital-related 
costs associated with LRTIs were €10.1 billion (80), rising to at least €17 billion in the US (81), 
with inpatient care accounting for more than half of the costs. The increasing rate of antibiotic 
resistance in respiratory pathogens and the substantial economic burden of LRTIs demonstrate 





1.1.5 Diagnosis using molecular-based techniques 
Rapid diagnosis would reduce turnaround time, allowing tailored antibiotic treatment to be 
started earlier. This will eventually lead to reduction in costs for the NHS, reduced antimicrobial 
resistance and improved patient outcomes. Molecular methods, as discussed by the UK 
Government 5-year AMR action plan and the O’Neill report (82-84), have the potential to 
overcome the limitations of culture-based diagnostics, as pathogens and the associated antibiotic 
resistance would be identified in a few hours, allowing early targeted therapy and better 
antibiotic stewardship.  
PCR-based techniques offer increased sensitivity and specificity compared to culture and enable 
easier detection of polymicrobial infections, hard-to-culture bacteria and atypical respiratory 
pathogens such as L. pneumophila (10, 85). Common and atypical respiratory pathogens and 
some selected resistance genes are the chosen targets for designing these assays (86). DNA 
extracted directly from primary respiratory samples (BAL, ETA, expectorated sputum) is used as 
an input for the reaction (87, 88).  
 
Initially PCR-based diagnostic tests could only target one or two pathogens or resistances. Over 
the years the number of targets have increased massively due to technology advances (such as 
the use of TaqMan sequence-specific probes) and now multiplex PCR assays can detect up to 
tens of gene targets (88). However, the use of PCR-based tests for diagnostics has been 
challenging mainly due to low-quality templates (89). Low-quality templates are consisted of 
PCR-inhibitory compounds coming from the extraction procedures. However, this challenge was 
overcome by the development of sample-in answer-out technologies (90, 91), which are rapid, 




Numerous diagnostics companies have also developed instruments and assays for pathogen and 
related antimicrobial resistance genes detection, targeting respiratory infections. Currently there 
are two PCR-based sample-in answer-out machines that are commercially available and provide 
panels for the diagnosis of LRTIs that are FDA-approved, the BIOFIRE® FILMARRAY® 
Pneumonia Panel plus (BioMérieux SA) and the Unyvero P55 Pneumonia Cartridge (Curetis 
AG). The BIOFIRE FILMARRAY panel allows the semi-quantitative identification of 18 
bacteria, nine viruses and seven antibiotic resistance targets (https://www.biomerieux-
diagnostics.com/biofire-filmarray-pneumonia-panel.) The Unyvero P55 Cartridge can identify 19 
respiratory bacteria and 10 resistances and can provide a semi-quantitative information (91) (see 
Table 1.4 for all bacteria and resistance gene targets utilised by these two systems).  
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Table 1.4. Bacterial targets and antimicrobial resistance gene markers used by two 
commercially-available PCR platforms 
 

































































Since their release, many clinical and comparative studies have evaluated these tests to compare 
their outputs against culture or in-house-developed PCR assays (92, 93). Gadsby et al. compared 
the Unyvero P55 Pneumonia Cartridge (Curetis AG) and an in-house PCR assay against culture 
for the diagnosis of bacterial respiratory infections. The Unyvero P55 was 56.9% sensitive and 
58.5% specific and their in-house PCR assay was 63.2% sensitive and 54.8% specific when 
compared against culture on 74 BAL samples(91). The authors concluded that the tested assays 
would only benefit clinical microbiology as an additional test to culture and not as the primary 
test (91). Another recent study evaluated the BIOFIRE FILMARRAY by testing 1,682 samples 
(846 BALs and 836 sputa). The test was 100% sensitive for 15/22 pathogenic targets and 10/24 
targets in BALs and sputa respectively and was 87.2% specific (94). These two platforms were 
also compared against routine microbiology in a recent study where 644 surplus respiratory 
samples from patients with HAP and VAP were tested. Enne et al. concluded that the Unyvero 
55 had a higher concordance with culture but the FILMARRAY had a higher clinical sensitivity 
and fewer major discordances with culture (95).  
Despite the major advantages PCR assays can offer, such as rapidity and increased sensitivity, 
challenges, remain. PCR tests are limited on their multiplexing targets, meaning only a number 
of bacterial targets and resistance genes can be included in an assay. Also, there is a constant 
need for updating the sequence target of PCR primers to be able to detect newly identified point 
mutations or resistance genes. Another concern with PCR tests is distinguishing pathogens from 
lung commensals belonging to the same genus, and therefore, increasing the numbers of false 
positive samples resulting in the unnecessary treatment of patients (96-99). A example of this, is 
the commensal bacteria of the Streptococcus genus, which can be misclassified as S. pneumoniae 
due to high genetic similarities (99, 100).  
An agnostic, non-targeted molecular approach such as metagenomic sequencing-based 
diagnostics could overcome the many of the challenges observed for culture and PCR, due to its 
35 
 
rapidity coupled with comprehensiveness and the unbiased approach of identifying all microbes 
present in a sample (101, 102). 
 
1.2 Next Generation Sequencing   
 
The incredible advancements in sequencing technology since 1977, when Sanger sequencing was 
developed, to the beginning of the 21st century when next generation sequencing (NGS) 
platforms were developed, is unquestionable (103, 104).  A good illustration of these 
advancements are the differences between the first human genome sequenced with the latest 
sequenced genomes. It took 14 years and $3 billion to sequence the first human genome back in 
2004, compared to only ~48 hrs using the NovaSeq (Illumina) in 2018. The MinION (Oxford 
Nanopore Technologies) was used to sequence the human genome in 2018 which only cost 
thousands of dollars (105-107).  
Sanger sequencing utilises dideoxy nucleotides (dNTPs), which are incorporated at the end of a 
DNA strand during an amplification cycle, giving a unique pattern, which will then be translated 
into the DNA sequence. For decades this sequencing technology was the only one available and 
due to the low error rates and cost is still used today, mainly for specific amplicon confirmation 
(104, 108). Sanger sequencing is still considered by reference laboratories as the “gold standard” 
for molecular typing of L. pneumophila (Day, J 2019, personal communication October 11). The 
major advancements in sequencing technology led to the development of NGS and third 
generation sequencing (refer to reference (109) for a comprehensive review on the history of 
sequencing). In the past two decades, the NGS industry was dominated by Illumina, Ion Torrent 
and Pacific Biosciences (PacBio) technologies, but the interest in nanopore sequencing 
developed by ONT has been growing significantly since its introduction in 2014 (110). Illumina 
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is a sequencing-by-synthesis technology and is based on the incorporation of dNTPs at the last 
position on the DNA strand during DNA synthesis. Once the incorporated dNTP is determined 
with specific fluorophore excitation, is then removed enzymatically and DNA synthesis can 
continue. The current Illumina platforms are the (iSeq, MiniSeq, MiSeq, NextSeq, HiSeq, 
NovaSeq) and enable high-throughput short read (single or paired end) sequencing (50-600bp 
long) (109). Conversely, the PacBio platforms (RSII and Sequel - average read length of 30kb 
(111)) and ONT platforms (longest reads >2Mb) allow high-throughput long-read sequencing. 
For comprehensive description of PacBio sequencing see (109).  
 
1.2.1 Nanopore sequencing  
 
Nanopore sequencing was first introduced in the 1980s, but ever since has been constantly 
developing. Unlike sequencing-by-synthesis approaches, nanopore-based sequencing directly 
‘reads’ the DNA sequence. Briefly, during nanopore sequencing, a dsDNA fragment is 
enzymatically unwound and then ssDNA is translocated through a nanopore protein/pore 
embedded in a membrane. The membrane is immersed in a charged solution, and as the ssDNA 
passes through the pore, a unique change in the current is created by each of the four bases, 
which is then used to identify the sequence of the DNA strand (107, 112, 113) (for a 
comprehensive review on the history of nanopore sequencing see (114)). 
In 2014, MinION, the first commercially available nanopore sequencer, was launched by ONT. 
Initially, MinION sequencing quality and yield restricted its applications and it was mainly used 
for amplicon and small genome sequencing. Significant improvements in accuracy and yield 
coupled with the introduction of additional technologies such as PromethION have made it 
suitable for most sequencing applications and it has even been used to sequence E. coli in space 
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(115). Nanopore sequencing initially, had low sequencing accuracy (~60-70%) due to the pores 
(R6 followed by R7) and basecalling technology used, when compared to other sequencing 
technologies e.g. Illumina sequencing is 99% (116). However, since then ONT has managed to 
improve the single-read error rate to ~10% (116). Improvements to single-read accuracy was 
mainly due to: i) improving the release of R9 pores, followed by R.9.4 and R9.4.1 pores (117) 
(Figure 1.3) and ii) the evolution in basecalling softwares from event-based basecalling to raw 
signal-based basecalling (Albacore v2.0.1) (116, 118). 
Additionally, in March 2019 ONT announced the release of the R10 pore which has a longer 
barrel allowing dual-reading of each nucleotide (Figure 1.3) - this has improved the sequencing 
of homopolymers and increased consensus accuracy to QS50 vs QS40 with the R9.4.1 chemistry 
(119). The most recent pore chemistry is R10.3, which is soon-to-be commercially available, and 
promises similar sequencing yield to the widely used R9.4.1 pore whilst improving accuracy 
(https://londoncallingconf.co.uk/about-us/news/r103-newest-nanopore-high-accuracy-nanopore-
sequencing-now-available-store). Nanopore sequencing does not have a read length limitation 
and can potentially sequence any length DNA molecule presented to it.  Hence it is considered a 
long-read sequencing technology (longest reads >2Mb). Long-read sequencing technology 
provides advantages over short read technologies.   
Whilst short-read sequencing technologies are more accurate and are cost-effective for high-
throughput sequencing, long-read sequencing provides advantages that can never be offered by 
short reads. Long reads can span big regions of a DNA sequence as they can be megabases-long 
(longest read from nanopore sequencing is > 2Mb). Such long reads provide a number of 
advantages such as: more accurate genome assemblies and improved mapping confidence (120), 
identification of the host by mapping flanking regions of a chromosomal resistance gene (121-
123) and can be used to identify genome rearrangements (124).  
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Also, a major advantage of nanopore sequencing (Flongle, MinION, GridION, PromethION) is 
that data are produced and available for analysis in real-time (101, 110, 125-127) making 
nanopore sequencing the fastest sequencing technology currently available on the market. This 
feature has been utilised to provide rapid answers for diagnostic purposes and to characterise 
outbreaks. For example, Votintseva et al. showed Mycobacterium tuberculosis could be detected 
from sputum in 7.5hrs (128), Schmidt et al. developed a 4hr-diagnostic pipeline for urinary tract 






Figure 1.3: Schematic representation of the barrels present within the two latest nanopore 
chemistries and cryogenic-electromagnetic (EM) structure of R.10 pore chemistry. Schematic 
representation of the complexes present in R10 pore (A) and R9.4.1 pore (B) chemistries. 
Cryogenic-EM structure of R.10 pore chemistry represented by different colours. Figure adapted 
by ref (131).  
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1.3 Clinical metagenomics  
 
Metagenomic sequencing-based approaches can combine speed and comprehensive coverage of 
all microorganisms present in a clinical sample, providing the potential to replace culture and 
PCR (especially for LRTIs) while also providing whole genome sequence data useful for public 
health microbiology applications. Metagenomics is defined as the identification and 
characterisation of all genomes present directly from the primary sample (environmental, clinical 
or food) (132, 133). When metagenomics is used for the characterisation of pathogens for 
diagnostic or epidemiological purposes directly from clinical samples, it is defined as clinical 
metagenomics (CMg) (134, 135).  
There are numerous advantages of clinical metagenomics over other sequencing-based 
approaches designed to characterise the microbial composition of clinical samples, such as 
16/18S rRNA sequencing or amplicon-based sequencing. Sequencing targeting the ribosomal 
rRNA (16S rRNA for bacteria or 18S rRNA for fungi) can only provide bacterial or fungal (not 
viral) identification information reliably down to the genus and cannot provide any information 
on antimicrobial resistance (122). Amplicon-based sequencing approaches suffer from many of 
the same drawbacks as PCR, utilizing primers targeting only a known set of pathogens and/or 
resistance genes. These targeted approaches cannot detect the breath of pathogens and 
resistances associated with respiratory infections or provide whole pathogen genomes. 
Conversely, CMg allows simultaneous identification of all microbes and associated resistance 
genes present in a clinical sample. Also, metagenomic data can provide whole pathogen genome 
data if sufficient genome coverage is recovered. This information can be used for both 
diagnostics (pathogen identification+AMR gene detection) and for public health applications 
(genome assemblies for outbreak characterisation and surveillance) (122).  
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1.3.1 Clinical metagenomics applied for diagnostics 
 
Current diagnosis of LRTIs still relies on culture despite the poor sensitivity and long turnaround 
times. Clinical metagenomics can replace current diagnostics and, in recent years, the interest in 
applying CMg for diagnostic purposes has increased. There are two approaches to diagnostic 
CMg: i) deep-metagenomic sequencing of genetic material (human and all microorganisms) 
present in clinical samples and ii) sequencing of genetic material directly from a clinical sample 
after microbial enrichment or human depletion is performed (102). 
For the first CMg approach, sample processing includes DNA extraction of both human and 
microbial genetic material present in the sample (102). Next, sequencing of the extracted DNA 
and RNA (reverse transcribed to cDNA) is done followed by data analysis (102, 136, 137). 
Wilson et al, used untargeted deep metagenomic sequencing directly from a cerebrospinal-fluid 
sample from a critically ill 14-old boy and identified a Leptospira infection (138). Another 
example was recently demonstrated by Wilson et al. (137). This multicenter study, evaluated the 
diagnostic efficiency of CMg for meningitis and encephalitis. Their pipeline included DNA and 
RNA extraction (both human and microbial) directly from CSF samples, followed by DNA and 
cDNA sequencing on an Illumina HiSeq instrument in rapid-run mode and data analysis (137). 
Metagenomics was concordant with clinical testing for 19 cases and identified 13 cases not 
previously identified by traditional diagnostics. Diagnostic output from metagenomic sequencing 
provided guidance for treatment for 7/13 cases identified by metagenomics only. Their pipeline 
however, failed to report 26 confirmed infections and failing of the 8/26 was due to low 
pathogenic titre in the samples. Pipelines utilising a CMg-based approach can also detect host 
infection biomarkers (transcriptome analysis) (139, 140). 
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Sensitivity of these CMg pipelines is related to the amount of human and microbial (non-
pathogenic) background present in clinical samples – higher background, lower sensitivity (102). 
This limitation was recently documented by Pendleton et al. that applied CMg for the diagnosis 
two confirmed cases of bacterial pneumonia without any human depletion or microbial 
enrichment strategy. This resulted in the majority of sequencing reads being of human origin 
(99%) and only three pathogenic reads were identified (one for P. aeruginosa and two for S. 
aureus) (141). In clinical samples the ratio to human:microbial DNA is very high, therefore, only 
with deep sequencing, enough genome coverage (for high-titre pathogens) can be recovered for 
pathogen identification to be possible (102). Deep sequencing results in slow turnaround times 
(>2 days) and high sequencing cost and is not a suitable approach for replacing culture. This 
approach is only beneficial as a ‘last-resort-test’ for cases where other tests (e.g. PCR, culture) 
have failed to identify a pathogen. 
The second CMg approach utilises human cell/DNA depletion or microbial/pathogen cell/DNA 
enrichment prior to sequencing to improve sensitivity and reduce turnaround time and cost  (122, 
142). The Pendleton et al. (141) study highlighted the importance of human depletion or 
microbial enrichment for the successful implementation of clinical metagenomics for the 
diagnosis of LRTIs. If CMg is ever going to be implemented for the routine diagnosis of LRTIs, 
turnaround time must be <8 hours (before second dose of antibiotics), cost must be reasonable 
(<$200 per test, similar to the cost of Filmarray and Unyvero multiplex tests) and sufficient 
genome coverage is required to identify pathogens and detect any drug resistance genes. CMg 
pipelines that utilise human depletion or microbial enrichment strategies coupled with rapid 
sequencing technology have the necessary characteristics for implementation. Hence, a CMg 
pipeline based on enrichment/depletion was considered more suitable for the aims of this PhD. 
The various steps involved in such a pipeline are introduced in the following sections.  
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1.3.2 Clinical metagenomics for public health applications 
 
CMg can be applied beyond the field of diagnostics. It has been specifically applied in molecular 
epidemiology and outbreaks (143-145), but has the potential to be utilised for diagnosis and 
public health applications simultaneously. Molecular epidemiological studies aim to provide 
answers beyond diagnosis, for example, characterizing the causes of infectious diseases and their 
distribution (i.e. hospital transmission or infectious outbreaks) (146, 147). The majority of 
studies utilizing sequencing for molecular epidemiology have used whole genome sequencing 
(WGS) or amplicon sequencing from bacteria isolated from clinical samples (148-150). CMg can 
be used for epidemiological studies directly from the primary specimen without the need of 
growing and isolating the pathogen first as generated data can be used to assemble whole 
genomes (122, 143) or sequence-based typing (used for linking L. pneumophila outbreaks) (151).   
Loman et al., used CMg with Illumina sequencing and was able to investigate the 2011 outbreak 
of the Shiga-toxin producing E. coli (STEC). After sequencing 45 fecal samples from patients with 
diarrhea, the authors were able to recover the strain’s genome from 26 samples with a >1x genome 
coverage and in 10 samples with a >10x coverage (152). Greninger et al. (2017)  and collaborators 
were able to implement changes to infection control procedures during a flu outbreak observed in 
a children’s hospital. Genomic assemblies of parainfluenza 3 virus (HPIV3) were generated from 
8/13 samples (all from the three flu cases) and phylogenetic clustering confirmed a suspected 
transmission pattern due to genetic similarities being observed in 2/3 cases (153).  
However, due to the constant improvement of nanopore sequencing in recent years, more CMg 
studies utilizing real-time nanopore sequencing for public health microbiology have been made 
available. Most recently, nanopore metagenomic sequencing was used in real-time for the 
characterization of the Lassa fever outbreak in Nigeria 2018 (145). Kafetzopoulou et al. (2018) 
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identified phylogenetic similarities with strains known to be transmitted through zoonotic hosts. 
This information was able to rule out the possibility of human-to-human transmission and led to 
a direct response from Nigerian authorities to design the most appropriate public health response 
(145). Nanopore metagenomic sequencing was also used during the current COVID-19 
pandemic for the identification of SARS-CoV-2. Moore et al. was able to identify SARS-CoV-2 
and characterize the lung microbiome directly from swabs with a turnaround time of 8 hrs (154).  
 
1.3.3 Host depletion and enrichment strategies   
 
For a rapid CMg pipeline, one of the most important steps during sample preparation, is 
pathogen enrichment or host depletion. Purulent sputum is the most commonly collected 
respiratory sample and is considered one of the most challenging clinical sample types, due to its 
complex sample matrix, which consists of mucus, leukocytes, pathogenic and commensal 
organisms (122). Normally, a purulent sputum has a variable pathogenic load and leukocytes - 
approximately 106/ml (based on our experience). Approximately one bacterial cell has 1000-fold 
less DNA (~5 fg for a typical bacterium) than a human cell (6.6 pg). So for example, a sputum 
sample that contains 106 pathogens, means only ~1 read out of every 1000 sequenced reads 
produced will be of pathogen origin as the ratio of human DNA:pathogen DNA would be 103:1 
(122). Hence, prior to sample sequencing, host depletion or pathogen enrichment should always 
be performed during sample preparation in order to reduce the ratio of human:pathogen DNA 
(Figure 1.4). 
Enrichment strategies allow the selection of one or more pathogenic agent/s present in a sample 
(122). Pathogen specific enrichment is possible when the infecting organism is known e.g. in 
patients with suspected tuberculosis (TB) and the target is M. tuberculosis (Mtb). An approach 
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for selecting the pathogen/s is by targeting the unique properties of the outer envelope of the 
pathogen (for example via antibody binding with the mycolic acids present on the cell wall of M. 
tuberculosis). Also, enrichment strategies using a cell-based approach are able to capture 
microbes un-selectively by using magnetic nanoparticles (MNPs) using different ligands (155). 
For example, amino-glycan-functionalised MNPs were used for the rapid selection of pathogenic 
bacteria in food samples (156). In another example, MNPs using aptamers specifically designed 
to bind S. aureus and E. coli enabled the detection at low-levels (10 cfu) in animal blood (157).  
Another approach for enriching specific pathogens, at the nucleic acid level, is by using capture 
bait probes. These probes utilise streptavidin-conjugated magnetic beads that carry nucleotides 
that can be up to 120bp long and are designed to hybridise with several genomic regions and/or 
genes e.g. AMR genes (158). At the moment there is a number of  commercially available 
capture-based methods which are widely used (158) such as: i) Illumina’s Nextera Rapid Capture 
Custom Enrichment (NRCCE) Kit (https://emea.illumina.com/products/by-type/sequencing-
kits/library-prep-kits/nextera-rapid-capture-custom-enrichment.html) designed to capture 
selected genes of ≤15 Mb long and ii) SureSelectQXT Reagent Kit from Agilent 
(https://www.agilent.com/en/product/next-generation-sequencing/hybridization-based-next-
generation-sequencing-ngs/dna-seq-reagents-kits-library-preparation-kits/sureselectqxt-reagent-
kits-232861) that allows the hybridisation of customised genetic targets in 3.5 hrs. A number of 
studies have utilised these capture-based methods coupled with a customised gene panel for 
pathogen enrichment and have demonstrated promising results (158-161). Nucleic-acid-based 
methods can also be used for pan-microbial enrichment. Deng et al. developed a spiked primer-
based enrichment strategy, which when coupled with metagenomic sequencing detected 14 viral 
pathogens and increased genome coverage (mean 47%) directly from plasma samples (162). The 
sequences for spiked primers are designed using pre-existing viral genomes as a reference and an 
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algorithm developed by Deng and collaborators (162). PCR-tiling approaches have also been 
used successfully mainly for the enrichment of viral genomes such as Ebola (130), Zika virus 
(163) and recently SARS-CoV-2 virus (164). 
The main caveat of enrichment strategies, however, is their limited target panel/s and although 
they can be efficient for certain applications (such as monomicrobial infectious diseases e.g. TB) 
they would not be beneficial for LRTIs. Respiratory infections can be caused by multiple 
organisms (bacterial, fungal, viral) and can also be mixed infections, therefore a targeted 
enrichment strategy is not always useful and a host depletion approach is more beneficial. 
Numerous studies have shown that in order for CMg to be successfully applied as a LRTI 
diagnostic tool, efficient host depletion is essential (122, 141).  
Currently, there are a number of commercially available human DNA depletion kits, including 
the HostZERO Microbial DNA kit by Zymo Research, the NEBNext Microbiome DNA 
Enrichment Kit by New England Biolabs, the QIAamp DNA Microbiome Kit by Qiagen and the 
MolYsis Basic5 kit by Molzym. The NEBNext Microbiome DNA Enrichment Kit uses 
immunomagnetic separation to capture and remove human DNA by utilising differences between 
human and bacterial DNA, specifically targeting the highly methylated human DNA (DNA 
methylation is rare in microbial species) (165). The MolYsis Basic5 and QIAamp DNA 
Microbiome kit, utilises differential cell lysis through a chaotropic buffer that lyses human cells 
but not microbial cells, followed by DNase treatment for the digestion of cell-free host DNA 
(166).  
Numerous studies have evaluated these kits and have produced variable outcomes in terms of the 
efficiency of human depletion but also with regards to the loss of microbial DNA (128, 165, 167-
169). An example of this, is the clinical metagenomics pipeline developed by Votintseva et al. 
which could provide an accurate Mtb diagnosis within 44 hours (whereas conventional TB 
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diagnostics provide results within weeks) (128). This pipeline incorporated the MolYsis Basic5 
kit which was followed by Mtb DNA extraction and metagenomic sequencing. From 37 culture-
positive samples tested, the correct species was identified in 35 and first-line antibiotics were 
predicted for 24/37 samples, which were 96% concordant with reference laboratory reports. Due 
to the sufficient removal of host nucleic acid, >90% of the mycobacterial genome was recovered 
in 21/37 samples. However, in 14/37 samples a high number of contaminant reads were observed 
and <12% genome coverage was achieved after a 16-hr MiSeq run (128).  
Thoendel et al. developed a clinical metagenomics pipeline for the identification of prosthetic 
joint infections (PJIs) using the MolYsis Basic5 kit for host depletion, followed by DNA 
extraction, whole genome amplification (WGA) and sequencing using the Illumina HiSeq, 2x 
250 cycles rapid mode (although not mentioned, turnaround would be >60 hrs due to the chosen 
sequencing mode) (166). In total, 408 samples (infected n=213 and non-infected n=195) were 
tested with this pipeline and metagenomic sequencing was concordant with culture for 109/115 
culture positive PJI samples. In culture-negative PJI samples, potential pathogens were identified 
by metagenomics in 43/98 and additional pathogens were identified in 11/115 culture-positive 
PJI samples. During this study, they observed a loss of P. aeruginosa after host depletion which 
is a noticeable limitation, they also did not test if the chaotropic agents had an adverse effect on 
common PJI pathogens (166). Schmidt et al. (129) demonstrated the diagnosis of UTIs in 4hrs 
by combining a simple host depletion strategy (using differential centrifugation followed by 
MolYsis) with the real-time analysis on the MinION. Despite early failures observed in the 
pipeline (i.e. depletion failure or poor quality of flow cells) pathogens were correctly identified 
by metagenomics. Also, CMg accurately detected antibiotic resistance, reporting 51 resistance 
genes from the spiked pathogen compared to 55 resistance genes reported after Illumina 
sequencing (129).  
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Studies that focus on the rapid diagnosis of LRTIs utilizing rapid CMg pipelines are still limited 
and although the studies discussed above were not applied for LRTI diagnostics, they provide 
evidence of the benefits that host depletion can provide for rapid diagnosis. 
 
1.3.4 Saponin-based host depletion  
 
Saponins are found naturally on plant cell walls as surface glycosides and mainly act as 
defensive molecules, although, their exact role in plants is not completely understood (170, 171). 
These chemical compounds are mainly used as soap but in recent years their importance in the 
pharmaceutical industry has grown as they have numerous biological activities (170). 
The chemical structure of saponins consists of a hydrophilic domain (a sugar moiety often 
glucose) and lipophilic domain (known as sapogenin or sapogenol) and their classification is 
dependent on the number of sugar chains they have; i.e monodesmosidic (one sugar chain 
attached on C3), diplodesmosidic (two sugar branches at C3 and C8). Here, I will focus on the 
activity of monodesmosidic saponins as there are most relevant to differential cell lysis.  
Monodesmosidic saponins can cause disruption of the biological membrane mainly by inducing 
pore formation or by increasing the permeability of the membrane (170, 171). Numerous studies 
have investigated the mechanisms behind this activity and concluded that the sugar chain of the 
saponin interacts with cholesterols present on the biological membranes (see (171) for a 
comprehensive review on the biological action of saponins). In one mechanism the sugar moiety 
of the saponin forms hydrophilic interactions with sterols, inducing the formation of three-
dimensional tubule-like structures and a new lipid phase of the biological membrane (171). This 
eventually leads to membrane rearrangements, increasing the permeability of the biological 
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membrane. In a different mechanism, the sugar chain interacts with the cholesterols inducing the 
formation of large micelles-like aggregations (10 nm long) increasing diffusion in and out of the 
cytoplasm (171, 172). Lytic activity of monodesmosidic saponins is reported to be more active 
than diplodesmosidic saponins (170, 172).  
Hence, saponins have been of great interest in research due to their effects on biological 
membranes such as hemolysis (170, 173, 174) and membrane-permeabilizing. Saponins have 
been used in cancer research due to their ability to inhibit cell proliferation but also induce  lysis 
of cancer cells (175, 176). However, it was reported that their therapeutic usage might be limited, 
as they also induce red blood cell lysis due to their high affinity for cholesterols (173). Orjih et 
al. (174) utilized the haemolytic activities of saponins in order to improve microscopic detection 
of malaria parasites directly from blood samples. After saponin treatment 20-6000 haemolyzed 
parasites per field were detected, in contrast to 1-15 parasites detected only in blood samples 
with no saponin treatment.  
In a number of studies, saponins have also been used for differential lysis of human cells, aiming 
to facilitate the design of culture-free rapid diagnostic methods. Zelenin et al. designed a 
microfluidic-based device which utilized a saponin-based rapid selective lysis of human cells 
directly from blood samples (177). Their device was designed to allow rapid diagnosis of BSIs 
without the need of culture, and was consisted of two phases: 1) Selective host cell lysis using 
saponin and 2) Osmotic shock to lyse damaged host cells. The microfluidic device consisted of 
three inlets, each used for loading the sample, the saponin and the water for the osmotic shock, 
and one outlet where cell debris and viable bacteria would be collected from. Also, the device 
has a herringbone-like structure to allow mixing of the samples for optimal blood cell lysis. 
Mixing was monitored by imaging, through all the different stages, as blood was mixed with a 
fluorescein solution (177). Diluted blood samples (by 4-fold) spiked with known Gram-negative 
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and Gram-positive bacterial cell densities were used to test device’s efficiency for host cell lysis 
and bacterial viability. After selective host cell lysis with 1% saponin, all blood cells were lysed 
but not white blood cells (determined via flexible flow cytometry) whilst 100% of the spiked 
viable bacteria were recovered (cell viability determined via plating) at all tested cell 
concentrations (104- 106). Their microfluidic device would accelerate culture-independent testing 
such as molecular testing of blood samples and is a ready-to-use device as it needs minimal 
handling. 
Anscombe et al. further optimized and adapted the saponin-based method published by Zelenin 
et al. to allow whole genome amplification of pathogens directly from sterile clinical samples to 
enable in-depth pathogen/s characterization (178). This version of the saponin method was 
coupled with bacterial isolation and bacterial DNA amplification (with multiple displacement 
amplification) followed by NGS and was performed directly on pathogen spiked horse blood. 
DNA sequencing from saponin-treated samples recovered 92% of the spiked pathogenic 
genomes, whilst only 7% of total reads were human. Turnaround time of the altered saponin 
method (from sample processing to DNA sequencing, not including sequencing duration) was 
3.5 hours. However, despite the promising outcomes, this pipeline was not tested on human 






1.3.5 Microbial DNA extraction and sequencing  
 
Once human cells/DNA are depleted or microbial cells are enriched, DNA is extracted from the 
sample (Figure 1.4). Majority of pipelines utilise chemical combined with enzymatic lysis. 
Consideration needs to be taken on the microbial DNA extraction method used, to ensure 
efficient lysis of hard-to-lyse microorganisms (such as S. aureus and Aspergillus spp. which are 
important HAP/VAP pathogens). Many studies, have highlighted the importance of adding 
mechanical lysis (i.e. beat-beading) (179, 180) to ensure efficient lysis of all microbes. (Figure 
1.4). A less-efficient lysis will lead to underrepresentation of hard-to-lyse bacteria and a biased 
representation of the microbial community present in the sample. Additional automated DNA 
extraction and purification steps can be included or this can be done manually using spin 
columns or commercially available DNA purification kits. Automated extraction is preferred as 
it is less laborious, is standardised, can be rapid and this is the approach typically used in clinical 
microbiology laboratories. The MagNA Pure Compact (Roche), MaxWell (Promega) and 
QIAcube (QIAGEN), are examples of automated systems which offer rapid DNA 
extraction/purification (181-183) (27 min for 8 samples on Compact, 36 min for 48 samples on 
Maxwell and 90 min for 96 samples on QIAcube). 
Prior to metagenomic sequencing, the extracted DNA is converted into a sequencing library - the 
choice of library preparation is based upon the sequencing technology (Figure 1.4). As 
turnaround time is very important, nanopore sequencing is the obvious choice as is the only real-
time sequencing technology currently on the market. Also, it is more cost-effective for low-
throughput sequencing in comparison with other sequencing platforms. This is important as it is 
not feasible to batch test (96 samples) respiratory samples from patients with e.g. HAP or VAP 
to make your CMg pipeline cost-effective.  
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Once the sequencing platform is chosen then the choice for the appropriate library preparation kit 
can be made. When the starting DNA quantity is low, a PCR-based library preparation would be 
preferred in order to amplify the starting material to a quantity sufficient for metagenomic 
sequencing. For example, respiratory samples,  after host depletion typically contain <2ng/µL 
DNA which is insufficient for PCR-free library preparation (122). 
There are various kits available from ONT, such as the ‘Rapid PCR barcoding kit’ (SQK-
RPB004 – previously known as SQK-RLB001) which allows preparation and multiplex 
metagenomic sequencing of ≤12 samples from low input DNA concentrations (<10 ng as starting 
material) (122). This workflow has been successfully used by numerous studies aiming to 
sequence low biomass samples (122, 184, 185). During this workflow initially, the extracted 
DNA is enzymatically fragmented and tagged with specifically-designed adapters. Then primers 
complementary to the tagmented adapter are used to PCR amplify the DNA (Figure 1.4). 
Alternatively, if high concentrations of input DNA are available then the PCR-free ‘Rapid 
Barcoding kit’ (SQK-RBK004) can be used instead which allows the preparation of ≤12 samples 
in 10 min, using the same steps as the RPB004 kit. However, this kit is not suitable for 
sequencing of low biomass samples, as it requires a minimum of 400 ng input DNA. Illumina 
also offers the Nextera XT DNA Library Preparation’ kit that also allows preparation and 
sequencing of low-biomass samples (1 ng of input DNA) which also utilises a 
fragmentation/tagmentation step followed by PCR amplification. This kit has also been used 








Figure 1.4: A schematic workflow showing examples of the steps a rapid CMg pipeline should 
include. Figure taken from (122) . 
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1.4 Microbial bioinformatics  
 
Following metagenomic sequencing, a large amount of data is generated which is used to profile 
the microbial community computationally. However choosing the right approach for data 
analysis is challenging and is dependent on the aim of the study (186).  
ONT provide a set of automated online bioinformatics pipelines, but many users opt for a 
customised pipeline utilizing offline tools, as this provides increased flexibility. Typically, the 
first steps in a bioinformatics pipeline involve basecalling the raw FAST5 files produced by the 
instrument, followed by quality control filtering in which low-quality data and adaptor sequence 
are removed (186). For the ONT sequencing platforms MinKNOW software (provided by ONT) 
is used to control the hardware (e.g. MinION, GridION). During sequencing, raw data (in the 
form of current measurements), are captured and stored by MinKNOW in real time into the raw 
FAST5 format. MinKNOW can also base-call raw FAST5 data in real-time and convert to 
basecalled FAST5 or FASTQ reads (187). As previously discussed, ONT is the only sequencing 
technology that offers real-time data analysis. For users who do not need real-time analysis, ONT 
provides the offline basecalling tools Guppy, Scrappie and Flappie (188). Guppy uses GPUs to 
improve execution speed but is offered only to ONT customers (138). Scrappie and Flappie 
(replacement of Scrappie) are described by ONT as technology demonstrators, for trialling new 
features that will later be applied to Guppy (187, 189). Scrappie allows direct basecalling of the 
raw signal (189) and Flappie uses a Connectionist Temporal Classification (CTC) for assigning 
bases (187). Other offline basecalling tools are offered by third parties, most notably Nanocall 
(190), DeepNano (191) and Chiron (192). 
After base-calling, an additional quality score (QC) and/or read length filtering step can be added 
to remove poor quality reads. These steps can be beneficial for downstream analysis, such as 




1.4.1 Bioinformatics pipelines for Clinical metagenomics diagnostics 
Following basecalling and filtering of the raw sequencing data, a wide range of downstream 
analysis tools are available. For diagnostic purposes, the next step usually involves 
microorganism identification and classification, hopefully, to genus and species level. 
Additionally, sequence data can provide information on antibiotic resistance (if any) relevant to 
the identified pathogen/s (122, 123). Prior to microbial classification and AMR gene detection, 
an additional step may be included to computationally remove any human reads that still remain 
after host depletion(123, 194). This can be performed using alignment-based tools (e.g. 
minimap2) to remove reads that map to the human reference genome (GRCh38.p13 latest human 
assembly - https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.39).  
Tools for taxonomic classification from metagenomic data utilise a number of algorithmic 
approaches. One approach involves aligning microbial reads to reference databases or aligning 
contigs (microbial reads assembled de novo into contiguous sequences) to reference databases. 
Other strategies include analysing k-mer (short sequences of size k) content, mapping marker 
genes or protein sequences translated from the DNA sequences (194).  
Table 1.5 provides an overview of common tools for metagenomic classification. BLAST, has 
for a number of years, remained the gold standard sequence classification tool. However, it is 
relatively slow due to its computational complexity. MetaPhlan (195) aligns clade-specific 
marker genes against sequences in order to identify taxa (194). Although not as sensitive as 
alignment-based tools, a number of classifiers rely on k-mer-based classification leading to much 
improved speed and reducing the computational power required (194). Additionally, the choice 
of k (length of the sequence) is very important for the sensitivity and specificity of k-mer-based 
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classifiers. Long k-mers can result in lower sensitivity as exact matches for certain k-mers may 
not be identified, possibly due to sequencing errors or actual differences in the sequenced data, 
whereas short k-mers can result in multiple matches per k-mer (possibly false) leading to reduced 
specificity (196). 
Kraken, (197) is a k-mer-based classifier which, uses a novel algorithm to identify precise k-mer 
alignment from the Kraken database. K-mer/s without a match from the database, are not 
classified and are discarded (197). Kraken utilises an in-memory k-mer database (all compressed 
in a table which is used for identification of exact matches), which needs a large amount of 
RAM, meaning it cannot be run on typical desktop or laptop computers (194). In contrast, 
Centrifuge utilises a memory efficient index scheme based on the Burrows-Wheeler transform 
(BWT) and the Ferragina-Manzini (FM) index, which enables it to index 4000 bacterial genomes 
in around 4.3 Gb of RAM. It can provide accurate and rapid results from large metagenomic data 
and can be performed using a conventional desktop computer (198).    
A recent study by Ye et al used simulated datasets to evaluate the performance of 20 recently-
developed benchmarked metagenomic classifiers, including k-mer based classifiers, protein-
based classifiers and classifiers utilising marker genes (199). DNA k-mer based classifiers using 
long k-mers provided more precise results with better abundance estimates when compared with 
protein- or marker-gene-based classifiers. However, it was highlighted that a caveat of recently-
developed classifiers, is the trade-off between fast classification speed and specificity. To 
achieve fast classification, current algorithms reduce the number of candidate hits, for example 
k-mer classifiers only seek for exact sequence matches of length k (typically k=31). As 
previously mentioned, although not as sensitive as BLAST, these classifiers are preferred as they 
are faster and require less computing requirements (199). 
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Classification of pathogens from metagenomic data can also be performed using metagenome-
assembled genomes (MAGs) (200). For this approach, common overlaps of the sequenced reads 
are identified to build contigs resulting in the construction of a metagenomic assembly (an 
assembly of multiple microbial genomes). Once the assembly is constructed, it is mapped against 
a reference database, to identify alignments of contigs against known-sequenced genomes. The 
use of contigs instead of shorter sequenced reads can improve the accuracy of pathogen 
classification but construction of MAGs comes with many limitations. The main difficulties of a 
metagenome assembly arise from the different abundances of microbial genomes present in 
metagenomic samples and the presence of many closely related species or strains. If sequencing 
depth is not high enough for low abundance organisms, then assemblies will be fragmented and 
classification may fail (200). Pathogen classification using MAGs is still in its infancy and more 










Table 1.5: Tools used for taxonomic classification for metagenomic data. Table adapted from 
(194).   
Tool Outline Source 
BLAST+ 
Aligner able to use 
nucleotide or 
translated-nucleotides 
as input – provides 
sensitive results. 
MegaBLAST (part of 
the BLAST+) can 
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Once a pathogen (if any) is detected and classified, then relevant AMR genes can be identified 
(122). This step is necessary to help determine the choice of antibiotics used for the patient’s 
treatment. The most common approach involves identifying alignments of single reads against an 
antimicrobial resistance gene database. An alternative approach is using whole genome (single or 
metagenomic) assemblies, which can increase the accuracy of resistance gene identification 
(200). However, if sufficient sequencing depth is not achieved then whole genomes or accurate 
MAGs cannot be constructed and AMR genes cannot be identified. Nonetheless, the chosen 
approach should be able to identify all resistance mechanisms, i.e. acquired resistance genes 
(including variants) and chromosomal resistance genes (including mutational resistance) (122).  
Identifying the resistance gene host is difficult from metagenomic data. However, using long-
read rather than short-read sequencing technology, can identify the origin of chromosomal 
resistance genes, by identifying the pathogen based on the genomic flanking regions (122, 123). 
Plasmid borne resistance genes are particularly difficult to associate with their host, although 
long-read sequencing makes it easier to assemble plasmids and potentially provide some 
information about their likely host. However, this approach is likely to fail when considering 
promiscuous plasmids. 
Perhaps the most challenging part of CMg is trying to predict pathogen phenotype (resistance 
and/or susceptibility) from metagenomic data. This is because gene expression, permeability and 
efflux all make resistance and susceptibility more complex that just presence or absence of 
resistance genes. A number of groups are working on this problem. Brinda et al., developed 
RASE, a tool able to predict resistance and susceptibility of pathogens from nanopore 
metagenomic data in real time by identifying a pathogen’s closest relatives (143). This technique 
when used with k-mer matching, was able to determine resistance within four hours from sample 
collection for S. pneumoniae directly from respiratory metagenomic sequencing data. Ruppé et 
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al., took an alternative approach by using a knowledge-based algorithm for antimicrobial 
resistance genes detection (202). The algorithm was used on WGS data from Enterobacterales 
and predictions were confirmed by disc diffusion. The algorithm correctly predicted 963 
susceptibilities and 257 resistances (202).  
An example, of a mature CMg analysis pipeline is the sequence-based ultrarapid pathogen 
identification (SURPI), an automated computational tool developed by Naccache et al. (203). 
SURPI+ was developed for metagenomic data analysis such as pathogen identification and 
classification. Initially, the SUPRI+ pipeline offers data pre-processing, followed by human read 
removal and microbial classification via alignment against the NCBI Nucleotide (NT) database. 
Results are then visualised in a user-friendly graphical interface and are readily available for 
interpretation (136).  
EPI2ME, despite not being clinically validated like SURPI, is also another example of a mature 
tool with a graphical interface. Users of nanopore sequencing have access to EPI2ME, which 
consists of a desktop agent for uploading reads and a user-friendly web interface that offers a 
number of pipelines for real-time data analysis including pathogen identification and AMR gene 
detection. The Antimicrobial Resistance pipeline within EPI2ME allows pathogen identification 
by combining the WIMP (What’s In My Pot) pipeline and antimicrobial resistance gene 
detection with ARMA. WIMP uses the Centrifuge classifier (described before), to map reads into 
the RefSeq database for identification of bacteria, viruses and fungi (122). ARMA identifies 
AMR genes by mapping reads to the ‘CARD’ (Comprehensive Antimicrobial Resistance 
Database) database (204). Reads are aligned using minimap2 and any alignments reported are 
only over ONT-chosen default thresholds (described in 2.8.2). ARMA also offers the ‘clinically 
relevant’ parameter which currently reports only acquired and chromosomal resistance genes, but 
not resistance mutations/SNPs. This feature was designed by ONT and collaborators to allow 
61 
 
rapid identification of clinically relevant AMR genes and exclude reporting of resistance genes 
that would not provide useful information for designing antibiotic treatment (122).  
Another example of an automated tool is NanoOK RT, which is designed for microbial 
classification and AMR gene detection using nanopore data as input (123). NanoOK aligns 
sequence data against the NCBI nucleotide database for microbial identification and against the 
CARD database for resistance gene detection in real-time. This tool also provides an additional 
feature, which aligns the flanking regions of detected chromosomal AMR genes to match the 
gene’s pathogen origin (123).  
1.4.2 Databases used for diagnostic purposes 
  
Bioinformatic tools used for microbial classification and antimicrobial resistance gene detection 
using metagenomic data rely on databases containing either DNA sequences and their translated 
protein sequences or previously sequenced whole genomes. Therefore, the accuracy and 
sensitivity of the CMg pipeline relies on the comprehensiveness and accuracy of the database 
used. The NCBI Taxonomy database (http://www.ncbi.nlm.nih.gov/taxonomy) is the repository 
for the standard nomenclature and classification for the INSDC, (International Nucleotide 
Sequence Database Collaboration). The INSDC (205) also contains the main databases such as 
GenBank, (a DNA sequence database available since 1992), the European Molecular Biology 
Laboratory (EMBL) and dbSNP (used for single-nucleotide polymorphisms) (206) (Table 1.6).  
Microbial classification however, is challenging especially for closely related species in a genus 
and closely related genera which can lead to assigning the wring taxonomy ID. For example, 
species of the Shigella genus are often misclassified as Escherichia (and vice versa) due to the 
high genetic similarity shared between these two genera (>97% similarity). Another example is 
commensal and pathogenic Streptococcus spp. (207). Often even well-established approaches 
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(e.g. Mass spectrometry or PCR-based assays) misclassify non-pathogenic Streptococcus species 
as S. pneumoniae (99, 208). Classification can be improved if sufficient sequencing depth and 
genome coverage are obtained or by increasing microbial classification scores, but a 
phylogenetic approach is the best strategy for an accurate classification (122). The main 
molecular phylogenetic approaches (discussed below) either use a gene-by gene comparison 
(multi locus sequence typing (MLST)) or SNP-based comparison of closely-related genomes 
(209). A phylogenetic approach is often used for outbreak studies to enable the identification of 
genetic similarities amongst numerous genomes of the same pathogen, enabling the source of an 
outbreak and transmission patterns to be determined (209, 210). Additionally, using curated 
databases such as RefSeq can increase classification accuracy, as additional filters, such as 
eliminating fragmented assemblies, are used for every new entry (Table 1.6). RefSeq genomes 
are regularly updated (i.e. when new information/genomes are available), in contrast to 
GenBank, where even fragmented genomes can be uploaded (211) (Table 1.6).  
The chosen database also needs to reflect the purpose of the metagenomic study. This is 
particularly relevant for databases used for AMR gene detection. Databases used for AMR gene 
detection in CMg pipelines should only contain clinically relevant genes and their detection 
would provide useful information for targeted antibiotic treatment. A data-restricted database 
would make data interpretation easier and reduce computational time for searching through big 
databases (194). The Resfinder database (212) and the Comprehensive Antibiotic Resistance 
Database (CARD) are examples of this. CARD provides a comprehensive set of antibiotic 
resistance gene sequences and their protein sequence along with their targets (213). Equally, the 
ResFinder database contains an exhaustive range of resistance genes and both acquired resistance 
genes and chromosomal mutations are now available (213). The ResFinder database is curated 
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and contains characterized and peer-reviewed gene sequences, which makes it a more 
appropriate choice for providing more accurate matches. 
 
Table 1.6. Number of entries of draft and complete microbial genomes in the most commonly 





















GenBank 2677 17 0 19078 997 1 
RefSeq 2586 7 7073 11217 190 3 
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1.4.3 Bioinformatic workflows for public health applications 
As previously discussed, metagenomic data can also be used to generate whole pathogen 
genomes which can provide additional information beyond diagnostics (214, 215). Briefly, 
during the process of assembling genomes, reads are overlapped to create contigs, which are then 
joined to form scaffolds to later form full or partial genomes (216). The fundamental approaches 
to generating genome assemblies are overlap–layout–consensus (OLC) and de-bruijn-graph 
(DBG) (217). The OLC approach involves three steps; during the first step, all reads are 
overlapped (O) and in the second step a layout (L) of the overlapped-reads is formed which is 
then used in the third step to form the consensus sequence (C). During the DBG approach, firstly 
all sequencing reads, are chopped into short k-mers which are then used to form the DBG. The 
DBG-based algorithm then, uses the k-mers to infer the genome sequence on the DBG graph  
generated during the previous step (217). 
Additionally, the genome assembly can be generated either by using a reference genome as a 
guide for assembly (122, 218) or by a de novo (i.e. no reference is used to assemble the genome) 
strategy. When trying to identify novel organisms (not previously sequenced), de novo assembly 
would be most appropriate as through this approach the complete genome of the organism (not 
previously sequenced) can be reconstructed. Conversely, if the identified organism shares 
genetic similarities with previously sequenced genomes then a reference-based approach can be 
used to reconstruct the genome (186).  
For the reference-based approach a suitable reference closest to the organism in question should 
be used. A reference can be chosen based on the most closely related strain identified by 
metagenomic read classification. However, if a reference-based rather than a de novo approach is 
used then genomic variants would be lost (186). Pandora (https://github.com/rmcolq/pandora) a 
recently-developed tool, designed for both long and short-read data, although not designed to be 
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used for CMg data, can be used as an alternative approach to identify reference genomes for 
alignment based genome assemblies where the pathogen is known. This tool uses available 
genomes in databases to identify conserved regions and nucleotide-level and longer variants to 
create a pangenome reference graph. The graph is then used to identify which genome shares the 
highest similarities with the sequenced genome. By using this alternative approach, conserved 
and novel regions of the sequenced genome can be identified. 
Additionally, a number of tools have been recently developed using nanopore long reads for 
genome assemblies. Currently the main strategies followed for the reconstruction of genomes 
using long-reads are; the hierarchical method, the hybrid and the direct method - for a review of 
the approaches used for long-read genome assembly see (219). Canu a long-read assembler 
(220), uses the hierarchical approach and its pipeline consists of three stages: i) correcting (reads 
are build into overlaps and ‘best’ overlaps are selected for correction), ii) trimming (removes 
unsupported regions of the overlaps) and iii) the assembly stage (identifies any final sequencing 
errors and creates the best overlap used for contig construction) (220). Canu has been used to 
generate continuous sequences with high accuracy (220). Alternatively for a quick assembly, 
Miniasm can be used. Miniasm is an OLC-based de novo long-read assembler which implements 
the overlap (‘O’) and layout (‘L’) steps of OLC assemblers but not the consensus step (‘C’) 
during which the error rate is corrected by creating a consensus sequence (described before). 
Miniasm, overlaps mapped raw reads (typically produced by minimap2) for genome assembly 
and, as it does not have a correction step, it can assemble genomes within minutes. Despite, the 
possibility of an ultrafast assembly, read selection is performed crudely by Miniasm, meaning 
sequencing error rate is carried through, from raw data (221). To improve assembly accuracy 
however, Miniasm can be coupled with long-read correcting tools such as Racon (222). Hybrid 
assemblies typically provide more accurate assemblies as they benefit from the coverage 
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provided by long reads and the per-base accuracy of short reads (223). Unicycler (224) and 
SPAdes (225, 226) are hybrid assemblers and both can use long- and short- reads as an input. 
1.4.3.1 Molecular typing methods 
 
Once a genome has been assembled, additional analysis is performed which is dependent on the 
research question. In outbreak studies, transmission patterns and identifying the outbreak source 
are often paramount. Therefore, steps would be necessary to identify mutations, variants and 
conserved regions which will help characterise the genomic evolution of the pathogen in 
question and carry out phylogenetic analysis by microbial typing (122).  
Traditional microbial typing used cultivation, as a method to differentiate bacterial species, by 
identifying a number of phenotypic markers. Molecular typing, initially used a PCR-based 
approach, during which the DNA sequence of phenotypic markers is amplified which then was 
used to identify bacterial species. The use of PCR allowed the introduction of sequence-based 
typing (SBT). SBT-based phylogenetic approaches mostly used two approaches; MLST which 
targets a number of genes of the genome and SNP-based typing which uses SNPs to identify 
bacterial strains. The MLST-based approach is then subdivided into core-genome MLST 
(cgMLST) and whole-genome (wgMLST) (209).  
CgMLST uses genes of the core genome to identify genetic similarities between species and 
initially used a 7-gene target which later then increased to a bigger number of gene loci. During 
this approach, assembled genomes are aligned to schemes – schemes are consisted of allelic 
sequences of the targeted genes loci and their associated allelic numbers – in order to identify the 
allelic profile of the genome in question, leading to further identification of the sequence type 
(ST). WgMLST, on the other hand, utilises both accessory genes and genes of the core 
genome/s. Closely-related species are distinguished with higher resolution as genetic similarities 
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with this approach are calculated using a bigger set of gene targets (227, 228). However, various 
studies reported similar findings between the two approaches. Pearce et al., demonstrated that 
there was no significant difference in the findings of  wgMLST and cgMLST for the typing of S. 
enterica during an Enteritidis outbreak (229). In a practical setting, both approaches should be 
used - cgMLST to be used initially on a dataset of numerous species, followed by wgMLST 
typing of closely related strains based on cgMLST-findings (209). 
The SNP-based approach utilizes the different SNPs present amongst different strains. The 
genomes in question are aligned against a reference genome in order to identify SNPs that maybe 
present in the sequences (209, 230). Once SNP distance is determined (number of SNPs 
identified between the query genome and reference) then genetic similarity is identified – the 
smaller the SNP distance the higher the genetic similarity is between the query genome/s and 
reference sequence. The choice of the reference genome is important for SNP-based typing. The 
chosen reference needs to cover as many positions as possible of the query genome/s in order to 
increase likelihood of identifying all SNPs that may be present (209). A distant reference 
genome, increases the likelihood of identifying inaccurate SNPs, as more differences would be 
present between query and reference genome. A commonly used approach, is to choose a 
reference genome from the same serogroup as the query genome. An alternative approach for 
identifying the reference genome, is to estimate the distance of the ‘unknown’ genome/s against 
a dataset of ‘known’ closely related genomes (231, 232). Molecular typing using any of the three 
approaches has provided consisted results. The advantage of using cgMLST is that conserved 
genes are targeted, hence providing an accurate identification at the species level. Strains from 
the same species however, share high genetic similarity, differing only by a few mutations, 
making SNP-based typing the best approach for such purpose.   
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In outbreaks of Legionnaire’s disease for example, a cgMLST approach is commonly used to 
identify the sequence type (ST). An allelic profile is used from seven housekeeping genes 
conserved amongst L. pneumophila (233). The seven gene targets used are, flaA, pilE, asd, mip, 
mompS, proA and neuA. Once the allelic profile is determined (i.e. the allele of each gene is 
identified) then the ST is automatically identified (233-235). As previously discussed, the 
majority of SBT utilises data from WGS-based studies and studies utilising CMg data for 
molecular typing are limited.  
Metagenomic sequencing has been used to identify Legionella spp. from environmental samples 
in various studies (236-238) but limited attempts have been made to detect Legionella spp. from 
clinical samples. CMg was only recently tested directly on spiked sputum samples with mock 
communities, consisting of different quantities of human, L. pneumophila and three other 

















The overall aim of my study was to develop, optimize and evaluate a CMg pipeline that could be 
applied for the rapid diagnosis of lower respiratory infections (including pathogen identification 
and AMR gene detection) and for public health purposes (such as rapid identification and 





• To develop and optimize a method that would deplete ≥ 99.9% of human DNA from 
respiratory samples (sputum, BAL or endotracheal tube aspirates).   
• To combine the host depletion method with an efficient DNA extraction, followed by low 
input library preparation and nanopore sequencing. 
• Optimise a bioinformatic pipeline for analysing the nanopore metagenomic data and 
identifying of respiratory pathogens and associated resistance genes. 
• To make the CMg method as rapid, simple and cost-effective as possible. 
• To evaluate the analytical performance of the method using spiked respiratory samples. 
• To evaluate the clinical performance of the method for the diagnosis of LRTIs. 
• To assess whether the method could be utilised to characterise Legionella spp. in 







2.1 Ethical approval for sample collection 
 
Ethical approval for the collection of all excess respiratory samples was provided by the UCL 
Infection DNA Bank (REC reference 12/LO/1089). Excess respiratory samples from patients 
with suspected lower respiratory infections (persistent (productive) cough, bronchiectasis, 
CAP/HAP, cystic fibrosis and exacerbation of chronic obstructive pulmonary disease (COPD, 
emphysema/chronic bronchitis)) were collected for the development and optimization of the 
human depletion method. Excess respiratory samples were initially used to develop and evaluate 
the first version of the CMg pipeline (refer to as pilot samples and pilot study), then additional 
optimization and testing was done for the optimized and final version of the pipeline and samples 
used for this are referred to as streamline samples (described in 3.1). The optimized CMg 
pipeline was also implemented in the INHALE trial to evaluate the diagnostic performance of the 
pipeline for HAP and VAP – described in 3.2. For this excess respiratory samples from patients 
with VAP/HAP were used. 
For all samples (pilot, streamline and INHALE) microbiology results were collected (describing 
the pathogen(s) identified by routine microbiology and their antibiotic susceptibility profiles) and 
no patient identifiable information was collected, hence informed consent was not required.  
The optimised CMg pipeline was also tested for the characterisation of Legionella spp. – this 
study is described in 3.3 and is referred to as the Legionella study and samples are referred as 
Legionella samples. For the implementation of CMg for the Legionella pneumophila study 
excess Legionella-positive samples from the Respiratory and Vaccine Preventable Bacteria 
Reference Unit (RVPBRU), Public Health England (PHE) were used. Ethical approval was not 
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required, as for the Legionella study excess samples were collected and no patient identifiable 
information was collected. Microbiological and molecular-based typing results were collected 
only, such as the identified Legionnella species and sequencing type (ST). 
 
2.2 Sample collection and storage 
 
Excess respiratory samples (sputa, ETA, BAL) were collected and stored at 4 °C prior to testing 
for clinical metagenomics, after routine microbiology was performed (described in section 2.3) at 
the Norfolk and Norwich University Hospitals (NNUH) Microbiology Department. Samples 
were deemed as either positive (contain one or more bacterial pathogen(s)) or as negative 
samples (NRFs (normal respiratory samples, NG (no growth) and NSG (no significant growth)) 
by clinical microbiology. To develop and optimize the CMg pipeline, 24 sputum samples were 
used and 40 samples, (comprising 34 sputa, four BALs and two ETAs) were used to test the 
CMg method. The CMg pipeline was further tested on additional 41 samples (comprising of 38 
sputa, one BAL and 2 ETAs). For the INHALE study 73 fresh respiratory samples were used 
(comprising of 32 sputa, 9 BALs, 29 endotracheal tube (ETT) exudates, 2 tracheostomy tube 
exudates and 1 tracheostomy exudate) and for the Legionella study 48 excess frozen samples (38 





2.3. Microbiological investigation of respiratory samples  
 
2.3.1. Routine testing for suspected lower respiratory tract infections (NNUH Clinical 
Microbiology) 
  
Sputum and ETAs were treated with sputasol (Oxoid-SR0233) in a 1:1 ratio and were incubated 
for a minimum of 15 min at 37 C. Sputasol-treated samples (10 µL) were added into 5 ml of 
sterile water and mixed, making the limit of detection (LoD) of culture ~5 x 105 CFU/ml. Then, 
each sample was streaked onto blood, chocolate and cysteine lactose electrolyte deficient 
(CLED) agar (10 µL per plate). For samples coming from the intensive care unit (ICU), 10 µL 
sputasol-treated sample was plated with no water dilution. BALs were not sputasol treated like 
other respiratory sample types. Instead these samples (total volume of sample) were centrifuged 
to concentrate microbial cells for a minimum of 10 min at 3000 rpm. Then samples were plated 
directly onto the agar plates and no further dilution occurred prior to plating. Depending on the 
source of the sample and clinical information, other agar plates were also used, such as: 
sabouraud, mannitol salt and Burkholderia cepacia selective agar. All inoculated agar plates 
were incubated at 37 C overnight and then examined for growth with the potential for re-
incubation up to 48 hours. If any significant organism was grown, then antibiotic susceptibility 
testing by agar diffusion using EUCAST methodology was performed. The laboratory’s Standard 
Operating Procedure is based on the Public Health England UK Standards for Microbiology 






2.3.2 Routine testing for the identification and isolation of Legionella spp. (PHE, Colindale) 
 
All samples from patients suspected with Legionella infection were cultured as described below: 
All sputum samples were initially sputasol-treated (1:1 ratio) and centrifuged for 15 min at 1000 
rpm. After centrifugation the supernatant was removed and the pellet re-suspended in 1 ml of 
sterile water. Additionally, 250 µL was heat-treated for 30 min at 50 C to kill human cells. 
Plating out was on the following media:  
- Buffered Charcoal Yeast Extract (BCYE) – 100 µL neat and heat-treated sample 
- Buffered polymyxin anisomycin (BMPA) – 100 µL of neat and heat-treated sample 
- Buffered Charcoal Yeast Extract with Cefamandole (BCY-C) – 100 µL of neat sample 
Diluted (1:100) samples (both neat and heat-treated) were also plated out on BCYE and BCY-C 
agar. All plates were then incubated statically at 35-37 C for a maximum of 10 days. After 4 
days of incubation the plates are initial examined for growth followed by re-confirmation at 10 
days. 
DNA was extracted from all samples for additional PCR-based testing. DNA was extracted using 
200 µL of the non-heated sample and added to 200 µL Bacterial-lysis buffer and 20 µL of 
proteinase K followed by heat treating at 65 C for 10 mins and at 95 C for 30 min. The lysed 
sample was then processed on the MagNA Pure Compact 2.0 automated instrument using 
DNA_BacteriaV2 program.  
The DNA extract was then used for triplex PCR targeting the mip, gfp and wzm genes of L. 
pneumophila (only on culture-positive samples (≥1 cell identified)). For non-pneumophila 
culture-positive samples a PCR targeting the 16S rRNA and mip gene was performed on the 
DNA extract and amplicon (amplicons targeting the mip region only) are then subjected to 
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Sanger sequencing for confirmation of the cultured species (see Table 2.1A for all primer 
sequences and gene targets used). A nested PCR targeting the seven housekeeping genes (flaA, 
pilE, asd, mip, mompS, proA, neuA) was performed on the DNA extract on all culture-negative 
samples to obtain a profile on L. pneumophila that failed to grow on plates (see Table 2.1B for 
all primer sequences used for the nested PCR).   
In addition to these tests, sequence based typing (SBT) was also done on L. pneumophila 
colonies identified in culture-positive samples. For SBT L. pneumophila colonies were isolated 
and DNA was extracted via a chelex extraction and then SBT with Sanger sequencing was 
performed. Briefly for the chelex extraction a loopful of L. pneumophila culture was emulsified 
in ~1 mL of sterile distilled water, followed by a 5 min centrifugation at 12,000 xg. Then, 
supernatant was discarded and pellet was resuspended in 200 µL of Instagene matrix (BIO-RAD 
cat no 732-6030). Sample was incubated at 56 °C for 30 min and 100 °C for 8 min and after that 
was centrifuged at 12,000 xg for 5 min. 20 µL of the supernatant was transferred to a clean tube 
and 180 µL of TE buffer was added and the extract is then subjected to SBT. A negative 













primer        
(5’-3’) 
Reverse                 
primer             
(5’-3’) 












































CG – BHQ2 
(241) 
















Table 2.1B: PCR Primer sequences and gene targets used for the nested PCR assay for routine 
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2.3.3 Research laboratory culture growth conditions (UEA) 
 
All bacterial isolates (Haemophilus influenzae, Klebsiella pneumoniae, Stenotrophomonas 
maltophilia, Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus, Pseudomonas 
aeruginosa) and fungal isolate (Candida albicans) were grown aerobically at 37 ˚C overnight, 
either with orbital shaking at 180 rpm or statically with 5% CO2, in 10ml of an appropriate liquid 
growth medium (i.e. luria broth – LB, tryptic soy broth – TSB or brain heart infusion – BHI from 
Thermo Fisher Scientific ). Organism specific growth conditions are detailed in Table 2.2.  
 
Table 2.2: Growth conditions for microbial cultures used for mock community and LoD experiments 
 




Haemophilus influenzae Blood TSB 37 with 5% CO2 NO 
Klebsiella pneumoniae Blood TSB 37 YES 
Stenotrophomonas maltophilia Blood TSB 37 YES 
Streptococcus pneumoniae Blood BHI 37 with 5% CO2 NO 
Escherichia coli LB LB 37 YES 
Staphylococcus aureus LB LB 37 YES 
Candida albicans LB LB 37 YES 





2.4 Clinical sample and microbial DNA extraction and purification 
 
Cell pellets from clinical and bacterial samples were resuspended in bacterial lysis buffer (Roche 
UK- 4659180001) (380 µL pilot samples or 400 µL for streamline, INHALE and Legionella 
samples after bead-beating) and 20 µL of proteinase K (>600 mAu/ml) (Qiagen -19133) was 
added for microbial DNA extraction. Samples were then incubated for 5 min (for streamline, 
INHALE and Legionella samples) or 10 min (for pilot samples) at 65 °C shaking at 800 RPM. 
Following this, samples used for the Legionella study were subjected to a heat-killing step, 
which involved a 30 min incubation at 95 °C.  
DNA was then purified using the Roche MagNAPure Compact DNA_bacteria_V3_2 protocol 
(MagNA pure compact NA isolation kit I, Roche UK - 03730964001) on a MagNA Pure 
Compact machine (Roche UK - 03731146001). Briefly, during the purification, DNA binds to 
magnetic glass particles, which are then pelleted using a magnet. Cells debris is then removed 
using multiple washes. Finally, DNA is separated from the magnetic glass particles using high 
temperature and eluted into 50 µL elution buffer.   
 
2.5 DNA quantification and quality control 
 
The quality and quantity of extracted DNA was assessed as follows. 
2.5.1 DNA quantification 
 
DNA quantification was performed using the high sensitivity dsDNA assay kit (Thermo Fisher - 
Q32851) on the Qubit 3.0 Fluorometer (Thermo Fisher - Q33226) or the Broad Range (BR) 
dsDNA assay kit (Thermo Fisher - Q32850). In brief, 199 µL of the working solution (199 µL of 
79 
 
Quant-iT™ dsDNA HS buffer and 1 µL of Qubit® dsDNA HS Reagent or 199 µL of Quant® 
dsDNA BR buffer and 1 µL of Qubit® dsDNA BR Reagent) and 1 µL of sample DNA was used 
for sample quantification. For the fluorometer’s calibration, 190 µL of the working solution was 
used per standard and 10 µL of either standard 1 (Qubit® dsDNA HS Standard #1 or Qubit® 
dsDNA BR Standard #1) or standard 2 (Qubit® dsDNA HS Standard #2 or Qubit® dsDNA BR 
Standard #2) was used. After DNA and standards were added in the working solution, samples 
were vortexed briefly and incubated at RT for 2 min in the dark. Then standards and samples 
were quantified using the dsDNA High Sensitivity or the dsDNA Broad Range assay program.  
 
2.5.2 DNA fragment size and quality analysis  
 
DNA quality and fragment size were assessed using the TapeStation 2200 (Agilent Technologies 
- G2964AA) automated electrophoresis platform with the Genomic ScreenTape (Agilent 
Technologies - 5067-5365 and a DNA ladder (200 to >60,000 bp, Agilent Technologies - 5067-
5366). This step was mainly used to the test the quality of:  i) products after the library 
preparation PCR, ii) MinION libraries prior to sequencing and iii) to test DNA extracts after 
MagNA Pure extractions from the host-depletion optimisation experiments.  
In brief, 1 µL of template DNA or ladder were added to 10 µL of sample buffer (Agilent 
Technologies - 5067-5365). Samples were vortexed briefly and placed in the TapeStation. Gels 






2.6 Quantitative polymerase chain reaction assays 
 
Quantitative polymerase chain reaction (qPCR) was used throughout this study to quantify 
human and microbial DNA before and after host depletion.  
Controls were run with every qPCR assay (detailed in sections 2.6.1 and 2.6.2), this included a 
template negative (where the template was replaced with PCR-grade H2O) and a process 
negative (where the template was water processed in the same way as clinical samples - 
including differential cell lysis with saponin and microbial extraction) control.  
All qPCRs were performed using the LightCycler® 480 system (LightCycler® 480 Instrument II 
cat no 05015278001 Roche).  
The Roche master mixes used in this study utilize the FastStart Taq Polymerase modified from 
the thermostable Taq DNA polymerase for a hot-start PCR. High temperature-activated 
polymerases prevent non-specific primer binding, hence inhibiting non-targeted amplification 
providing higher specificity and sensitivity of the reactions.  
Sequences of primers and probes (and their gene targets) used in this study can be found in Table 
2.3. 
2.6.1 Probe based qPCR assays 
 
All probe-based qPCR master mixes consisted of the 2x master mix (LightCycler® 480 Probes 
Master cat no 04707494001 Roche). This master mix utilizes the FastStart Taq Polymerase 
(modified from the thermostable Taq DNA polymerase), for a hot-start PCR.  
Probe-based qPCR was performed to quantify human and microbial (Candida albicans, 
Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
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Moraxella catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae and S. pyogenes) 
DNA. The qPCR master mix contained (total volume of 20 µL):  
- 3.6-6.6 µL of PCR-grade H2O  
- 10 µL master mix (2x) 
- 0.5 µL 10 µM forward primer (final conc. 0.25 µM) 
- 0.5 µL 10 µM reverse primer (final conc. 0.25 µM) 
- 0.4 µL 10 µM hydrolysis probe (final conc. 0.2 µM) 
- 2-5 µL template DNA  
- PCR-grade H2O to make up the 20 µL total volume  
 
The qPCR conditions were as follows:  
- pre-incubation: 95 °C 5 min  
- amplification: 95 °C 30 sec 
 55 °C 30 sec                  
 72 °C 30 sec 
- final extension: 72 °C for 5 min. 
For all LoD experiments, 45 cycles were used instead to provide accurate Cq measurements at 
>35 Cq. The qPCR conditions described above were used throughout this study, except for 
confirmatory qPCR, for which reaction conditions were taken from Fukumoto et al. (98) which 
were:  




- amplification: 94 °C 15 sec 
  60 °C 1 min                 
 
2.6.2 SYBR green based qPCR assay 
 
All SYBR Green based qPCR assays consisted of the 2x SYBR Green master mix 
(LightCycler® 480 SYBR Green I Master cat no: 04 707 516 001 Roche) and were used to 
detect and quantify universal bacterial and Stenotrophomonas maltophilia DNA before and after 
host depletion. Universal bacterial DNA detection was achieved using the 16S rRNA V3-V4 
gene fragment and the 23S rRNA gene was used for S. maltophilia detection.  
For all SYBR green based qPCR assays, the master mix consisted of (total volume of 20 µL):  
- 6 µL of PCR-grade H2O  
- 10 µL master mix (2x) 
- 1 µL 10 mM forward primer (final conc. 0.5 µM) 
- 1 µL 10 mM reverse primer (final conc. 0.5 µM) 
- 2 µL template DNA  
PCR conditions were as follows:  
- pre-incubation: 95 °C 5 min,  
- amplification: 95 °C 30 sec  
 55 °C 30 sec                  
 72 °C 30 sec 





- Melt curve analysis was performed at 95 °C for 5 sec then 65 °C for 1 min (ramping to 95 °C at 







































































































































































2.7 Library preparation and MinION sequencing 
 
Sequencing libraries for singleplex and multiplex runs were prepared using the ONT low-input 
kits rapid kits (SQK-RLI001, SQK-RLB001, SQK-RPB004) with some modifications to the 
manufacturer’s instructions (modifications are detailed throughout section 3.1). 
The manufacturer’s instructions for singleplex sequencing with the SQK-RLI001 kit were as 
follows: 
Fragmentation/Tagmentation reaction:  
-  FRM: 2.5 µL 
- Template DNA:  ≤ 7.5 µL (≥ 10 ng)  
- Nuclease free water (NFW): <7.5 µL (to make up the 10 µL volume) 
The reagents were mixed by gentle flicking of the tube and were incubated at 30 °C for 1 min 
and at 75 °C for 1 min.  
PCR reaction was then performed on the tagmented DNA according to the manufacturer’s 
instructions: 
- 14 µL of nuclease free water (NFW)  
- 1 µL primer  
- 25 µL of 2x Long Amp Taq Polymerase (New England Biolabs – M0533S) 
- 10 µL tagmented DNA  
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The recommended PCR reaction conditions were:  
Initial denaturation 95 °C for 3 min, cycling conditions 14 cycles: denaturation at 95 °C for 15 
sec, annealing at 56 °C for 15 sec, elongation at 65 °C for 6 min and final extension at 65 °C for 
6 min.  
Multiplexed sequencing libraries were prepared using multiple iterations of the ONT rapid 
barcoding kit SQK-RLB001 and SQK-RPB001. This section will only describe the 
manufacturer’s instructions, modifications tested on these kits are described in section 3.1.  
Initially, the tagmentation/fragmentation reaction was set up as follows:  
- FRM: 1 µL 
- Template DNA:  ≤ 4 µL (= 5 ng)  
- NFW: < 4 µL (to make up the 5 µL volume) 
The reagents were mixed by gentle flicking of the tube and were incubated at 30 °C for 1 min 
and at 75 °C for 1 min (SQK-RLB001) or at 80 °C (SQK-RPB004) for 1 min.  
Then PCR reaction was set up for each sample separately as per manufacturer’s instructions: 
- 20 µL of nuclease free water (NFW)  
- 1 µL of rapid barcode primer (RPB1-12A)  
- 25 µL of 2x Long Amp Taq Polymerase (New England Biolabs – M0533S) 
- 4 µL template DNA  
 The recommended PCR cycling conditions were the same as the SKQ-RLI001 kit described 
above. 
Following the PCR reaction/s for singleplex and multiplex libraries, amplicon products were 
then subjected to a 0.6x AMPure XP (Beckman Coulter-A63881) bead wash. During the wash, a 
0.6:1 ratio of beads to DNA was added to the amplified DNA (i.e. 60 µL of beads and 100 µL 
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PCR product). Samples were mixed by pipetting and were incubated on the Hula Mixer 
(parameters: rotation speed 15 & timer 10; reciprocal tilting turning angle 45° & timer 5; 
vibration turning angle 5° & timer 5) for 5 min. Then samples were spun down (pulse) and were 
placed on a magnetic tube rack for 5 min to pellet the beads. The clear solution was then 
carefully removed and beads were washed with 500 μl ethanol (70%) for 30 sec. Ethanol was 
carefully removed and the wash was repeated. After the two ethanol washes, ethanol was 
carefully removed and tubes were left to air-dry on the magnetic rack with the cap open for 2-3 
min. 14 µL of the elution buffer (10 μl 50 mM NaCl, 10 mM Tris.HCl pH8.0) was added and 
incubated at room temperature for 5 min to elute DNA. Tubes were then placed back on the 
magnetic rack for 5 min to separate beads from the DNA. The eluted DNA was transferred to a 
clean tube and was prepared for MinION sequencing (described below). 
The MinION flow cell (either R 9.4.1 (FLO-MIN106 Oxford Nanopore Technologies) / R 9.5 / 
R. 9.4) was then inserted into the MinION device and the dry quality control (QC) step was 
done, by double clicking on “check flowcell” on the MinKNOW GUI (ONT). During the dry 
QC, the MUX scan begins, during which the flow cells pores are assessed and divided into four 
groups.  
After dry QC, the MinION library was prepared for sequencing as follows:  
1 µL Rapid Adapter (RAD for SQK-RLI001, RPR for SKQ-RLB001 and RPD for SQK-
RPB004) was added into 10 µL of bead-washed PCR products (consisting of 50-300 fmol). 
Solution was then mixed by gentle flicking and was incubated at room temperature for 5 min.  
After adapter ligation the library was prepared for MinION sequencing. The following reagents 
were thawed and mixed, then added in the following order with a final volume of 75 µL and 
mixed gently by pipetting (SQK-RPB004): 
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- 34 µL of sequencing buffer (SQB) 
- 25.5 µL of loading beads (LB) which were mixed just before use 
- 4.5 µL nuclease free water (NFW) 
- 11 µL of adapted DNA library  
(Libraries prepared using SQK-RLI001 and SQK-RLB001 used 35 µL of RBF (not SQB) 
and 3.5 µL of NFW instead). 
The library was then stored on ice, until it was loaded into the flow cell. The flow cell was then 
primed according to the manufacturer’s instructions, prior to loading the library. Firstly, the 
bubble was removed from the flow cell, by using a P1000 pipette, the tip was inserted into the 
priming port and a small volume of buffer was removed (<50 µL). Then through the same port 
800 µL of the priming mix (consisting of 1ml of Flush Buffer (FB) mixed with 30 µL Flush 
Tether (FLT) for SQK-RPB004; 480 μl of running buffer (RBF) and 520 μl of NFW for SQK-
RLI001 and SQK-RLB001) was added, with care to avoid the introduction of any air bubbles.  
After 5 min, the SpotON sample port was gently opened and 200 µL of priming mix was added 
in the priming port as described above. Then the mixed DNA library was added via the SpotON 
sample port in a dropwise fashion in order to ensure all the library was loaded into/on to the flow 
cell.  
After the library was loaded, a new experiment was set up, in MinKNOW. Experiment name was 
added, kit and sequencing duration was selected before the sequencing run was started.  
Once the flow cells temperature had reached 34 °C, a MUX scan was performed automatically, 
known as the wet QC, to check the pores after addition of the library. The MinION was run for 




2.8 Bioinformatics analysis 
 
Initial sequence processing was performed using the MinKNOW software (versions 1.4 -
18.12.9). This software was used to operate the MinION device but also allowed: i) raw data 
acquisition in real-time in FAST5 format and ii) basecalled raw data in real-time (raw FAST5 
files converted to base called FAST5 or FASTQ files). However, for this study, offline base 
calling was performed using Albacore (versions 1.2.2-2.3.4) or Guppy (versions 2.1.3-3.2.1 
(Guppy was used for base calling raw data for all Legionella samples only as Albacore was by 
this time discontinued)), offline tools provided by ONT. 
The command used to operate Albacore was:  
"c:/Program Files/OxfordNanopore/ont-albacore/read_fast5_basecaller.exe" -f 
FLO-MIN106 -k sequencing-kit-number --barcoding -o fastq --input 
‘path_to_input_folder’ -s ‘path_to_output’ -r -t 4 
The command used to operate Guppy was:  
guppy_basecaller --input_path ‘path_to_input_folder’ --recursive --save_path ‘path_to_output_folder’ --
flowcell FLO-MIN106 --kit sequencing-kit-number  
 
The output format used for downstream analysis was FASTQ reads. For the pilot study the first 
24 000 reads were used for this analysis, for the optimised and INHALE study the data produced 
within the first 2 hours of sequencing were analysed and for the Legionella study data after 24 





2.8.1 Human read removal  
 
Human reads were filtered out from FASTQ files using minimap2 (v2.6-2.10) to align to the 
human hg38 genome (GCA_000001405.15 “soft-masked” assembly) prior to EPI2ME and 
downstream analysis for pilot and streamline samples. Only unassigned (non-human) reads were 
exported to a bam file using Samtools (-f 4 parameter) and were converted back to FASTQ 
format using bam2fastx. These FASTQ files were processed for pathogen identification using 
WIMP (1.137-3.3.1), antibiotic resistance gene detection with ARMA (1.136-1.1.5) and for 




2.8.2 Real-time pathogen identification 
 
The EPI2ME desktop agent provided by ONT (versions 2.47-2.59.1896509) was used for initial 
data analysis for pilot, streamline and INHALE samples. The Antimicrobial Resistance pipeline, 
available on EPI2ME, was used for pathogen identification and antimicrobial resistance (AMR) 
gene detection (AMR gene detection is described below in 2.8.3). For pathogen identification, 
this pipeline utilizes WIMP which enables microbial identification including: bacteria, viruses, 
fungi, archaea and human reads (described in 1.4.1). 
 
Parameters used for pathogen identification were: 
- Minimum basecalling quality score: 7 (default of EPI2ME) 
- WIMP alignment q-score: >19 (available in the csv file) 
- Bacterial classified reads to be ≥1% of microbial reads 
 
2.8.3 Real-time AMR gene detection 
For the detection of antibiotic resistance genes for streamline and INHALE samples, ARMA 
(Antimicrobial Resistance Mapping Application – versions 1.136-1.1.5) was used. ARMA is also 
part of the Antimicrobial Resistance pipeline (described before in 1.4.1). AMR genes are 
identified by mapping reads using minimap2 against the ‘CARD’ database (204). Alignments 
over ONT-chosen default thresholds (>75% accuracy and >40% horizontal coverage) are only 
reported.  
Antibiotic resistance genes were recorded if  >1 gene alignment was present using the ‘clinically 
relevant’ parameter (described in 1.4.1) available in ARMA (rev. 1.1.5). As previously described 
this feature was designed by ONT in a collaboration with David Livermore, Vicky Enne and 
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Justin O’Grady to allow rapid identification of clinically relevant AMR genes and exclude 
reporting of resistance genes that would not provide useful information for designing antibiotic 
treatment. 
Comprehensive manuals explaining WIMP and ARMA are publicly available on the ONT 
website (https://nanoporetech.com/EPI2ME-amr).  
2.8.4 Offline data analysis  
Offline tools were used for the downstream analysis of the sequencing data. Downstream 
analysis included, pathogen identification using Centrifuge(198) and Supernatant for the 
Legionella study using default parameters (described below) and genome assemblies using 2 hrs 
and 48 hrs of sequencing data of streamline samples and 24 hrs of sequencing data for the 
Legionella study (described below). Offline data analysis was also performed for species specific 
gene analysis and timepoint analysis using 2 hrs of sequencing data.  
 
2.8.4.1 Bacterial genome assembly 
 
Reference-based genome assemblies were generated from metagenomic data as follows:  Firstly, 
using Albacore, raw FAST5 reads were basecalled to FASTQ reads. Reads shorter than 2000 bp 
and reads with a quality score <7 were filtered out using the Fastq-to-Fastq script within the 
Fast5-to-Fastq tool (https://github.com/rrwick/Fast5-to-Fastq). Porechop was then used to 
remove sequencing adapters located in the middle and/or at the end of DNA sequences and for 
multiplex runs, re-identification of barcodes was performed using the –b parameter (v0.2.3) 
(https://github.com/rrwick/Porechop). Next, minimap2(246) (v2.6-2.10) was used to map reads 
to a reference-genome (the reference-genome chosen was the strain of the pathogen with the 
most aligned reads reported by the EPI2ME AMR pipeline), using the default parameters for 
nanopore data (-a -x map-ont). Finally, Canu (220, 247)was used to generate a genome assembly 
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of the aligned reads, using the default parameters (v1.6). Comparison of the assemblies was 
performed using BLAST Ring Image Generator (BRIG) (248). 
Raw sequencing data (FAST5 reads) generated from the Legionella study (described in 3.3) were 
initially basecalled to FASTQ reads using Guppy and were used for de novo or reference-based 
genomic assemblies. For the de novo approach, initially Legionella spp. reads were classified 
using the basecalled FASTQ reads with Centrifuge (centrifuge_index_oct2018 was used with 
default parameters). Then using Supernatant, Centrifuge-classified Legionella spp. reads with a 
centrifuge score >300 were extracted and used for genomic assemblies with Canu (described 
above) and for pathogen identification.  
For the reference-based approach, basecalled FASTQ reads were mapped against a concatenated 
reference containing all complete genomes of L. pneumophila available on NCBI using 
minimap2 as described above. Aligned reads were then used to generate a genome assembly 
using Canu as described above.  
 
  2.8.4.2 Species-specific gene analysis and timepoint analysis 
 
Species-specific gene alignments were performed throughout this study, to confirm the presence 
or absence of organisms identified by the metagenomic analysis which were not previously 
reported by culture. Genes used for this analysis are specific for the bacterial species in question 
and were chosen from a literature search of targets used in peer-reviewed qPCR assays for 
pathogen/s in interest (Table 2.4). For this analysis, reads from the first two hours of sequencing 
for the streamline samples (after human DNA removal for the streamline samples only) and the 
INHALE samples were aligned to species-specific genes. 
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For streamline samples this analysis was carried out for samples positive for H. influenzae or S. 
pneumoniae by metagenomics only (culture-negative for these pathogens). For INHALE samples 
this analysis was done for any pathogen identified by metagenomics but not identified by culture 
or either of the two multiplex PCR platforms.  
This analysis was performed only for pathogens that had read numbers above the chosen thresholds 
for pathogen identification (described in 2.8.2). Minimap2 was used to generate alignments as 
described above and the number of mapped reads were visualized using qualimap. If a sample 
contained >1 alignment of the specific gene tested, then it was considered as a true positive sample 






Table 2.4: Species-specific genes and their targets  
Pathogen Gene Encoded Protein 
Accession 
number 
Escherichia coli cyaA Adenylate cyclase NC_000913.3 
Streptococcus agalactiae cfb CAMP-factor NC_004116.1 
Streptococcus pneumoniae ply pneumolysin NC_003098.1 
Haemophilus influenzae siaT 
Sialic acid TRAP 
transporter permease 
DQ054471.1 




Stenotrophomonas maltophilia smeT 
transcriptional regulator of 
SmeDEF efflux pump 
AY450955.1 




Klebsiella pneumoniae mdh Malate dehydrogenase ACI09474.1 
Klebsiella oxytoca pheX Polygalacturonase AAL49975.1 






2.8.4.3 Multi-locus sequence typing analysis 
 
A Legionella pneumophila typing scheme containing 2837 L. pneumophila ST and all known 
alleles IDs of the seven L. pneumophila housekeeping genes - flaA, pile, asd, mip, mompS, proA, 
neuA, was used for the MLST analysis (scheme generated by Natalie Groves, PHE).  
Metagenomic sequencing data from L. pneumophila positive samples were used for multi-locus 
sequence typing (MLST) analysis either using Mlst (https://github.com/tseemann/mlst) or 
Krocus (249). For the Mlst tool (v.2.x), genome assemblies generated (de novo or reference-
based described in 2.8.4.1) were used to determine the pathogen’s sequence type (ST) using 
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default parameters. For Krocus, L. pneumophila FASTQ reads either classified by Centrifuge or 
identified by mapping against the concatenated reference (both described in 2.8.4.1) were used 
for sequence-based typing (SBT) with default parameters. 
 
2.9 Declaration of contribution  
 
In this study everything, including samples processing and data analysis was carried out by 
myself, Themoula Charalampous, except for the following:  
- Antibiotic resistance gene analysis for streamline samples was done by Professor David 
Livermore. 
- Time-point analysis of streamline sample set (S1 and S16) was done by Dr. Gemma Kay 
(described in 2.8.4.2) 
- Human depletion and sequencing of 23 samples included in the Legionella study were 
performed by Jessica Day (PHE).  
- The molecular pipeline (described in 2.8.4.3) including Supernatant (described in 2.8.4) 
used for MLST analysis for the Legionella study was designed by Natalie Groves (PHE) 











3.1 Development, optimization and testing of a clinical metagenomics 
pipeline with a host depletion method for the diagnosis of LRTIs  
 
 
A purulent sputum sample typically contains about 1 million leukocytes per mL and a pathogen 
load ranging anywhere from 103-109 CFU/mL. Therefore, at best, the human:pathogen DNA 
ratio is approx. 1:1 and at worst is approx. 103:1. Hence, as previously discussed,  in  order for 
implementation of clinical metagenomics to be feasible in terms of cost and time, host depletion 
is necessary, to allow detection of pathogens and resistance genes in a rapid timeframe using 
metagenomic sequencing.  
According to the literature saponin had been mostly used for red blood cell (RBC) lysis, as it 
forms pores by interacting with cholesterols present on RBCs. Recently the lytic abilities of 
saponins have also been tested on other human cells such as leukocytes. Various saponin-based 
methods have been developed for the lysis of human cells followed by the depletion of human 
DNA, however the method originally developed by Zelenin et al. (177) and modified by 










3.1.1 The effect of different saponin concentrations and incubation times on host depletion  
 
Firstly, we aimed to test the saponin-based host depletion as published to assess its depletion 
efficacy on respiratory samples. The saponin-based depletion method was performed as follows:  
Sputasol-treated sputum samples (250 µL) were centrifuged at 8000 xg for 5 min, after which the 
supernatant was carefully removed and the pellet resuspended in 250 µL of PBS. Saponin 
(Tokyo Chemical Industry- S0019) was added to a final concentration of 1.43% (100 µL of 5 % 
saponin), mixed well and incubated at room temperature (RT) for 3 min to promote host cell 
lysis. Following this incubation, 350 µL of water and 10.5 µL of 5 M NaCl was added to deliver 
an osmotic shock, lysing the damaged host cells. Samples were next centrifuged at 4000 xg for 5 
min, with the supernatant removed and the pellet resuspended in 43 µL of PBS.  5 µL of 10X 
Turbo DNase buffer (ThermoFisher – AM2238) was added with 2 µL Turbo DNase 
(ThermoFisher – AM1907) and incubated for 15 min at 37 °C. Finally, the host-DNA depleted 
samples were washed three times with decreasing volumes of PBS (250 µL, 100 µL, 50 µL). 
After each wash, the sample was centrifuged at 6000 xg for 3 min, the supernatant was discarded 
and the pellet was resuspended in PBS. This was followed by nucleic acid extraction and 
purification was followed as described in section 2.4. DNA quantification and quality control 
was performed after extraction (described in 2.5). Also, host depletion and bacterial loss/gain 
were monitored using qPCR assays (described in 2.6). These steps were always performed unless 
otherwise stated.  
This version of saponin-based protocol by Anscombe et al. (178) was initially tested on four 
excess sputum samples. Undepleted controls (where DNA extraction was performed after initial 
spin without host depletion), were included to determine the level of host depletion (sputum 
samples used for the optimization of the host depletion are referred to as test samples – T). Host 
depletion was observed at ≥5.8-fold in T1 and T2 but was <2-fold in T3 and T4 samples (Table 
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3.1). To further increase this level of host depletion, increased saponin concentration (10%) and 
various saponin incubation times (3, 5 or 10 min) were tested. Also the following modifications 
were made to the protocol described above: 
- 400 µL of sputasol-treated sputum sample were processed instead of 250 µL to increase 
microbial yield 
- 200 µL of saponin was used instead of 100 µL in order to be 1:1 ratio of sample to 
saponin 
A ~5 fold of host depletion was observed with 4.44% saponin as the final concentration but the 
saponin concentration which gave the greatest host depletion (>74-fold) with no bacterial loss, 
was 2.22% saponin final concentration (Table 3.2). No significant microbial loss was observed 
with either of the saponin incubation times (5 or 10 min). However, some bacterial loss was 
observed in the samples tested with a 4.44% final saponin concentration. Hence, for all further 
host depletion experiments, the longer incubation time (10 min) with 2.22% saponin was chosen, 





Table 3.1: Human and bacterial DNA qPCR results for sputum samples processed with the 
original saponin-based protocol. 
 
Sample Human qPCR assay (Cq) 
Human DNA depletion 
(ΔCq) 
T1-Undepleted control 20.61 
2.92                                  
(7.6 fold) 
T1-Depleted  23.53 
T2-Undepleted control 20.11 
2.56                                    
(5.8 fold) 
T2-Depleted 22.67 













Table 3.2: Human and bacterial DNA qPCR results for sputum samples processed with different 








16S rRNA gene 
V3-V4 fragment 
qPCR assay (Cq) 
Bacterial DNA 




23.52 - 21.93 - 
Original saponin 
depletion (1.43% 
+ 3 min) 
24.28 






(2.22% + 5 min) 
29.82 






(2.22% +10 min) 
29.72 






(4.44% + 5 min) 
26.78 
3.26                 
(9.57 fold) 
25.89 
3.96                    
(15.5 fold)  
Saponin depletion 
(4.44% + 10 min) 
25.92 
2.4                 
(5.27 fold) 
23.16 





3.1.2. Optimisation of the nuclease treatment 
 
The nuclease treatment was optimized to increase host DNA depletion efficiency and remove 
digested/degraded host DNA. Initial method development utilized Turbo DNase but previous 
research (within the O’Grady group) had shown HL-SAN DNase was more efficient and robust 
when using clinical samples. Hence, the HL-SAN DNase was tested against the Turbo DNase in 
two sputum samples (T5 and T6) and was further tested on three additional sputasol-treated 
sputum samples (T7, T8 and T9) (Table 3.3). For the HL-SAN DNase treatment the following 
conditions were followed:  
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- 5 µL of HL-SAN DNase was added with 100 µL of PBS and 100 µL of HL-SAN buffer 
(5.5 M of NaCl and 100 mM MgCl2 in 50 ml of H2O) and samples were incubated at 37 
°C for 15 min shaking at 800 RPM.  
Also, along with the change of DNase, only one PBS wash was performed instead of three to 
streamline the method as follows: 
- 300 µL of PBS was added and centrifuged at 6000 xg for 3 min  
DNA extraction and purification was followed as described in 2.4 (for pilot samples). 
 
The use of HL-SAN resulted in better depletion compared to the Turbo DNase in both samples 
(Table 3.3). Bacterial loss (7-fold) was observed in T5 but very little loss was observed in the 
other samples. The removal of host nucleic acid was variable amongst the three remaining sputa 
- 209.38 fold depletion of human DNA was observed in T7 but only 8.6 fold difference was 
observed in T9 (Table 3.3). Despite the variable results, due to the improved efficiency of host 
















16S rRNA gene 
V3-V4 fragment 











6.01                    
(64.4 fold) 
35 





8.44                 
(347.3 fold) 
35 




24.04 - 21.48 - 
T6-Depleted 
(Turbo) 
25.77 1.73                         
(3.31 fold) 












24.13 7.71                   
(209.38 fold)          
23.92 1.2 




























Next, we aimed to further improve host depletion without affecting bacterial cells. Therefore, we 
optimised different steps of the depletion method as follows:  
- After initial 15 min DNase treatment, 2 µL of HL-SAN DNase was added and sample 
was incubated for a further 15 min at 37 °C with shaking at 800 rpm. The second DNase 
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treatment was added to improve digestion of human nucleic acid. 
- The three PBS washes (with higher volumes) were re-introduced after the DNAse 
treatment as based on experiments above we believed the addition of more than one 
washing step would facilitate to the removal of more host nucleic acid. For this step 
sample was washed three times with decreasing volumes of PBS (300 µL, 150 µL, 50 
µL). After each PBS wash,  sample was centrifuged at 6000 xg for 3 min, supernatant 
was carefully removed and pellet was re-suspended in decreasing volumes of  PBS. DNA 
was extracted and purified as described in 2.4 (for pilot samples).  
 
These changes to the depletion protocol were initially tested separately on two sputum samples - 
T10 and T11 (Table 3.4). Efficiency of host depletion was compared against the version of the 
method used for  T7-T9 samples (with HL-SAN DNase). The addition of the three washing steps 
had a minor improvement in host depletion in T11 (25.8 fold versus 8.8 fold with the previous 
version) but it was less efficient in T10 when compared with the previous version (78.2 fold 
versus 184.8 fold). The extended DNAse treatement also showed a similar trend in the two 
samples tested when compared with the older version – an improvement was observed in T11 
(53.82 fold vs 8.8) but not in T10 (153.27 fold vs 184.8 fold) (Table3.4). We then combined 
these two steps and tested on two more sputum samples (T12 and T13) to see if their 
combination could increase the removal of host nucleic acid (Table 3.4). The combination of the 
extended DNase treatment and the washing steps increased host depletion up to 99.9% or ~103 
fold without any bacterial loss. In T12 a >349.7 fold of host depletion was recorded and a 1871.5 






Table 3.4: Human and bacterial DNA qPCR results for respiratory samples processed with an 








16S rRNA gene 
V3-V4 fragment 







24.85 - 19.53 - 
T10-Depleted 32.38 
7.53                 
(184.8. fold) 
20.64 





7.26             
(153.27 fold) 
20.63 





6.29                
(78.2 fold) 
20.73 




23.85 . 23.58 . 
T11-Depleted 26.99 













































3.1.3 Optimization of low input library preparation to enable sequencing of low biomass 
clinical samples  
 
Clinical samples after host depletion have very low DNA concentrations (often <0.01 ng/µL), as 
the majority of human nucleic acid is removed and mainly only microbial DNA remains. When 
this research was being performed, the library preparation kits available by ONT required a high 
amount of input DNA (>200 ng). However, in early 2017 ONT released a low input kit (that 
followed a similar principal as the Nextera XT DNA library prep kit) that required a minimum 
10 ng of DNA, which enabled sequencing of low-biomass samples. The first version of the 
protocol, which enabled low-input DNA singleplex sequencing (SQK-RLI001), included a 
tagmentation step, during which DNA was enzymatically fragmented and tagged simultaneously. 
Long range PCR was then performed using a primer complementary to the tag added during 
tagmentation step.  
 
Samples T10 (3.86 ng/µL) and T11 (2.96 ng/uL) were prepared for singleplex sequencing using 
the RLI001 kit to test if sequencing was possible after host depletion, according to the 
manufacturer’s instructions (as described in 2.7) except PCR cycles were increased from 14 to 
20 to increase yield and sensitivity.  Sequencing was successful for both samples that were 
processed with the altered SQK-RLI001 workflow producing >1.2 million reads for T10 and 
>1.8 million reads for T11 (>99% were passed reads in both samples) after 48 hrs of sequencing 









produced after    
48 hrs  
Total passed* 









































*passed reads had ≥7 quality score (Q score) and failed reads had Q score of <7. 
 
 
Singleplex metagenomic sequencing of clinical samples is not cost-effective as the flowcell cost 
is high (min £400). Sequencing multiple samples on a single flowcell, therefore, would 
significantly decrease overall cost. Shortly after the release of RLI001, ONT released the SQK-
RLB001 kit, which allowed multiplex sequencing (up to 12) of low-biomass samples. It works 
using the same principal as the RLI001 kit, with the addition of barcodes to the primers used to 
amplify the tagmented library. The barcodes are produced with click chemistry at the 5’ ends to 
enable rapid sequencing adapter attachment. 
We then tested the SQK-RLB001 kit for multiplex sequencing of respiratory samples. For initial 
testing, DNA from depleted samples T14, T15, T16 was prepared using the both RLI001 and 
RLB001. DNA concentrations of PCR products using the multiplex kit were between 0.6-2.56 
ng/µL in contrast to the singleplex kit which gave yields of 7-23 ng/µL using the same amount of 



















T14 6.9 7.72 1.56 
T15 0.218 9.44 0.672 
T16 10.7 23.6 2.56 
 
*SQK-RLB001 is the multiplex kit and SQK-RLI001 is the singleplex kit 
 
Hence, in order to increase the sensitivity of the multiplex PCR reaction using the rapid 
barcoding kits (SQK-RLB1001 and later SQK-RPB004), the following changes to the protocol 
were made:  
- the number of cycles was increased from 20 to 25  
- 2.5 µL of tagmentation enzyme (FRM) instead of 1 µL was added and volume of the 
tagmentation reaction increased from 4 µL to 10 µL (as in RLI001).  
- the volume of the PCR reaction was doubled (50 µL of the 2x PCR mix, 2 µL of 
barcode primer, 10 µL tagmented DNA and 38 µL water) to reduce inhibition 
caused by the sputum DNA. 
- a bead-based DNA washing step was introduced prior to library preparation (the 
same bead wash described in 2.7 except using 1.2x beads to DNA volume) again to 




The increase in the number of PCR cycles and reagent volume was first tested separately (using 
DNA from sputum samples T17, T18, T19) and then these changes were combined with the 
bead-wash and were tested on five clinical samples (T20, T21, T22, T23,T24). Increasing the 
number of cycles and reagent volume improved the yield and PCR sensitivity (a 3.6 fold increase 
in DNA yield was observed in T18) but not in all samples tested (Table 3.7). However, the 
addition of the bead-washing in combination with the increased number of PCR cycles, FRM 
and PCR reaction volumes showed the biggest improvement in the multiplex PCR reaction. The 
optimized method was tested against the SQK-RL001 singleplex PCR on five host-depleted 
respiratory samples. DNA concentrations of PCR products were between 43-58 ng/µL for the 
multiplex PCR and 1-18 ng/µL for the singleplex PCR using the same amount of input DNA 
(Table 3.8).   
 










PCR with SQK-RLB001 
(ng/µL) 
T17 12.6 19 1.01 
T18 10.3 27.2 98.6 
T19 2.28 3.86 0.88 
 
*with increased number of cycles and reagents volume 


















PCR with SQK-RLB001 
(ng/µL) 
T20 0.228 3.54 45.6 
T21 0.598 1.15 46 
T22 2.84 18.6 58.6 
T23 1.19 9.1 43.8 
T24 3.1 1.05 52.8 
 
*no bead-wash, ^with bead-wash, +SQK-RLB001 is the multiplex kit and SQK-RLI001 is the 
singleplex kit. 
 
3.1.4 Testing of the pilot clinical metagenomics pipeline  
 
The performance of the optimized host depletion and low-input multiplex library preparation 
method, i.e. the pilot clinical metagenomics (CMg) pipeline (Figure 3.1), was evaluated in a pilot 
study on 40 respiratory samples from patients with suspected bacterial LRTIs.  
Respiratory samples (400 µL) were centrifuged at 8000 xg for 5 min, after which the supernatant 
was carefully removed and the pellet resuspended in 250 µL of PBS. Saponin (Tokyo Chemical 
Industry- S0019) was added to a final concentration of 2.22% (200 µL of 5% saponin), mixed 
well and incubated at room temperature (RT) for 10 min to promote host cell lysis. Following 
this incubation, 350 µL of water was added and incubation was continued at RT for 30 s, after 
which 12 µL of 5 M NaCl was added to deliver an osmotic shock, lysing the damaged host cells. 
Samples were next centrifuged at 6000 xg for 5 min, with the supernatant removed and the pellet 
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resuspended in 100 µL of PBS. HL-SAN buffer (5.5 M NaCl and 100 mM MgCl2 in nuclease-
free water) was added (100 µL) with 5 µL HL-SAN DNase (25,000 units, Articzymes - 70910-
202) and incubated for 15 min at 37 °C with shaking at 800 RPM for host DNA digestion. An 
additional 2 µL of HL-SAN DNase was added to the sample, which was then incubated for a 
further 15 min at 37 °C with shaking at 800 RPM. Finally, the host-DNA depleted samples were 
washed three times with decreasing volumes of PBS (300 µL, 150 µL, 50 µL). After each wash, 
the sample was centrifuged at 6000 xg for 3 min, the supernatant discarded and the pellet 
resuspended in PBS. After the final wash step of the host depletion, nucleic acid extraction 
purification was followed as described in section 2.4.  
 
Library preparation was then followed either for singleplex using the SQK-RL001 (described in 
2.7, but with 20 cycles were used instead of 14) or for multiplex runs using the SQK-RLB001 
(described in 2.7) but with applying the final changes tested (the addition of the 1.2x bead wash 
after DNA extraction and the increase of PCR cycles and reaction volume - described in 3.1.3). 
After the PCR reaction, adapter ligation, preparation of library for sequencing and MinION 
sequencing was followed as described in 2.7.  
 
Data analysis was performed using ~24,000 reads, including base-calling of raw data, human 
read removal and real-time pathogen detection using the WIMP pipeline as described in 2.8.1-
2.8.3. The WIMP parameters described in 2.8.2 were applied for pathogen detection, as initial 
analysis revealed that thresholds were necessary to improve the accuracy of metagenomic 
pathogen detection. The chosen parameters for WIMP pathogen identification were used: i) to 
remove misidentified reads introduced through the pipeline or ii) to remove reads arising from 




The pilot CMg pipeline (Figure 3.1) was tested on 40 respiratory samples (34 culture-positive 
samples and 6 culture-negative samples), from patients with suspected bacterial LRIs previously 
tested by clinical microbiology (described in 2.3.1).  Up to 99.9% or ~103 fold (median 352-fold, 
interquartile range 144-714; maximum 1024-fold) of host nucleic acid was removed using 
saponin depletion described above, as measured by qPCR (described in 2.6) and the overall 
turnaround time from sample to result (pathogen identification) was eight hours.  
CMg detected the correct pathogen in 31/34 culture-positive samples tested. This included single 
bacterial infections (27/28) and samples with mixed bacterial infections (4/6). Single bacterial 
infections reported correctly by metagenomics were: five coliform infections (P1, P5, P6, P7 and  
P11), two P. aeruginosa infections (P22 and P32),  seven H. influenzae (P8, P9, P24,P25, P27, 
P29 and P35), six S. aureus infections (P15, P16, P23, P39 including two MRSA cases in P10 
and P38), two K. pneumoniae infections (P12 and P21), three S. pneumoniae infections (P30, 
P33 and P36), one E. coli infection (P13) and one M. catarrhalis infection (P26) (Table3.9). 
Mixed bacterial infections correctly identified by metagenomic sequencing were: K. pneumoniae 
and E. cloacae in P14 and two H. influenzae and S. pneumoniae infections confirmed in P28 and 
P40. Metagenomics was also in agreement with routine microbiology for all of the six culture-
negative samples (P2, P4, P17, P18, P19 and P20) as no additional pathogens were identified 
above our chosen thresholds.  
Three pathogens in 3/34 sequenced positive samples were missed by metagenomic sequencing. 
These included mixed infections in 2/3 samples, where one of the two pathogens present was not 
detected by the pilot method – specifically, S. pneumoniae in P3 and H. influenzae in P37 were 
missed and a reported S. aureus missed in P34 (Table 3.9).  
In 5/40 sequenced samples additional potential pathogens were detected, but were not previously 
reported by microbiological culture. These included, H. influenzae detected in P22 and P30; M. 
113 
 
catarrhalis in P8; E. coli in P14 and K. pneumoniae and M. catarrhalis in P29 (Table 3.9). Based 
on these results the pilot pipeline was 91.2% sensitive (95% CI; 75.2-97.7%) and 100% specific 
(95% CI; 54.07-100%) when additional organisms identified in culture-positive samples were 































             Sample 
Pathogen cultured by 
microbiology 
Pathogen identified from 
metagenomic pipeline 
P1 Coliform* P. mirabilis 







P4 NRF None 
P5 Coliform* E. coli 
P6 Coliform* K. pneumoniae 
P7 Coliform* S. marcescens 
P8 H. influenzae 
H. influenzae 
M. catarrhalis 
P9 H. influenzae H. influenzae 
P10 MRSA MRSA 
P11 Coliform* E. coli 
P12 K. pneumoniae K. pneumoniae 








P15 S. aureus S. aureus 
P16 S. aureus S. aureus 
P17 NRF None 
P18 NRF None 
P19 NRF None 
P20 NRF None 
P21 K. pneumoniae K. pneumoniae 
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P23 S. aureus S. aureus 
P24 H. influenzae H. influenzae 
P25 H. influenzae H. influenzae 
P26 M. catarrhalis M. catarrhalis 
























P32 P. aeruginosa P. aeruginosa 
P33 S. pneumoniae S. pneumoniae 
P34 S. aureus  
P35 H. influenzae H. influenzae 







P38 MRSA MRSA 








3.1.5 Optimization of the clinical metagenomics protocol   
 
Next we aimed to improve the sensitivity (8.8% false negative rate) of the pilot CMg pipeline.  
Therefore, we sought to improve bacterial cell lysis to ensure difficult-to-lyse pathogens (e.g. S. 
aureus) were not missed, while refining the method to reduce the turnaround time without 
affecting clinical sensitivity. 
The following lysis methods were tested:  
- a bead-beating step - - pelleted samples after the PBS washes were re-suspended in 
BLB (500 µL), transferred to a bead-beating tube and bead-beaten at maximum 
speed for 3 min in a Tissue Lyser bead-beater.  
- the addition of an enzyme cocktail 
The following changes were made for streamlining the host depletion method:  
- the second DNase treatment was removed and one round of DNase treatment was 
done instead where 10 µL of HL-SAN DNase was added instead and a single 15 min 
incubation was carried out with at 37 °C  
-  the number of washes was reduced to two with increasing volumes of PBS (800 µL 
and 1 ml).  
The lysis methods were tested separately and combined with changes for reducing turnaround 
time. Two culture-positive sputa, one containing S. aureus (Gram-positive) and one containing 
P. aeruginosa (Gram-negative) previously processed by routine microbiology (as described in 
2.3.1), were used to test the efficiency of the host depletion method and qPCR results were 
compared to the pilot method (described in 2.6).   
Neither pre-treatment (enzymatic cocktail or bead-beating) affected the bacterial DNA yield in 
the P. aeruginosa sample. The enzyme cocktail increased the amount of bacterial DNA in the S. 
aureus sample by approx. 3-fold, and the bead-beating step by 21-fold, compared with the pilot 
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method (Table 3.10), as determined by 16S rRNA qPCR. The increased bacterial yield in the 
bead-beaten S. aureus sample was likely to have been associated with improved lysis of S. 
aureus, as the pathogen dominated the bacterial community (approx. 80% of reads) present in the 
sample. Also, changes made to streamline the method, reduced turnaround time of the host 
depletion from 90 to 50 min without affecting human DNA depletion as compared to the pilot 
method (Table 3.10). Hence, based on these results, the streamlined host depletion method with 

















Table 3.10: Comparison of bacterial DNA extraction methods using qPCR. 
 
 


























































































12.18 0.12 27.95 0.03 
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Turnaround was cut down more by reducing the library preparation PCR extension time from six 
to four minutes. Sensitivity of the PCR reaction with a four minutes extension was compared 
against the previously used reaction (six minutes extension) as described in 3.1.3. Microbial 
communities were also determined (as described in 2.8.2) to investigate if the change in the 
extension time would affect the microbial community after sequencing. No significant changes 
in the microbial community profile (organisms with ≥0.5% classified reads) were observed 
between libraries produced with four and six-minute extension times. The only differences 
observed were in the abundance of minor members of the community and a reduction in average 


















































































The changes (described above) for improving bacterial lysis, streamlining host depletion and 
reducing duration of the PCR reaction of the library preparation were all combined for the final 
version of the CMg pipeline (the optimised CMg pipeline). The differences in the final version of 
the optimised CMg pipeline (Figure 3.1) from the pilot pipeline are summarized below:  
 
i) After the first centrifugation, up to 50 µL of supernatant was left for the saponin treatment so 
as not to disturb the pellet (final saponin conc. 2.2-2.5%).  
ii) One round of DNase treatment was done where the amount of HL-SAN DNase was increased 
to 10 µL and a single 15 min incubation was carried out with the same conditions as before (37 
°C with shaking at 800 RPM)  
iii) The number of washes was reduced to two with increasing volumes of PBS (800 µL and 1 
mL).  
iiii) After the final wash, the pellet was re-suspended in 500 µL of bacterial lysis buffer and 
bead-beaten for 3 min. The bead-beaten sample was centrifuged at 20,000 xg for 1 min and ~230 
µL of supernatant was transferred to a fresh tube for DNA extraction.  
 
In total these alterations reduced the metagenomic library preparation to 2.5 hrs with an overall 
turnaround time of less than four hours before DNA sequencing. Total turnaround to results was 











Figure 3.1: Schematic representation of the optimised and pilot metagenomics pipeline.   
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3.1.6 Limit of detection experiments 
 
The LoD of the optimised clinical metagenomics pipeline was determined for the detection of 
one Gram-positive and one Gram-negative bacterium in sputum. Commensal microbial 
communities vary in composition and abundance in sputum samples and this may affect the 
sensitivity of detection of pathogens. Hence, while performing LoD experiments, we chose 
sputum samples from the clinical microbiology lab that tested negative for pathogens (normal 
respiratory flora, NRF, samples) with different abundance of normal flora (as determined by 16S 
qPCR) to see how this would affect detection of pathogens spiked at different concentrations. An 
NRF sample with a confirmed high bacterial background (22 Cq with the 16S rRNA qPCR 
assay) and a NRF sample with a confirmed low bacterial background (27 Cq with the 16S rRNA 
qPCR assay) were chosen for spiking. Ten-fold serial dilutions (105-10 cfu/ml) of cultured E. coli 
(H141480453) and S. aureus (NCTC 6571) were spiked into the chosen NRF sputum samples. 
The serial dilutions were plated in triplicate on LB agar (described in 2.3.2) to determine colony 
forming units (CFU). Host depletion and DNA extraction was followed as shown in Figure 3.1. 
Detection and quantification of bacterial DNA was performed using probe-based qPCR assays 
(described in 2.6) and MinION sequencing (described in 2.7). Each replicate was defined as 
positive for the spiked ‘pathogen’ if present at 1% classified microbial reads.  
If two of the three replicates were positive for the spiked pathogen, then it was considered 
positive at that dilution. S. aureus was detected in all replicates spiked with 100,000 cells and in 
2/3 replicates spiked with 10,000 cells in a high microbial background. Detection of E. coli in a 
high microbial background, however, was only possible in samples spiked with 100,000 cells. 
Hence, the LoD of the optimised CMg pipeline was determined to be 100,000 (105) cells for E. 
coli and 10,000 (104) cells for S. aureus when in a high bacterial background (Table 3.12A).  
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The LoD was determined to be lower in sputum samples with a lower bacterial background 
(Table 3.12B). Detection of both pathogens was possible in the lowest dilution tested (103 for S. 
aureus and E. coli) with >12% of S. aureus classified reads in all samples spiked with 1000 S. 
aureus cells and >4% of E. coli  reads in all replicates spiked with 1000 E. coli cells (Table 
3.13B). Hence, the LoD of the optimised CMg pipeline ranges from 103-105 CFU/mL, however, 































Table3.12A: Sputum sample with a high bacterial background* spiked with Gram-positive and Gram-negative organisms processed 
with the optimised method to determine limit of detection. 
*22Cq bacterial 16S rRNA gene V3-V4 fragment qPCR assay, **number of reads detected was below the 1% of classified microbial 
reads and WIMP assignment q-score 20 cut-off required for a sample to be considered positive. 
 





















































































































































Table 3.12B: Sputum sample with a low bacterial background* spiked with Gram-positive and Gram-negative organisms processed 
with the optimised method to determine limit of detection. 
 
*27Cq bacterial 16S rRNA gene V3-V4 fragment qPCR assay. **The number of reads detected for all samples was above the ≥1% of 
classified reads and WIMP assignment q-score ≥20 required for a sample to be considered positive. 



























































































































































3.1.7 Mock community experiments  
 
Clinical isolates from respiratory samples were used to generate a mock community consisting of 
S. pneumoniae, K. pneumoniae, H. influenzae, S. maltophilia, P. aeruginosa and C. albicans. E. 
coli and S. aureus strains were also included (H141480453 and NCTC 6571 respectively). 
Selected pathogens, were cultured (as described in 2.3.3) and were then spiked into an NRF 
sample (~103-106 CFU/pathogen) and then tested in triplicate with the optimised CMg pipeline, 
to determine if saponin depletion would result in inadvertent lysis of pathogens and loss of their 
DNA. All spiked samples were processed alongside undepleted controls. qPCR assays (as 
described in 2.6) were used to determine the relative quantity of each spiked pathogen in 
depleted and undepleted spiked sputum samples.  
Results of the qPCR assays revealed that depleting host nucleic acid (103 fold loss) did not result 
in loss of bacterial DNA for seven out of the eight spiked pathogens, as on average <1 Cq 
difference was observed between depleted and undepleted samples (Table 3.13). The seven 
organisms that were not affected by host depletion were:  C. albicans, E. coli, H. influenzae, K. 
pneumoniae, P. aeruginosa, S. aureus and S. maltophilia.  The only pathogen affected by host 
depletion was S. pneumoniae, as a 5.8-fold loss was observed (average ΔCq 2.52) between 








Table 3.13: Mock community qPCR results in triplicate for spiked NRF samples with and 
































Undepleted 24.20 24.27 25.27 24.58 9.9 
(103 fold) Depleted 33.97 34.52 34.96 34.48 
C. albicans 
Undepleted 26.71 26.48 26.29 26.49 
0.04 
Depleted 27.12 25.68 26.80 26.53 
E. coli 
Undepleted 23.47 23.53 23.99 23.66 0.12 
 Depleted 23.73 23.94 23.68 23.78 
H. influenzae 
Undepleted 30.60 30.53 30.55 30.38 
0.77 
Depleted 31.55 30.66 31.25 31.15 
K. pneumoniae 
Undepleted 29.96 29.78 30.29 30.01 
0.05 
Depleted 30.08 30.26 29.85 30.06 
P. aeruginosa 
Undepleted 22.78 22.77 23.15 22.90 
0.17 
Depleted 23.07 23.14 22.99 23.07 
S. aureus 
Undepleted 26.23 26.62 27.99 26.94 
0.16 
Depleted 26.19 27.35 26.80 26.78 
S. maltophilia 
Undepleted 24.96 24.96 25.66 25.29 
0.02 
Depleted 25.56 24.93 25.45 25.31 
S. pneumoniae 
Undepleted 25.66 25.70 26.68 26.01 2.52 
(5.8 fold) Depleted 28.18 28.81 28.62 28.53 
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3.1.8 Investigation of Streptococcus pneumoniae loss observed in the mock 
community experiments  
 
The S. pneumoniae loss observed in the mock community experiments was further investigated.  
S. pneumoniae positive clinical pilot samples were tested by S. pneumoniae qPCR (described in 
2.6) to detect any S. pneumoniae loss compared to undepleted controls. In four samples (P3, P28, 
P30 and P33), S. pneumoniae loss was observed (minimum ΔCq= 1.7 and maximum ΔCq= 5.84) 
and no loss was observed in the other 2 samples; P36 and P40 (Table 3.14A).  
 
Table 3.14A: qPCR results of  S. pneumoniae-positive pilot samples.  
 
Sample 
S. pneumoniae ply gene qPCR-
probe based assay (Cq) 
S. pneumoniae DNA loss/gain 
after host depletion (ΔCq) 
P3-Undepleted control 21.09 1.7                                               
(3.2 fold) P3-Depleted 22.79 
P28-Undepleted control 19.75 3.17                                              
(9 fold) 
P28-Depleted 22.92 
P30-Undepleted control 19.21 
5.84                                                
(57.28 fold) 
P30-Depleted 25.05 
P33-Undepleted control 21.70 
3.64                                               
(12.5 fold) 
P33-Depleted 25.34 
P36-Undepleted control 20.7 0.18 
(1.13 fold) 
P36-Depleted 20.52 






These results and the mock community results suggested that S. pneumoniae cells can be lysed 
during host depletion, hence we further investigated which step(s) damage the S. pneumoniae 
cell wall.  
Initially, the high salt buffer was altered to observe if this was damaging the S. pneumoniae cell 
wall. Using an S. pneumoniae-positive sample (SP0), 1 M NaCl for the nuclease buffer 
(manufacturer’s recommended salt concentration for HL-SAN DNase) was compared to the 5.5 
M salt buffer (no changes were made to the rest of the optimized protocol). The 1 M salt buffer 
sample had a 2.77 fold loss (ΔCq= 1.47) and the 5.5 M salt buffer sample had 13.83-fold loss 
(ΔCq= 3.79), showing that the HL-SAN buffer could potentially lyse (or lead to lysis) S. 
pneumoniae cells (Table 3.14B).  
 




S. pneumoniae ply gene qPCR-
probe based assay (Cq) 
S. pneumoniae DNA loss/gain 
after host depletion (ΔCq) 
SP0-Undepletd control 20 
- 
SP0-Depleted (1M NaCl) 21.47 
1.47                                                 
(2.77 fold) 
SP0-Depleted (5.5M NaCl) 23.79 




Next, each step of the host DNA depletion method was tested to investigate the effect on S. 
pneumoniae. An S. pneumoniae-spiked (PMEN1 strain cultured for 24 hrs -as described in 2.3.3) 
NRF sputum sample was processed in duplicate with the original method (SP1 and SP2 in Table 
3.14C) and an altered method where either the saponin treatment (SP3 and SP4 in Table 3.14C) 
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or the osmotic shock (SP5 and SP6 in Table 3.14C) was removed. Duplicate undepleted spiked 
controls were also included (SP7 and SP8 in Table 3.14C). Each duplicate was compared for S. 
pneumoniae loss compared to the undepleted controls, using probe-based qPCR assay (described 
in 2.6)  
In the duplicates (SP1 and SP2) where the optimised CMg method was carried out with no 
alterations a 430.5-fold loss of S. pneumoniae was observed (Table 3.14C). Loss was increased 
to 831.7-fold in the two duplicates where the osmotic shock was removed (SP5 and SP6) when 
compared with the undepleted controls (Table 3.14C). However, some S. pneumoniae loss (26.7-
fold) was still observed in the duplicates (SP3 and SP4) where the saponin-treatment was not 
performed but still included DNase treatment with HL-SAN DNase and buffer.  
These results suggest that all the main steps (saponin treatment, high salt osmotic shock and 
possibly HL-SAN buffer) in the host depletion can result in S. pneumoniae loss, with the saponin 
treatment causing the biggest loss. However, this was not a systemic observation as S. 
pneumoniae loss was not recorded in 2/6 culture-positive S. pneumoniae samples tested with the 










Table 3.14C: qPCR results of a S. pneumoniae-spiked sample tested on different conditions of 

































SP1 Yes Yes Yes Yes Yes 23.6 
8.75                                           
(430.5 fold) 





Yes Yes Yes 19.49 






Yes Yes Yes 20.05 




Yes Yes 24.23 
9.7                                             
(831.7 fold) 




Yes Yes 25.23 
SP7 Yes No No No No 15.09 
- 
 










3.1.9 Evaluation of the optimised clinical metagenomics pipeline for the diagnosis of 
bacterial LRTIs  
 
The optimised pipeline was then tested on a set of respiratory samples to determine its clinical 
sensitivity and specificity compared to clinical microbiology (pathogen and AMR detection).  
In total, 41 excess respiratory samples from patients with suspected bacterial LRIs (previously 
processed by routine microbiology – described in 2.3.1) were collected (described in 2.2) and 
tested with the optimised method (Figure 3.1).  Host depletion was measured by qPCR 
(described in 2.6) and pathogen and AMR gene detection was determined using 2 hours of 
sequencing data (described in 2.8.2 and 2.8.3).   
A maximum of 104-fold depletion of human nucleic acid was reported (in 5/41 samples), but the 
average was 103-fold depletion (median 600-fold; interquartile range 168-1156 fold; maximum 
18,054 fold - see Table 3.15).  Metagenomic sequencing data also revealed the efficiency of the 
host depletion as human reads represented <18% of classified reads on average after 2 hrs of 
sequencing (Table3.16). 
No significant loss of bacteria was observed for the majority of the samples but a ≥6-fold 
bacterial loss was observed in 7/41 samples and bacterial gain was observed 2/41 between 
depleted samples (Table 3.15). 
CMg was concordant with culture for 28/29 culture-positive samples (including 3/28 confirmed 
mixed infections) tested. Single-bacterial infections that were correctly characterized were: eight 
H. influenzae confirmed samples, five S. aureus confirmed samples (including two MRSA-
positive samples), four P. aeruginosa confirmed samples, two S. marcescens, M. catarrhalis, E. 
coli and Klebsiella spp. infections. The three mixed-bacterial infections that were correctly 
identified were two H. influenzae and S. aureus infections and one P. aeruginosa and S. aureus 
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infection (S27, S38 and S41 - Table 3.15). The pathogenic organism reported by routine 
microbiology was detected by metagenomics together with an additional pathogen (not reported 
by culture) in eight samples: K. pneumoniae in S5, P. aeruginosa in S7, M. catarrhalis in S14 
and S39, S. pneumoniae in S8 and S15, S. aureus in S29 and S. pyogenes in S27 (Table 3.15). Up 
to two potentially pathogenic bacteria were also observed in seven culture-negative samples 
(reported as NRF/ NSG) by routine microbiology) i.e. H. influenzae and S. pneumoniae in S10 
and S21; S. pneumoniae in S11 and S28; M. catarrhalis and H. influenzae in S12; H. influenzae 
in S31 and E. coli in S32 (Table 3.15).  
Only one pathogen reported by routine microbiology in S9 was missed by clinical 
metagenomics. For this sample metagenomics detected E. coli only, whereas culture reported S9 
as a mixed infection with P. aeruginosa and E. coli.  
Based on these results, the overall sensitivity of the optimised method for respiratory pathogen 
detection was 96.6% (95% CI, 80.4-99.8%) and specificity was 41.7% (95% CI, 16.5-71.4%), 
not counting additional organisms detected by metagenomics in culture-positive samples as false 
positives. The turnaround time from sample to result (including two hours of MinION 







Table 3.15. Human and bacterial DNA qPCR results for respiratory samples infected by Gram-








































ETA E. coli E. coli 




Depleted 35.00 15.73 
S2 
 
Sputum K.pneumoniae K.pneumoniae 




Depleted 33.71 15.65 
S3 
 
Sputum P. aeruginosa P. aeruginosa 




Depleted 32.34 13.98 
S4 
 
Sputum S. marcescen S. marcescens 




Depleted 36.27 17.48 
S5 Sputum K. oxytoca 




K.pneumoniae Depleted 31.54 12.03 
S6 
 
Sputum S. aureus S. aureus 




Depleted 31.72 17.54 
S7 
 
Sputum H. influenzae 

















& E. coli 
































M. catarrhalis Depleted 31.42 17.56 
S13 
 
Sputum S. marcescens S. marcescens 




Depleted 29.59 11.98 
S14 
 
Sputum S. aureus 









Sputum S. aureus 






Depleted 31.13 18.65 
S16 
 
Sputum MRSA MRSA 




Depleted 31.94 15.56 
S17 
 
Sputum NRF None 




Depleted 33.15 20.72 
S18 
 
Sputum H. influenzae H. influenzae 




Depleted 35.00 15.10 
S19 
 
Sputum NRF None 




Depleted 33.81 19.00 
S20 
 
Sputum H. influenzae H. influenzae 












S. neumoniae Depleted 35.00 17.42 
S22 
 
Sputum NRF None 
















Depleted 35.00 18.64 
S24 
 
Sputum H. influenzae H. influenzae 




Depleted 32.41 17.33 
S25 
 
Sputum H. influenzae H. influenzae 




Depleted 31.79 19.26 
S26 
 
Sputum M.catarrhalis M. catarrhalis 









& S. aureus 




7.92 S. aureus 











Depleted 35.00 25.08 
S29 
 
Sputum P. aeruginosa 




S. aureus Depleted 29.13 17.77 
S30 
 
BAL P. aeruginosa P. aeruginosa 




Depleted >35.00 22.68 
S31 
 
Sputum NRF H. influenzae 




Depleted 29.83 21.44 
S32 
 
Sputum NSG E. coli 




Depleted 34.24 16.45 
S33 
 
Sputum NRF None 









Sputum NSG None 




Depleted 30.57 22.93 
S35 
 
Sputum E. coli E. coli 




Depleted 26.29 17.07 
S36 
 
Sputum H. influenzae H. influenzae 




Depleted 32.28 18.51 
S37 
 
Sputum P. aeruginosa P. eruginosa 
















P. aeruginosa Depleted 27.63 20.66 
S39 
 
Sputum H. influenzae 




M. catarrhalis Depleted 35.00 17.24 
S40 
 
ETA MRSA MRSA 




Depleted 25.97 18.29 
S41 Sputum 
H. influenzae 









In addition to these findings, in 29/41 samples metagenomic sequencing also identified 
additional non-pathogenic organisms that normally reside in the lower respiratory tract. The 
majority of bacteria identified in the depleted samples were different species of the Streptococci 
genus. Additional organisms identified were H. parainfluenzae, Rothia mucilaginosa, Veillonella 
parvulla, Neisseria sicca and different species of the Lactobacillus genus (see Table 3.16 for a 
















Total       
raw       
reads  
Number of 







ed  reads 
Organisms identified from 
metagenomic pipeline above 
chosen thresholds 
(number of pathogenic reads) 
S1 108610 108346 264 107971 364 Escherichia coli (91178) 
S2 17516 17485 31 17303 182 
Klebsiella pneumoniae (1692) 
Streptococcus parasanguinis 
S3 26641 26257 384 24673 1583 
Pseudomonas aeruginosa (15817) 
Streptococcus oralis 
Streptococcus parasanguinis 
S4 7358 7348 10 6602 743 






S5 19888 19865 23 19224 636 
Klebsiella oxytoca (3254) 
Citrobacter freundii 
Klebsiella sp. M5al 
Klebsiella pneumoniae (906) 
Klebsiella michiganensis 
S6 16403 13295 3108 13271 24 Staphylococcus aureus (11307) 
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S7 32730 21690 11040 17398 4289 
Streptococcus parasanguinis 




Haemophilus influenzae (232) 
Haemophilus parainfluenzae 
Neisseria sicca 
S8 49277 44120 5157 35023 9088 











S9 29111 28969 142 28527 437 




S10 56005 51610 4395 49850 1743 
Haemophilus influenzae (35348) 
Streptococcus pseudopneumoniae 
Streptococcus sp. oral taxon 431 





S11 43088 40944 2144 34012 6927 
Streptococcus parasanguinis 





Streptococcus pneumoniae (693) 
Streptococcus sp. I-P16 
Streptococcus sp. I-G2 
Haemophilus parainfluenzae 







S13 27592 27406 186 26979 425 Serratia marcescens(22758) 
S14 41154 40622 532 35413 5205 
Staphylococcus aureus (95465) 










S15 37500 36537 963 30473 6058 









Streptococcus pneumoniae (390) 
Prevotella melaninogenica 
S16 85298 85057 241 83750 1301 
Staphylococcus aureus (59392) 
Streptococcus oralis 
Lactobacillus rhamnosus 





Streptococcus sp. oral taxon 431 
Streptococcus sp. A12 
Streptococcus sp. NPS 308 
Streptococcus sp.FDAARGOS_192 
S18 38902 38744 158 38092 650 Haemophilus influenzae (34396) 
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Streptococcus sp. oral taxon 431 
Streptococcus gordonii 
Streptococcus constellatus 
S20 46331 43070 3261 42143 920 




S21 45214 45075 139 39288 5780 




Streptococcus sp. oral taxon 431 
Streptococcus salivarius 
Streptococcus oralis 
Streptococcus pneumoniae (408) 











Streptococcus sp. A12 
Streptococcus cristatus 
S23 33140 32933 207 29164 3766 








S24 58752 57669 1083 51978 5686 






Streptococcus sp. oral taxon 431 
S25 36621 35808 813 35716 89 Haemophilus influenzae (33307) 
S26 38138 36910 1228 33541 3367 
Streptococcus oralis 
Streptococcus mutans 







S27 78311 78064 247 74697 3357 
Haemophilus influenzae (31884) 
Streptococcus pyogenes (19544) 










Streptococcus sp. A12 
Streptococcus sanguinis 
Rothia mucilaginosa 
Streptococcus sp. oral taxon 431 
Streptococcus parasanguinis 
Streptococcus pneumoniae (464) 
Streptococcus pseudopneumoniae 
Prevotella melaninogenica 
Streptococcus sp. I-G2 
Streptococcus sp. I-P16 
Haemophilus parainfluenzae 
S29 57865 9429 48436 9153 275 
Pseudomonas aeruginosa (688) 
Staphylococcus aureus (1187) 
S30 27371 27217 154 27154 60 Pseudomonas aeruginosa (21577) 
S31 43823 13463 30360 9567 3895 













S32 48271 47988 283 46882 1101 Escherichia coli (35094) 







S34 40998 35522 5476 35031 489 
Candida albicans 
Enterococcus faecalis 
S35 47893 29765 18128 29663 96 Escherichia coli (26316) 
S36 33155 32774 381 31170 1603 




S37 60495 60083 412 59644 432 Pseudomonas aeruginosa (47138) 
S38 23889 12947 10942 12833 113 
Staphylococcus aureus (1248) 
Pseudomonas aeruginosa (253) 
S39 60316 59972 344 57940 2029 
Moraxella catarrhalis (32133) 
Haemophilus influenzae (14404) 
Streptococcus parasanguinis 
S40 48848 7444 41404 7340 104 




S41 2320 2129 191 2040 89 
Staphylococcus aureus (744) 
Haemophilus influenzae(343) 
Neisseria sicca 
Escherichia coli (35) 
*above chosen thresholds 
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3.1.10 Confirmatory analysis of additional and missed pathogens  
 
Confirmatory probe-based qPCR (described in 2.6) was used to confirm the presence or absence 
of the missed/additional pathogens (described above) detected by the optimised CMg pipeline in 
16 samples (1 sample with a missed pathogen, 15 samples with additional pathogen/s detected – 
including 7 culture-negative samples; total of 19 pathogens) and in matched controls i.e. an equal 
number of samples that neither culture or metagenomics detected the pathogen (Table 3.17A). 
Probe-based qPCR was performed on DNA extracts from samples that did not undergo the 
depletion process (undepleted controls), to eliminate depletion as a potential cause of 
missed/additional pathogen/s reported. In total 12/19  additional pathogens detected by 
metagenomics in 16 samples were confirmed by qPCR. This included 5/7 culture-negative (S10, 
S11,S12, S31,S32) and 5/9 culture-positive samples (S7, S14, S27, S29 and S39) (Table 3.17A). 
This analysis, increased the specificity of the optimised method to 83.3% (95% CI, 36.5-99.1%) 
– as culture-negative samples where additional pathogens detected were confirmed by qPCR 
were now considered as true positive samples and additional organisms detected by 
metagenomics only in culture-positive samples were not counted as false positives. Pathogenic 
organisms (not including pathobionts such as H. influenzae and S. pneumoniae) identified by 
metagenomics only and not confirmed by qPCR were: K. pneumoniae in S5, likely a k-mer mis-
classification of K. oxytoca reads, and E. coli in S41, likely a laboratory/kit contaminant. Also, 
qPCR was negative for P. aeruginosa (S9) increasing the sensitivity of the optimised method to 





Table 3.17A: Confirmatory qPCR analysis of additional pathogen detected by the optimised 
clinical metagenomics pipeline. 
 


























Pseudomonas aeruginosa* S9 oprL - 
Pseudomonas aeruginosa1 S7 oprL 32.9 










Streptococcus pyogenes1 S27 sdaB 28.7 







Next, a species-specific gene analysis (described in 2.8.4.2) was performed for all samples 
positive for H. influenzae and S. pneumoniae. These two organisms are pathobionts (i.e. 
potentially pathogenic organisms which may reside as commensals in the lung), which share 
genetic similarities with commensal species residing in the lungs (there were 18 samples 
containing 20 pathobionts). This species-specific analysis was used to identify k-mer mis-
classification of commensal reads as pathogenic reads by WIMP. For this analysis samples 
containing >1 pathobiont specific gene alignment (siaT gene for H. influenzae and ply gene S. 
pneumoniae) were considered positive for that organism. Pathobiont specific genes were 
identified in 13/14 H.influenzae sample tested and in 2/6 S. pneumoniae samples tested. No 
alignments of either of the genes were identified in 5/18 samples analysed, including three 
originally culture-negative samples (H.influenzae in S12 and S. pneumoniae in S21 and S8) and 
two culture-positive samples where the pathobionts (S. pneumoniae in S18 and S15) were 
reported by metagenomics only. No alignments confirmed k-mer mis-classification and the 
absence of H. influenzae/S. pneumoniae. The only remaining culture-negative sample (S28) was 
also negative by qPCR analysis (see Table 3.17A) and as they were also negative for pathobiont 
specific genes, resulted in the optimised CMg method being 100% specific (95% CI, 51.7-100%) 





Table 3.17B. Species-specific gene analysis for H. influenzae and S. pneumoniae identified by 
the clinical metagenomics pipeline only. 
 





Number of reads 





































3.1.11 Detection of AMR genes using the clinical metagenomics pipeline. 
 
Resistance genes in the respiratory samples were also identified (described 2.8.3) using data 
from 2 hours of MinION sequencing. Detection of AMR genes was performed to demonstrate 
that resistance can be determined using rapid CMg. The samples tested using the optimised 
method were mostly susceptible with little antibiotic resistance, according to routine results 
(Table 3.18A). Amongst the 33 cultivated organisms, only 43 instances of resistance and 
intermediate resistance were recorded by culture (described in 2.3.1) with some of these likely 
reflecting single underlying mechanisms (Table 3.18A). Metagenomic sequencing reported 183 
resistance genes across the 41 samples (with multiple genes reported when ARMA identified 
multiple variants of e.g. blaTEM). All genes detected by ARMA are listed in Table 3.18A and are 












S1 E. coli 
Amoxicillin R, Gentamicin S, Co-amoxiclav R, 
Co-trimoxazole R, Tazocin I, Ciprofloxacin S, 
Meropenem S, Aztreonam S, Ceftazidime S, 
Ceftriaxone S, Cefuroxime S, Amikacin S, 








S2 K. pneumoniae 
Amoxicillin R, Gentamicin S, Co-amoxiclav R, 
Co-trimoxazole S, Tazocin I, Ciprofloxacin S, 
Meropenem S, Aztreonam S, Ceftazidime S, 
Ceftriaxone S, Cefuroxime S, Amikacin S, 






S3 P. aeruginosa 
Gentamicin S, Tazocin S, Ciprofloxacin S, 






S4 S. marcescens 
Gentamicin S, Co-trimoxazole S, Ciprofloxacin 
S, Meropenem S, Aztreonam S, Ceftazidime S, 
Amikacin S, Tigecycline S, Tobramycin S, 
Levofloxacin S, Colistin R, Cefepime S, 




S5 K. oxytoca 
Gentamicin S, Co-trimoxazole S, Tazocin I, 
Ciprofloxacin S, Meropenem S, Aztreonam S, 
Ceftazidime S, Amikacin S, Tigecycline S, 
Tobramycin S, Levofloxacin S, Colistin S, 







S6 S. aureus 
Flucloxacillin S, Erythromycin/clarithromycin 
S, Clindamicin S, Fuscidic acid S, 
Tetracycline/doxycycline S, Mupirocin S 
tet38 
S7 H. influenzae 
Amoxicillin R, Doxycycline S, Ceftriaxone S, 





S8 M. catarrhalis 
Amoxicillin R, Doxycycline S, Ceftriaxone S, 










Gentamicin S, Tazocin S, Ciprofloxacin S, 











Co-amoxiclav R, Co-trimoxazole R, Tazocin S, 
Ciprofloxacin S, Meropenem S, Aztreonam S, 
Ceftazidime S, Ceftriaxone S, Cefuroxime S, 
Amikacin S, Ertapenem S, Tigecycline S, 
Tobramycin R, Cefepime S 
















S13 S. marcescens 
Gentamicin S, Co-amoxiclav R, Co-
trimoxazole S, Ciprofloxacin S, Meropenem S, 
Aztreonam S, Ceftazidime S, Ceftriaxone S, 
Cefuroxime R, Amikacin S, Ertapenem S, 
Tigecycline I, Tobramycin S, Cefepime S 
AAC(6’)-lc 
oqxB 
S14 S. aureus 
Flucloxacillin S, Erythromycin/clarithromycin 
S, Clindamicin S, Fuscidic acid S, 





S15 S. aureus 
Flucloxacillin S, Erythromycin/clarithromycin 
S, Clindamicin S, Fuscidic acid S, 







S16 S. aureus/MRSA 
Penicillin R, Flucloxacillin R, Oxacillin R, 
Erythromycin S, Clindamycin S, Trimethoprim 
R, Gentamicin R, Ciprofloxacin R, Fusidic acid 
R, Mupirocin S, Rifampicin S, Vancomycin S, 


















S18 H. influenzae 
Amoxicillin R, Tetracycline/doxycycline S, 
Ceftriaxone S, Co-amoxiclav S, Ciprofloxacin 
















S20 H. influenzae 
Amoxicillin S, Doxycycline S, Ceftriaxone S, 
















S23 H. influenzae 
Amoxicillin S, Tetracycline/doxycycline S, 
Ceftriaxone S, Co-amoxiclav S, Ciprofloxacin 





S24 H. influenzae 
Amoxicillin S, Doxycycline S, Ceftriaxone S, 









S25 H. influenzae 
Amoxicillin S, Doxycycline S, Ceftriaxone S, 







S26 M. catarrhalis 
Amoxicillin R, Doxycycline S, Ceftriaxone S, 









Amoxicillin S, Doxycycline S, Ceftriaxone S, 





mefA S. aureus 
Flucloxacillin S, Erythromycin R, Clindamycin 
R, Fuscidic acid S, Tetracycline S, Mupirocin S 







S29 P. aeruginosa 
Gentamicin S, Tazocin S, Ciprofloxacin S, 





S30 P. aeruginosa 
Gentamicin S, Tazocin S, Ciprofloxacin S, 





S31 NRF ND 
TEM-4 
tetC 
















S35 E. coli 
Amoxicillin R, Gentamicin S, Co-amoxiclav R, 
Co-trimoxazole S, Tazocin R, Ciprofloxacin S, 
Meropenem S, Aztreonam S, Ceftazidime I, 
Ceftriaxone S, Cefuroxime S, Amikacin S, 










S36 H. influenzae 
Amoxicillin R, Doxycycline S, Ceftriaxone S, 







S37 P. aeruginosa 
Gentamicin S, Tazocin R, Ciprofloxacin S, 







Gentamicin S, Tazocin S, Ciprofloxacin S, 
Meropenem S, Ceftazidime S 
TEM-4 
tetC 
tet38 S. aureus 
 
 
Flucloxacillin S, Erythromycin S, Clindamycin 
S, Fuscidic acid S, Tetracycline S, Mupirocin S 
S39 H. influenzae 
Amoxicillin S, Doxycycline S, Ceftriaxone S, 









Penicillin R, Flucloxacillin R, Oxacillin R, 
Erythromycin S, Doxycycline S, Clindamycin 
S, Trimethoprim S, Gentamicin S, 
Ciprofloxacin R, Fuscidic acid S, Rifampicin S, 
Vancomycin S, Teicoplanin S, Tigecycline S, 







Flucloxacillin S, Erythromycin S, Clindamycin 




Tetracycline S, Amoxicillin S, Ceftriaxone S, 
Co-amoxiclav S, Ciprofloxacin S, Co-
trimoxazole R 






Among the 183 resistance genes, 26 were inherent to the species identified by culture (e.g. 
oqxA/B for K. pneumoniae or blaOXA-50 in P. aeruginosa), from the remaining 157, 24 resistance 
genes matched the observed phenotype (Table 3.18B). These included, mecA found in both 
MRSA (S16 and S40), sul1 and dfrA12 or dfrA17 in both co-trimoxazole-resistant E. coli (S1 
and S9), aac(3’)-IIa (and IIc) in a tobramycin-resistant E. coli (S9) and a total of 13 blaTEM 
variants spread across two amoxicillin-resistant E. coli (S1 and S35) and two amoxicillin-
resistant H. influenzae (S18 and S36). A caveat regarding the identification of blaTEM variants, 
was that ARMA did not flag blaTEM-1, which was the likeliest variant to be present in these 
samples, given (i) that it is considerably the most prevalent type and (ii) that the isolated 
organisms remained susceptible to oxyimino- cephalosporins whereas many of the blaTEM 
variants, flagged by ARMA, should encode extended-spectrum variants. Depending on their 
strength of expression blaTEM or blaOXY may have explained non-susceptibility to penicillin/β-
lactamase inhibitor combinations in Enterobacteriales (4/183 resistance genes recorded), but 
quantification of gene expression was not possible by ARMA. A blaTEM4 gene (1/183) was also 
found by ARMA in a ceftazidime- and piperacillin/tazobactam- resistant P. aeruginosa (S37); 
which could explain the phenotype reported by routine testing, but is questionable in this species, 
as β-lactam resistance often results from the up-regulation of chromosomal ampC or efflux. 
There were 14/183 recorded genes where any associated resistance could not be established as 
the relevant drug(s) was not tested by routine microbiology. An example of these, were the tet 
genes identified in several samples (S2, S8, S9, S16, S30, S35, S38 and S39) and tetracycline 
was not tested against the isolates cultured. Sixteen genes identified by ARMA did not match the 
reported phenotype of the cultivated isolates, which remained susceptible to relevant antibiotics 
according to culture, and 42 genes were unlikely to be from species identified by routine testing. 
157 
 
Finally, multiple genes (56/183) likely originated from the normal lung microbiota. For example, 
tet(M) and blaTEM-4 genes, each were found in 8/12 NRF/NSG samples, and mefA and mel were 
each found in 9/12 culture-negative samples (Table 3.18B). 
There were nine samples where phenotypic resistances could not be explained by resistance 
genes reported by ARMA. This included two amoxicillin-resistant M. catarrhalis (S8 and S26), 
where BRO β-lactamase genes (most likely to be responsible for the observed phenotype) were 
not represented in the database utilised by ARMA. The remaining seven out of the nine samples 
included ampicillin- and co-trimoxazole- resistant H. influenzae (S7, S18, S36, S39 and S41), 
trimethoprim-, ciprofloxacin- gentamicin- and fusidic acid- resistant S. aureus (S16) and a K. 
pneumoniae (S2) resistant to both co-amoxiclav and piperacillin/tazobactam where no acquired 
β-lactamase genes were identified by ARMA (Table 3.18B).   
The specificity and sensitivity for resistance gene detection of the optimised method was not 
calculated as this would have required isolate cultivation and sequencing of all bacteria 
(pathogens and commensals) present– a prohibitive and unaffordable task for the duration of this 





Table 3.18B:  Resistance genes detected by ARMA in relation to pathogens grown for samples 
processed with clinical metagenomics*.  
 
 
ARMA vs. culture result No. genes Principal examples 
Gene endogenous in species 26 
Mostly efflux components; also blaOXA-50, 
aph(3’)-IIb and catB7 from P. aeruginosa 
and aac(6’)-Ic from S. marcescens 
Match to observed R 24 
Variously including mecA in MRSA, 
blaTEM in Enterobacteriaceae and H. 
influenzae, also sul1 and dfr determinants 
for E. coli 
Partial match to observed 
resistances 
4 
Instances where blaTEM was found but 
where MinION flagged an ESBL-
encoding variant, usually blaTEM-4, but 
where the phenotype indicated only a 
classical penicillinase, without oxyimino-
cephalosporin resistance 
Unlikely match to observed 
phenotype 
1 
P. aeruginosa with blaTEM resistant to 
piperacillin/tazobactam and ceftazidime – 
see text 
Possibly present, but relevant drug 
not tested by clinical lab 
14 
Commonly (i) where tet(C) found but lab 
tested doxycycline, which is not a 
substrate for this pump, or (ii) where 
streptomycin, kanamycin and macrolide 
determinants were found in gram-
negative bacteria but these drugs were not 
tested, as not relevant to therapy. 
Does not match phenotype of isolate 16 
Mostly where blaTEM (as blaTEM-4) was 
recorded but the isolate (commonly H. 
influenzae) was susceptible to penicillins 
as well as cephalosporins, or where tet(M) 
was found together with a tetracycline-
susceptible S. aureus 
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Genes unlikely to be from species 
grown by the laboratory 
42 
Mostly gram-positive-associated genes 
when a gram-negative organism was 
grown, or vice versa: commonly 
including tet(M) and mefA 
Gene recorded in a specimen with 
no pathogen grown 
56 
Mostly tet, mef mel, blaTEM-4 
determinants, likely to be associated with 
normal flora 
Total 183  










3.1.12 Impact of host DNA depletion for reference-based genome assembly  
 
Two samples (S1 and S16) containing antibiotic resistant bacteria (confirmed by culture and 
metagenomics) were chosen as examples to generate reference-based genome assemblies (as 
described in 2.8.4.1) using the metagenomic data. This analysis was performed to demonstrate 
that CMg data can be used to generate whole pathogen genomes directly from respiratory 
samples which could be used for public health and infection control applications. 
Reference-based assemblies were generated for an MRSA (S16) and an E. coli resistant to 
amoxicillin, co-amoxiclav and co-trimoxazole (S1). The assemblies were compared with those 
generated from the undepleted controls after 2 and 48 hours of sequencing to demonstrate the 
effect of successfully removing host nucleic acid on genome assemblies. For the first two hours 
of sequencing the depleted MRSA sample had 47.9x genome coverage with an assembly of 28 
contigs (GCA_900660255: longest contig = 478718 and N50=400 kbp). After 48hrs of 
sequencing, genome coverage increased to 228.7x, with a final assembly consisting of 22 contigs 
(GCA_900660245: longest contig = 481 kbp and N50=403 kbp). In contrast, after 2hrs of 
sequencing the undepleted control for the MRSA sample had an assembly of 69 contigs with 
3.9x coverage (GCA_900660235: longest contig = 47kbp and N50=146 kbp), and 33 contigs 
(17.5x coverage) after 48 hours of sequencing (GCA_900660205: longest contig = 416 kbp and 
N50=263kbp) (Figure 3.2A). 
For the depleted sample positive for a resistant E. coli (S1) there was 33.5x genome coverage 
with an assembly of 83 contigs (GCA_900660265: longest contig = 437 kbp and N50=165 kbp) 
within two hours of sequencing. Genome coverage after 48 hrs, was increased to 165.7x with the 
final E. coli assembly having 72 contigs (GCA_900660275: longest contig = 474 kbp and 
N50=178 kbp). The undepleted sample only had 0.2x coverage after 2hrs, increasing to 1.1x 
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genome coverage after 48 hrs of sequencing (Figure 3.2B). Genome assemblies could not be 
generated for either of the two chosen timepoints (2 hours and 48 hours) for the undepleted 
sample. 
This analysis highlights the importance of host depletion being incorporated with CMg when 
pathogen load is low compared to host (an assembly was not possible for S1 without host 
depletion even after 48 hrs of sequencing) or in time-critical situations (for S16, 47.9x of the 
MRSA genome was recovered after 2 hours of sequencing).  
 
 
3.1.13 The effect host DNA depletion has on rapid pathogen identification and AMR gene 
detection 
 
Using the same sample set (S1 and S16) used for the reference-based genome assemblies, a 
timepoint analysis (described in 2.8.4.2) was carried out using data from the first two hours of 
sequencing. Genome recovery and alignments of confirmed resistance genes identified in 
depleted samples were compared with their undepleted controls over chosen timepoints to 
highlight the importance of host depletion for rapid results.  
Within the first 5 min of sequencing the depleted MRSA sample (S16) had 1.6x genome 
coverage and was increased to 64.2x after 2 hours of sequencing. In contrast the undepleted 
control had 0.2x coverage after 5 min of sequencing and 5.8x after 2 hours (Figure 3.2C). Also 
no mecA gene alignments were detected in the undepleted sample in the first 30 min of 
sequencing, whereas two mecA gene alignments were recorded in the depleted sample in the first 
5 min of sequencing (Figure 3.2D). 
A similar trend was also reported for S1 - the depleted sample had 5.7x genome coverage of E. 
coli after 20 min of sequencing, which increased to 45.6x after 2 hours. The undepleted control 
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however, had 0.06x genome coverage in the first 20 min of sequencing increasing to only 0.2x 
after 2 hours (Figure 3.2E). This E. coli was resistant to amoxicillin (blaTEM gene), co-amoxiclav 
(possibly owing to blaTEM if gene is strongly expressed) and co-trimoxazole (sul1 and dfrA17 
genes). Hence, sequencing data were aligned against these genes for the analysis. No blaTEM and 
dfrA17 gene alignments were detected in the undepleted sample within two hours of sequencing 
and only one alignment was detected for sul1. Conversely, at least one gene alignment was 
identified for all three resistance genes within 20 min of sequencing in the depleted sample, 
increasing to 47 blaTEM, 37 sulf1 and 21 dfrA17 alignments after two hours of sequencing (Figure 
3.2F). 
These results demonstrate rapid diagnosis, including both pathogen and resistance gene 


















Figure 3.2 (continued): Genome coverage and antibiotic gene detection in depleted versus undepleted samples. C, MRSA genome coverage of 
depleted versus undepleted during 2 h of sequencing. D, mecA gene alignment of depleted versus undepleted during 2 h of sequencing. E, E. coli 
genome coverage of depleted versus undepleted during 2 h of sequencing. F, blaTEM, sul1 and dfrA17 gene alignment of depleted versus 





3.2 Implementation of the clinical metagenomics pipeline  
 
The optimised clinical metagenomics pipeline (Figure 3.1) was initially evaluated on a set of 
respiratory samples in a proof-of-concept study to establish the sensitivity and specificity of the method 
against microbiological cultures – detailed in 3.1. We then sought to further test the optimised CMg 
pipeline in a larger prospective study against culture and molecular PCR-based tests as part of the 
clinical trial entitled - INHALE: Potential of Molecular Diagnostics for Hospital Acquired and 
Ventilator-Associated Pneumonia in UK Critical Care (https://www.ucl.ac.uk/inhale-project/).  
The primary aim of the INHALE trial is to assess the potential, molecular tests would have for the 
diagnosis of HAP and VAP in UK ICUs. The aim of the first phase of the trial (month 1-24) was to 
evaluate the performance of three rapid molecular platforms for the diagnosis of HAP and VAP, in 
terms of pathogen identification and resistance gene detection against culture. Additionally, INHALE 
aimed to assess the speed, cost, ease of use and implementability of the workflow/platform in the 
clinical setting. The platform/workflow with the best performance would then progress into a 
randomised controlled trial versus standard of care (https://www.ucl.ac.uk/inhale-
project/project/project-work-plan). 
Initially, the three molecular diagnostic tests chosen for evalutation against routine culture were all 
PCR-based platforms (https://www.ucl.ac.uk/inhale-project/project/project-goals), but halfway through 
the first phase of the trial, one of the three PCR platforms was not sufficiently developed for testing and 
was replaced by our optimised CMg pipeline. The three final tests, were the CMg pipeline (122) and 
the two PCR-based platforms, namely Curetis Unyvero Hospitalised Pneumonia test 
(https://www.ucl.ac.uk/inhale-project/project/technology-curetis-platform) and BIOFIRE Filmarray 
Pneumonia panel (https://www.ucl.ac.uk/inhale-project/project/technology-biofire-filmarray-platform).  
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The diagnostic performance of the three tests was evaluated by using samples collected from ICUs 
across fifteen UK hospitals: Norwich & Norfolk University Hospitals (NNUH), University College 
London Hospitals (UCLH), Great Ormond Street Hospital Children's Charity (GOSH), BUPA 
Cromwell Hospital, Royal Free Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, 
City Hospitals Sunderland, Dudley Group NHS Foundation Trust, James Paget University Hospitals 
NHS Foundation Trust, Queen Elizabeth Hospital Kings Lynn NHS Trust, Aintree University Hospital 
NHS Foundation Trust, Guy’s and St Thomas’ NHS Foundation Trust, North Middlesex University 
Hospital NHS Trust, Royal Liverpool and Broadgreen University Hospitals NHS Trust and University 
Hospitals of North Midlands (UHNM) (95). Collected samples were processed at the two main sites of 
the trial – the Norwich Medical School at University of East Anglia (UEA) and Royal Free Hospitals 
(RHF). I only tested samples collected for the Norwich sites (which included samples from NNUH, 
UHNM and James Paget, Queen Elizabeth and Sunderland hospitals), hence only these samples will be 
presented and discussed in the thesis. The full analysis of all the samples is still underway and is 
expected to be published by the end of 2020. 
 
3.2.1 Effect of sample freezing of CMg assay performance  
 
A number of samples collected during the INHALE trial had been frozen at -20 C right away. The 
optimised CMg pipeline was not previously tested on frozen samples, therefore we had to determine if 
freezing the samples would have any undesired effect (e.g. damage/lysing of bacterial cells before host 
depletion, leading to bacterial DNA loss) on pathogen detection and negatively affect the performance 
of the pipeline. Hence, a set of 13 frozen samples were chosen for testing with the CMg pipeline (Table 
3.19).   
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From the 13 samples processed, two samples (YS030 and YS033) produced <500 reads after 2 hrs of 
sequencing  and were considered sequencing failures. From the remaining samples, clinical 
metagenomics was in agreement with culture in 5/11 samples, including 4 culture-positive samples 
(YS051, YS023, YS032, YS022) and 1 culture negative sample (YS031). Clinical metagenomics 
however, was discordant with culture in the remaining 6 samples analysed (5 culture-positive and 1 
culture-negative) as pathogens were completely missed or pathogenic reads were below the chosen 
thresholds (≥1% of microbial reads and >19 of alignment score - described in 2.8.2). The pathogens 
missed after metagenomics analysis were: Pseudomonas in YS040, S. pneumoniae in YS037, S. 
marcescens in YS029, S. aureus in YS028 and S. pyogenes in YS038.  In YS052, S. aureus was 
identified by metagenomics only (Table 3.19).  These results suggested that freeze/thawing cycles 
combined with the host depletion method can damage/lyse bacterial cells eventually affecting pathogen 
detection. As this would affect the sensitivity of the optimised pipeline, we decided to exclude all 




Table 3.19: Sequencing data* of frozen INHALE samples processed with clinical metagenomics. 
























reads               






E. coli  36,552 10,354 5,449 
26,198                 
(71.7%) 
YS052 Negative S. aureus  17,495 2,263 676 







E. coli                      




721                      
(1.3%) 
YS023 H. influenzae 
H. influenzae            









P. aeruginosa  201 96 56 
105                     
(52.2%) 
YS031 Negative  1,184 1,150  





S. agalactiae             
S. aureus                 
S. pyogenes  
59,894 59,195 
45,424 
12,463   
3,258 
699                       
(1.2%) 
YS029 
E. coli                      
S. marcescens 
E. coli 5,517 849 352 





 76 51  






S. aureus  61,555 61,065 6,060 
490                        
(0.8%) 
YS022 H. influenzae 
H. influenzae   
S. agalactiae  
57,529 27,968 
965        
333 
29,561                       
(51.4 %) 
YS028 S. aureus  4,154 275  





 6,031 164  




3.2.2 NNUH INHALE sample testing  
 
The optimised method was tested on a total of 73 fresh respiratory samples (n= 34 culture-positive 
confirmed samples and n= 39 culture-negative samples (NRF or NG/NSG/NBG)) collected for the 
INHALE study. Initial analysis highlighted the need for additional parameters/thresholds to be put in 
place to accurately and effectively analyse this data to ensure the exclusion of both host depletion and 
sequencing failures. Therefore, any sample which produced <500 total reads was excluded as 
sequencing failures and any sample with <10% microbial reads was considered as a host depletion 
failure. After applying these thresholds, 47 samples remained for analysis (n=26 culture-positive and 
n=21 culture-negative samples). A processed-negative control rule was then applied to the remaining 
47 samples to identify and eliminate contamination and barcode leakage. The same number of 
pathogenic reads identified in the processed-negative control were removed from each sample on the 
multiplexed sequencing run. Then pathogen identification was carried out as previously described 
(section 2.8.2) using two hours of MinION metagenomic sequencing data.  
Clinical metagenomics was concordant with culture for 21/26 culture-positive samples (Table 3.20), 
including three mixed infections as reported by routine microbiology (NS041, NS064, YS018). Single 
bacterial infections included: P.aeruginosa in nine samples (JS015, NS070, NS075, NS078, NS080, 
QS005, SS004, YS011 and YS013), S.aureus in three samples (JS019, NS037 and NS042),  E. coli in 
NS043, Enterobacter cloacae group in NS044, S. marcescens in NS050, Proteus spp. in NS057 and 
Klebsiella spp. in two samples (NS063, YS025). The three mixed infections, identified correctly by 
metagenomics were: an E. coli and S. marcescens infection in NS041, and H. influenzae and S.aureus 
in NS064 and K. aerogenes and H. influenzae in YS018. Additional pathogens were identified by 
metagenomics (not by culture) in 14/26 culture-positive samples; C. freundii in QS005, E. coli in 
JS015, in NS063 and NS078, K. oxytoca in NS041, H. influenzae in NS050 and NS057 and QS006, M. 
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morgannii in NS070, S. agalactiae in JS019 and NS079, S. aureus NS057, S. maltophilia in YS013, S. 
pneumoniae in NS042 and K. pneumoniae and E. coli in NS044. Culture-positive samples including 
pathogens identified by metagenomics only were not reported as false positive. 
Potentially pathogenic bacteria were also identified in nine culture-negative samples (reported as 
NRF/NSG/NG) by routine microbiology) i.e. E. aerogenes in YS020, E. coli in JS016, NS067, YS020, 
YS034, YS044, and NS073, K. pneumoniae in YS034, H. influenzae in NS048, NS073 and YS020, P. 
mirabilis in NS072, S. aureus in NS073 and YS020 and S. maltophilia in YS042 (Table 3.20). 
However, pathogens in five samples were missed by metagenomics (identified by culture), i.e. E. coli 
in NS071 and YS059, K. pneumoniae in QS006, P. aeruginosa in NS079 and S. aureus in YS053 
(Table3.20).  
Based on these results, the optimised clinical metagenomics pipeline was 80.77% sensitive (95% CI; 
60.65% to 93.45%) and 57.14% specific (95% CI; 34.02% to 78.18%) when used as the third test for 
the INHALE trial. The overall performance of the test is still being evaluated for the INHALE study 

























JS007 37,768 36,582 Negative  Negative 
JS013 3,831 2,136 Negative  Negative 
JS015 26,205 26,097 
E. coli  
P. aeruginosa 
10,462 








JS019 75,397 33,532 
S. aureus  
S. agalactiae 
31,398 








NS038 4,650 4,479 Negative  Negative 
NS039 18,686 4,821 Negative  Negative 
NS041 41,762 41,098 
E. coli  
K. oxytoca  
Serratia marcescens 
9,877 
(24.03%)               
665 





NS042 66,889 17,642 











NS044 49,712 49,640 
Enterobacter cloaceae 













NS047 1,852 1,501 Negative  Negative 




NS049 7,750 3,644 Negative  Negative 
NS050 58,702 58,686 
H. influenzae  
S. marcescens 
1,060  




NS057 25,859 23,551 
H. influenzae  
Proteus mirabilis                                             
S. aureus 
3,425 
(14.54%)                
13,854 




NS063 4,159 1,745 
E. coli  
K. pneumoniae 
28  




NS064 61,248 60,488 
H. influenzae  
S. aureus 
55,485 









NS069 4,562 4,003 Negative  Negative 
NS070 67,389 52,241 
Morganella morganii  
P. aeruginosa 
1,803 













NS073 8,883 984 
E. coli  
H. influenzae                                                    
S. aureus  
33 (3.35%                               
34 (3.4%)                              
30 (3.05%) 
Negative 
NS074 51,887 49,867 Negative  Negative 




NS077 32,912 10,100 Negative  Negative 
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NS078 759 647 
E. coli  
P. aeruginosa 
24  












QS005 42,119 42,083 
Citrobacter freundii  
P. aeruginosa 
481  




QS006 28,655 28,526 
H. influenzae                                                    
P. mirabilis 
3,602 













YS013 57,839 15,954 
P. aeruginosa  
S. maltophilia 
12,064 




YS014 22,898 19,744 Negative  Negative 
YS018 118,804 118,284 
Enterobacter aerogenes  
H. influenzae 
12,759 





YS020 9,255 6,398 
E. aerogenes  
E. coli  
H. influenzae  
S. aureus                                  
217  
(3.39%)                         
236  
(3.69%)                         
1,050 
(16.41%)                    
600 
 (9.37%)                             
Negative 




YS034 68,899 67,912 







YS036 60,393 50,502 Negative  Negative 
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YS057 15,893 15,851 Negative  Negative 








3.2.2.1 Further analysis of the performance of the CMg pipeline  
 
 
The performance of the CMg test was reassessed using the results from the PCR tests run on the same 
samples (Biofire and Curetis) and pathogen specific gene analysis. Pathogens identified in six out of 
the nine false positive samples were also reported by at least one of the PCR-based machines. The 
organisms identified by both metagenomics and by BIOFIRE were: E. coli in JS016, H. influenzae in 
NS048, E. coli in NS067, P. mirabilis in NS072, E. coli and H. influenzae in YS020 and E. coli and K. 
pneumoniae in YS034 (Table 3.23). Curetis confirmed the presence of S. maltophilia in YS042 (S. 
maltophilia is only detectable by Curetis). Samples concordant with the PCR tests were then classified 
as true positives and not false positives, which increased the specificity to 80% (95% CI; 51.91% to 
95.67%) but also increased the sensitivity to 84.38% (95% CI; 67.21% to 94.72%) due to these samples 
now being considered as true positives (i.e. in total there were 27/32 true positive samples).   
Species-specific gene analysis (described in 2.8.4.2) was carried out on the remaining organisms in the 
false positive samples (YS020, YS044, NS073) in a similar way as previously done after testing the 
optimised method (specificity of the optimised method initially was 41.7% and then was 100% after 
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additional analysis – described in 3.1.10). Genes selected from the literature (listed in Table 3.21) were 
used to either confirm the presence of the pathogen or identify contaminants or k-mer mis-classification 
of commensal organisms. Any sample containing >1 specific gene alignment after this analysis, was 
considered positive for that organism or negative if no gene alignments were detected. Only one gene 
alignment was detected, E. aerogenes (atpD) in YS020 (Table 3.21). The detection of K. aerogenes by 
metagenomics was probably due to barcode leakage as this sample was sequenced in a multiplex run 
containing a culture-positive sample for K. aerogenes (YS018 – see Table 3.20). The metagenomics 
pipeline was 84.38% sensitive (95% CI; 67.21% to 94.72%) and 93.33% specific (95% CI; 68.05% to 
99.83%) after this analysis. 
 
Table 3.21: Species-specific gene analysis for additional pathogenic organisms identified. 
Pathogens identified from 
metagenomic pipeline 


















3.2.3 Antibiotic resistance analysis of INHALE samples   
 
Clinical metagenomics can detect pathogens but also provide information on antimicrobial resistance 
(if any) directly from samples taken from ICU patients – this data could potentially be used to guide 
antimicrobial therapy. Sequence data from the INHALE samples was analysed for the presence of 
acquired antibiotic resistance genes (as described in 2.8.3) using 2 hours of sequencing data.  
The INHALE samples (n=47) were not highly resistant, according to culture. Amongst the 33 
organisms tested by routine microbiology for susceptibility/resistance, only 35 instances of resistance 
(n=34) and intermediate resistance (n=1) were recorded by culture (Table 3.22A). Metagenomic 
sequencing was able to identify 26 clinically relevant resistance genes across the 47 specimens (all 
clinically-relevant genes detected by ARMA are listed in Table 3.22A and are summarised/explained in 
Table 3.22B) 
In three culture-positive samples, genes identified by ARMA (n=9 genes) matched the phenotype 
reported by routine testing (Table 3.22B). These included blaTEM and blaSHV in an ampicillin and 
cefpodoxime resistant E. coli (NS043), blaACT genes for S. marcescens (NS041) and E. cloacae 
(NS044), both resistant to amoxicillin-clavulanate and ampicillin. ARMA identified blaTEM-4 genes in a 
meropenem and piperacillin/tazobactam resistant P. aeruginosa (JS015 – see Table 3.22B), which 
could explain the β-lactam resistance reported by routine microbiology (Table 3.22A) but is uncertain 
in this species as this phenotype is often due to the up-regulation of efflux pumps or chromosomal 
ampC (122).  
Clinically-relevant resistance genes (n=14 genes) were identified in nine culture-negative (YS034, 
YS014, NS073, YS044, NS074, NS077, YS036, YS020 and YS057) and three culture-positive samples 
(JS019, NS071 and YS018) with susceptible organisms according to routine microbiology (Table 
3.22B). Genes found in these samples are likely to be from the normal respiratory microbiota of the 
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lung. ARMA identified resistance genes (n=2) that could not explain the phenotype reported by routine 
microbiology in two culture-positive samples. These included the blaTEM genes reported both in NS064 
and NS078. NS064 was positive for a susceptible H. influenzae and a clindamycin and erythromycin 
resistant S. aureus, - blaTEM genes cannot explain the reported resistance for S. aureus (for example erm 
genes confer macrolide resistance in Staphylococci (250, 251)). Also, NS078 was positive for a 
meropenem-resistant P. aeruginosa and blaTEM genes do not confer carbapenem resistance, which is 
primarily caused by efflux-pump upregulation (252) (Table 3.22A).  
The phenotype reported by routine microbiology could not be explained by ARMA in five samples. 
These included fucidic acid resistant S. aureus (NS037), meropenem resistant P. aeruginosa (NS070, 
NS075 and YS011) and a penicillin- cephalosporin-resistant S. marcescens (NS050). Fucidic acid 
resistant resistance in S. aureus and cephalosporin resistance in S. marcescens are primarily due to 
chromosomal mutations (252) and the AMR pipeline was not designed for SNP detection. Also, as said 
before, meropenem resistance in P. aeruginosa is commonly mediated by to the up-regulation of efflux 
pumps. As the analysis presented in this thesis is preliminary we did not seek to characterise such 
resistances. Also, CMg did not detect the resistant organism in three samples (QS006, NS071 and 
YS059), hence the relevant resistance genes could not be identified.  
The specificity and sensitivity of the optimised CMg pipeline for detecting resistance genes could not 
be calculated, as it would have required isolation, cultivation and sequencing of all bacteria present in 
all the respiratory samples. This task was beyond the scope of this PhD study. 
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NS037 S. aureus 
Fucidic acid R, clarithromycin S, 
flucloxacillin S, mupirocin S, 
tetracycline S 
       ND 
QS006 
     P. mirabilis            
H. influenzae 
Amoxicillin-clavulanate S, Aztreonam 
S, Cefpodoxime S, Cefpodoxime S, 
Ceftazidime S, Ciprofloxacin S, Co-
trimoxazole S, Ertapenem S, 
Gentamicin S, Meropenem S, 
Piperacillin-tazobactam S, Amoxicillin 
R, Cefuroxime R 
ND 
NS039 NSG ND ND 
NS038 NSG ND ND 
QS005 P. aeruginosa 
Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem S, 
Piperacillin-tazobactam S 
ND 
NS043 E. coli 
Amoxicillin-clavulanate S, Ceftazidime 
S, Cefuroxime S, Aztreonam S, 
Ciprofloxacin S, co-Trimoxazole S, 
Ertapenem S, Gentamicin S, 
Meropenem S, Piperacillin-tazobactam 




NS044 E. colacae group 
Cefpodoxime S, Ciprofloxacin S, 
Gentamicin S, Meropenem S, 
Piperacillin-tazobactam S, Ampicillin 






NS047 NRF ND ND 
NS048 NG ND ND 
NS050 S.marcescens 
Aztreonam S, Ceftazidime S, 
Ciprofloxacin S, Co-trimoxazole  S, 
Ertapenem S, Gentamicin S, 
Meropenem S, Piperacillin-Tazobactam  




clavulanate R, Cefpodoxime R, 
Cefuroxime R 
NS049 NSG ND ND 
JS007 NSG ND ND 
NS042 S. aureus 
Fucidic acid R, Clarithromycin S, 
Clindamycin S 





Ampicillin S, Amoxicillin-Clavulanate 
S, Ciprofloxacin S, Gentamicin S, 
Meropenem S, Piperacillin-Tazobactam    
S, Meropenem S,  
Piperacillin-Tazobactam S ACT-5 
S. marcescens 
Ampicillin R, Amoxicillin-clavulanate  
R, Ciprofloxacin S, Gentamicin S, 
Meropenem S,  Piperacillin-
Tazobactam S 
NS063 K.  pneumoniae 
Amikacin S, Amoxicillin S, 
Amoxicillin-clavulanate S, Aztreonam 
S, Cefixime S, Cefotaxime S, 
Ceftazidime S, Cefuroxime S, 
Ciprofloxacin S, Co-trimoxazole  S, 
Ertapenem S , Gentamicin S, 
Meropenem S, Piperacillin-tazobactam  
S, Tigecycline S, Tobramycin S, 
Ampicillin R 
ND 
JS013 NSG ND ND 
NS057 Proteus spp. 
Ampicillin S, Amoxicillin-clavulanate 
S, Cefpodoxime S, Ciprofloxacin S, 
Gentamicin S, Meropenem S, 
Piperacillin-tazobactam S 
ND 
NS067 NRF ND ND 
NS069 NRF ND ND 
YS013 P. aeruginosa 
Ciprofloxacin S, Gentamicin S, 
Meropenem S 
ND 
JS015 P.  aeruginosa 
Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem R, 
Piperacillin-tazobactam R 
TEM-4 
JS016 Negative ND ND 
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NS080 P.  aeruginosa 
Ciprofloxacin S, Gentamicin S, 
Meropenem S, Piperacillin-tazobactam 
S 
ND 
JS019 S. aureus 
Clindamycin S, Doxycycline S, 
Erythromycin S, 
Flucloxacillin S, Mupirocin S 
TEM-4 
YS057 NRF ND TEM-4 
YS059 
S. aureus 
Clarithromycin S, Co-trimoxazole  S, 
Flucloxacillin S, Tetracycline S. 
ND 
E. coli 
Amoxicillin-clavulanate S, Aztreonam 
S, Co-trimoxazole S, Fosfomycin S, 
Gentamicin S, Amoxicillin R 
YS020 NSG ND 
ACT-4 , 
TEM-4 
NS075 P. aeruginosa 
Ceftazidime S, Ciprofloxacin S, 




Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem R, 
Piperacillin-tazobactam S 
ND 
YS036 NG ND TEM-4 
YS018 
H. influenzae 
Amoxicillin S, Co-trimoxazole  S, 
Tetracycline S ACT, 
CMY-98 
K. aerogenes ND 
YS011 P.aeruginosa 
Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem R, 
Piperacillin-tazobactam S 
ND 
NS077 NSG ND TEM-4 
NS074 NSG ND TEM-4 
YS044 NSG ND TEM-4 
NS078 P. aeruginosa 
Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem R, 
Piperacillin-tazobactam S 
TEM-4 
YS042 NSG ND ND 
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NS073 NG ND TEM-4 
NS064 
H. influenzae 
Ampicillin S, Amoxicillin-Clavulanate 
S, Cefuroxime S, Ciprofloxacin S,  Co-
trimoxazole  S, Tetracycline S 
TEM-4 
S. aureus 
Flucloxacillin S, Fusidic acid  S, 
Mupirocin S, Tetracycline S, 
Clindamycin R, Erythromycin R 
SS004 P.aeruginosa 
Ceftazidime S, Ciprofloxacin S, 
Gentamicin S, Meropenem S, 
Piperacillin-tazobactam S 
ND 
YS014 NSG ND TEM-4 
YS025 K. oxytoca ND ND 
YS034 NRF ND TEM-4 
NS079 P. aeruginosa 
Ceftazidime S, Ciprofloxacin S, 





Ceftazidime S, Ciprofloxacin S, 




Clarithromycin S, Flucloxacilin S, 
Tetracycline S 
NS071 
S.  aureus 
Clindamycin S, Erythromycin S, 
Flucloxacilin S,Fusidic acid S, 
Mupirocin S, Tetracycline S. 
mecA 
E. coli 
Ertapenem S, Gentamicin S, 
Meropenem S, Amikacin I, Ampicillin 
R, Amoxicillin-Clavulanate R, 
Aztreonam R, Cefotaxime R, 
Cefpodoxime R,  Ceftazidime R, 
Cefuroxime R, Ciprofloxacin R, Co-
Trimoxazole R, Piperacillin-
Tazobactam R, Tobramycin R 
NS072 NSG ND ND 
R=resistant, S= sensitive, I= intermediate resistance, ND= Not Detected  
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Table 3.22B Resistance genes detected by ARMA in relation to phenotypic resistance of pathogens 





reported by routine 
Number of AMR genes detected Examples 
NS041 



















Genes reported in 
culture-negative samples 




blaTEM genes that 
are likely to be 














Genes reported did not 
explain phenotypic 
resistance of the isolate 
2 
blaTEM genes found 
in samples with 
susceptible 
organisms (e.g. 









3.2.4 Concordance of metagenomics with PCR-based machines  
 
INHALE samples (n=47) processed with the optimised CMg pipeline were also processed with two 
PCR-based platforms (CURETIS and BIOFIRE) for the detection of respiratory pathogens (previously 
described in 3.2.1). Hence, we compared results generated from metagenomics and BIOFIRE in order 
to examine the similarities and differences in their performance for diagnosing HAP and VAP. 
BIOFIRE results were only used for this comparison, as, BIOFIRE was the machine chosen for the 
INHALE RCT. Therefore, for this analysis when both tests (i.e. CMg and BIOFIRE) were in complete 
agreement for the detection/absence of pathogen, they were deemed as concordant and discordant if 
not. Partially concordant samples had at least one pathogen detected by both metagenomics and 
BIOFIRE (Table 3.23).  
Metagenomics was concordant with BIOFIRE for 18/47 samples. Of these, both tests reported one 
organism in 8/18 samples (NS043, NS048, NS067, NS072, SS004,YS011, YS013, YS025) and two 
organisms in 1/18 samples (JS015); neither test reported pathogens for 9/18 samples (JS007, JS013, 
NS047, NS069 NS074, NS077, YS014, YS036 and YS057). The two techniques were discordant for 
7/47 samples, from which, 4/7 metagenomics did not report pathogens detected by BIOFIRE (NS038, 
NS039, NS049 and YS042) and 1/7 BIOFIRE did not detect pathogen reported by metagenomic 
sequencing (YS044). In 2/7 discordant samples different pathogens were reported by each test; 
metagenomics reported S. pneumoniae in NS079, whereas BIOFIRE reported E. coli and P. aeruginosa 
and in NS073, BIOFIRE reported S. pneumoniae and CMg detected E. coli, H. influenzae and S. 
aureus. 
For the remaining 22/47 samples the two platforms were partially concordant, with BIOFIRE reporting 
more pathogens than metagenomics in 15/22 partially concordant samples; one additional organism 
was reported in 10/15 samples (QS006, NS050, NS042, NS080, JS016, JS019, YS059, NS075, YS018, 
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and NS064, two additional organisms were reported in 4/15 samples (NS037,NS071, YS034 and 
YS053) and four additional organisms were reported in 1/15 samples (NS041). In 5/22 partially 
concordant samples metagenomics detected more pathogenic organisms than BIOFIRE; one additional 
organism was reported in 3/5 samples (NS057, NS063 and NS078) and two additional organisms were 
reported in 2/5 samples (NS044 and YS020). In 2/22 partially concordant samples (QS005 and NS070) 
both metagenomics and BIOFIRE reported the same number of pathogens; i.e. P. aeruginosa was 
reported by both techniques for both samples, but metagenomics reported Citrobacter freundii (QS005) 
and Morganella morganii (NS070), whereas BIOFIRE reported Enterobacter cloacae complex 
(QS005) and E. aerogenes (NS070) (see Table 3.23 for a list of pathogens reported).  
These results show that BIOFIRE detected more potential pathogens than metagenomics, suggesting 
that BIOFIRE was more sensitive than metagenomics. Overall, pathogens reported by metagenomics 
(in terms of pathogen detection and/or absence) were more similar to the results reported by culture 
than BIOFIRE, suggesting that the sensitivity of our CMg test is closer to the sensitivity of culture than 





Table 3.23: Comparison of pathogenic organisms detected by metagenomics and BIOFIRE. 
 
Sample ID 
Pathogens identified by 
metagenomics 
Pathogens identified by 
BIOFIRE 
Concordance (C),    
Partial Concordance 
(P),                
Discordant (D) 
NS037 Staphylococcus aureus 





Proteus mirabilis                 
Haemophilus influenzae 
Haemophilus influenzae 
Klebsiella pneumoniae  
Proteus spp. 
P 
NS039  Staphylococcus aureus D 
NS038  







Enterobacter cloacae complex 
Pseudomonas aeruginosa 
P 
NS043 Escherichia coli Escherichia coli C 
NS044 
Enterobacter cloacae group  
Escherichia coli  
Klebsiella pneumoniae 
Enterobacter cloacae complex P 
NS047   C 




Haemophilus influenzae  
Serratia marcescens  
Staphylococcus aureus 
P 
NS049  Streptococcus pneumoniae D 




Haemophilus influenzae  





Escherichia coli           
Klebsiella oxytoca 
Enterobacter cloaceae complex 
Escherichia coli  
Haemophilus influenzae 





Serratia marcescens  
Staphylococcus aureus 
NS063 
Escherichia coli                        
Klebsiella pneumoniae 
Klebsiella pneumoniae P 





Haemophilus influenzae  
Proteus spp. 
P 
NS067 Escherichia coli Escherichia coli C 









Escherichia coli  
Pseudomonas aeruginosa 
C 




NS080 Pseudomonas aeruginosa 




Staphylococcus aureus            
Streptococcus agalactiae 
Staphylococcus aureus  
Streptococcus agalactiae  
Streptococcus pyogenes 
P 
YS057   C 
YS059 Staphylococcus aureus 




Staphylococcus aureus            
Klebsiella aerogenes 
Escherichia coli  
Haemophilus influenzae 
Escherichia coli  
Haemophilus influenzae 
p 
NS075 Pseudomonas aeruginosa 




Pseudomonas aeruginosa       
Morganella morgannii 
Enterobacter aerogenes  
Pseudomonas aeruginosa 
P 




Enterobacter cloaceae complex  
Enterobacter aerogenes  
Haemophilus influenzae 
P 
YS011 Pseudomonas aeruginosa Pseudomonas aeruginosa C 
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NS077   C 
NS074   C 
YS044 Escherichia coli             D 
NS078 
Pseudomonas aeruginosa       
Escherichia coli 




Streptococcus pneumoniae D 
NS073 
Escherichia coli      
Haemophilus influenzae 
Staphylococcus aureus 




Haemophilus influenzae  
Moraxella catarrhalis  
Staphylococcus aureus 
P 
SS004 Pseudomonas aeruginosa Pseudomonas aeruginosa C 
YS014   C 
YS025 Klebsiella oxytoca Klebsiella oxytoca C 
YS034 
Escherichia coli           
Klebsiella pneumoniae 
Enterobacter cloaceae complex  
Escherichia coli  
Klebsiella oxytoca  
Klebsiella pneumoniae 
P 
NS079 Streptococcus pneumoniae 
Escherichia coli  
Pseudomonas aeruginosa 
D 
YS053 Pseudomonas aeruginosa 




NS071 Staphylococcus aureus 
Escherichia coli  
Staphylococcus aureus  
Streptococcus agalactiae 
P 
NS072 Proteus mirabilis Proteus spp. C 







3.3 Application of clinical metagenomics for public health 
 
 
The respiratory metagenomics pipeline demonstrated excellent performance for the diagnosis of LRTIs 
(described in 3.1) and for the diagnosis of nosocomial pneumonia for the INHALE trial (described in 
3.2). Next, we sought to implement our CMg pipeline for public health applications – could the data 
generated directly from primary samples using our methods also be used for rapid outbreak detection, 
surveillance and strain characterization? To investigate this, we tested a set of retrospectively collected 
respiratory samples (collected from >5 years ago) previously tested for Legionella spp. using 
traditional methods and qPCR at Public Health England (PHE), Colindale. The specific aim was to 
determine whether we could detect Legionella spp. directly in respiratory samples, correctly identify 
the species present and get enough genome coverage to sequence type the strains without the need for 
culture. Identification of the sequence type is invaluable for L. pneumophila outbreaks as it can identify 
the source of the infection and identify epidemiological links between environmental and clinical 
isolates (234). There are clear benefits to being able to sequence type directly from respiratory samples 
within hours such as: 1) rapidly determining whether the patient is actually infected with Legionella, 2) 
rapidly determining whether the infection is part of an outbreak or is a sporadic case and 3) rapidly 
determining the common source of infection in outbreak situations. This would lead to faster 
containment, thereby reducing the size and severity of potential outbreaks. Infected patients would also 
receive appropriate treatment in a timely fashion, improving patient outcomes and reducing patient 





3.3.1 Identification of Legionella spp. using clinical metagenomics 
    
Clinical samples n=48, (42 culture-PCR-positive for Legionella spp. and 6 culture-PCR-negative - 
Table 3.24) were processed with the clinical metagenomics pipeline (Figure 3.1) using the sequence 
data collected after 24 hours. The data was analyzed with Centrifuge (198) using default parameters 
(centrifuge score of >300) followed by Supernatant (developed by Natalie Groves, PHE), to filter the 
Centrifuge output, thereby improving the read identification quality (described in section 2.8.4). 
Samples were considered positive for Legionella species (L. pneumophila, L. longbeachae and L. 
sainthelensi) if supernatant-extracted Legionella reads were >0.01% of microbial reads and were ≥5 
reads in total. A sequencing positive control was included in 4/6 multiplex sequencing runs (1 ng of L. 
pneumophila extracted DNA was added) to monitor sequencing failures. Hence, a negative control rule 
was applied to remove contamination and/or barcode leakage that could be introduced from the 
sequencing positive control, where the same number of Legionella reads observed in the extraction 
control was removed from the samples tested on the same flowcell. The microbial read proportion 
threshold for Legionella positive samples was set lower than for previous applications due to the 
relatively low abundance of Legionella spp. in some of the samples pre-depletion as determined by 
qPCR (Cq median value = 28.37, interquartile range 25.35-30; maximum 39.03). The median 
Legionella classified microbial read proportion in positive samples was 3.03% (interquartile range 
0.11%-20.75; maximum= 76%) after removing the contaminant reads, whereas the highest Legionella 
read proportion number observed in culture-negative samples was 0.005% of classified microbial reads. 
Hence, we determined that the best threshold to discriminate negative and positive samples was 
>0.01% of Legionella spp. reads as a proportion of total microbial reads. 
CMg results were concordant with routine diagnostics (PCR and culture) for 30/36 Legionella 
pneumophila-positive samples using the thresholds described above. In 22/30 samples L. pneumophila 
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reads were ≥1% of microbial reads (L2, L4, L6, L7, L8, L9, L10, L11, L12, L13, L15, L16, L17, L18, 
L20, L23, L24, L31, L34, L40, L41 and L42) and in the remaining 8 samples (L1, L3, L5, L14, L32, 
L35, L36 and L38) L. pneumophila reads represented ≥0.01% of microbial reads (Table 3.24). CMg 
was also in agreement with routine testing for 6/6 samples where non-pneumophila Legionella spp. 
were reported by routine methods. These included L. sainthelensi in L30 and L. longbeachae in L25, 
L26, L27, L29 and L30. Legionella reads were low in one sample (0.1%, L27) but significantly higher 
in the other samples (13.3-73.3% of microbial reads – Table 3.24). Legionella spp. were not detected 
by CMg after applying the chosen thresholds in the six PCR-and-culture negative samples i.e.; L33, 
L37, L39, L45, L47 and L48 (Table 3.24). Additional Legionella spp. (≥5 microbial classified reads 
and ≥0.01% of microbial reads) were detected by CMg in seven L. pneumophila positive samples 
(L12, L25, L26, L27, L29, L30 and L31) that were not reported by culture or PCR (Table 3.24). This 
was likely due to k-mer misclassification (multiple Legionella spp. were also reported in the positive 
controls spiked with L. pneumophila DNA), therefore these samples were not reported as false 
positives (Table 3.24).   
The six L. pneumophila positive samples missed by CMg (L19, L21, L22, L43, L44 and L46) had 
higher Cqs than samples correctly identified by CMg (false negative samples mean Cq = 33.24 vs true 
positive samples mean Cq = 26.6), which indicates that missed samples had very low cell numbers 
(<100) (Table 3.24).  Additional analysis with a Legionella qPCR assay (methods section 2.3.2) was 
carried out on the pre- and post-depleted DNA extract on 24/42 positive samples. L. pneumophila 
DNA loss was reported in 23/24 of the frozen samples processed (median 30.27-fold, interquartile 
range 15.13-84.56; maximum 7702-fold) suggesting that freeze-thawing lyses L. pneumophila cells 
and the DNA is then lost during the host depletion step of the CMg pipeline (see Table 3.25).  
Another issue observed from analyzing the processed extraction controls was the presence of cross-
contamination between the sequencing positive control and clinical samples. In the process extraction 
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control 8, L. pneumophila was identified (511 reads reported), suggesting contamination occurred 
during sample processing (barcode leakage is not typically this high). Hence, contaminant and 
pathogenic reads could not be distinguished in L43, L44 and L46 and these samples were deemed 
negative.  
Based on these results CMg was 85.71% (95% CI: 71.46% to 94.57%) sensitive and 100% (95% CI: 
54.07% to 100%) specific for the detection of Legionella spp. when compared against routine 























L1 57932 6154 7 7 L. pneumophila L. pneumophila 22 
L2 22150 9093 5754 5754 L. pneumophila L. pneumophila 23 
L3 220092 4929 32 32 L. pneumophila L. pneumophila 26.3 
L4 16334 5107 351 351 L. pneumophila L. pneumophila 27 
L5 783278 146282 95 95 L. pneumophila L. pneumophila 28.75 




0 0 0 0 N/A N/A N/A 
L7 39520 25878 5373 5373 L. pneumophila L. pneumophila 18.5 
L8 9250 5720 660 660 L. pneumophila L. pneumophila 29.13 
L9 28302 179 64 64 L. pneumophila L. pneumophila 29.09 
L10 351262 5,862 2187 2187 L. pneumophila L. pneumophila 29.09 
L11 28542 368 5 5 L. pneumophila L. pneumophila 23 
L12 79260 52013 
10034 10034 L. pneumophila  
L. pneumophila 22 
7 7 L. longbeachae 




0 0 0 0 N/A N/A N/A 
L14 85165 30584 164 107 L. pneumophila L. pneumophila 30 
L15 18166 13295 333 276 L. pneumophila L. pneumophila 29 
L16 1098 125 101 44 L. pneumophila L. pneumophila 27 
L17 18897 2213 159 102 L. pneumophila L. pneumophila 29.09 










873460 862195 851458 851401 L. pneumophila N/A N/A 
L19 146932 112269 1 1  L. pneumophila 26.91 
L20 9015 181 40 40 L. pneumophila L. pneumophila 26 
L21 4680 827 0 0  L. pneumophila 30 
L22 605760 512904 20 20  L. pneumophila 30 
L23 112 75 57 57 L. pneumophila L. pneumophila 29 









17792 17792 L. pneumophila 
N/A N/A 
6 6 L. longbeachae 
L25 325797 25342 
17605 17605 L. longbeachae 
L. longbeachae 24 
1213 1213 L. pneumophila 
295 295 L. sainthelensi 
227 227 L. fallonii 
64 64 L. spiritensis 
136 136 L waltersii 
5 5 L. oakridgensis 
L26 339422 1081 
144 144 L. longbeachae 
L. longbeachae 17.44 
12 12 L. pneumophila 
L27 322839 10063 
11 11 L. longbeachae 
L. longbeachae NR 
7 7 L. pneumophila 
L28 70174 154 32 32 L. longbeachae L. longbeachae 33.2 
L29 373634 182197 34,493 34,493 L. longbeachae L. longbeachae 21.87 
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1259 1259 L. pneumophila 
734 734 L. sainthelensi 
226 226 L. waltersii 
L30 12025 60 
44 44 L. sainthelensi 
L. sainthelensi 21 









111070 111070 L. pneumophila 
N/A N/A 12 12 L. sainthelensi 
18 18 L. clemsonensis 
11 11 L. fallonii 
L31 3600 2856 
2122 2111 L. pneumophila 
L. pneumophila 28 
7 7 L. clemsonensis 
L32 75949 29135 21 10 L. pneumophila L. pneumophila 32 
L33 101008 69600 15 4   N/A 
L34 79497 8405 175 164 L. pneumophila L. pneumophila 26 
L35 134524 92347 31 20 L. pneumophila L. pneumophila 32.55 









85660 85649 L. pneumophila 
N/A N/A 
14 14 L. clemsonensis 
L37 1777 224 5 0   N/A 
L38 78454 44273 32 25 L. pneumophila L. pneumophila 26.94 
L39 214 32 7 0   N/A 
L40 5411 105 20 13 L. pneumophila L. pneumophila 30.37 
L41 1170 109 21 14 L. pneumophila L. pneumophila 22 
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93561 93554 L. pneumophila 
N/A N/A 
12 12 L. clemsonensis 
L43 44830 19866 259 0  L. pneumophila 39.03 
L44 190091 40386 371 0  L. pneumophila 37.53 
L45 575 406 143 0   N/A 
L46 18568 10930 111 0  L. pneumophila 36 
L47 488 165 64 0   N/A 














*total number of passed reads from 24 hrs after basecalling with guppy and demultiplexing with porechop. + Legionella reads after applying 
the negative control rule. ^CMg output presented after applying the chosen thresholds. NR=Not Reported. 
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loss/gain ΔCq (fold 
loss) 
L1 22 25.13 
3.13 
(8.75) 
L2 23 35.91 
12.91 
(7702) 
L3 26.3 28.29 
1.99 
(3.97) 
L4 27 31.82 
4.82 
(28.24) 
L5 28.75 35.51 
6.76 
(108.38) 
L6 29.1 33.41 
4.31 
(19.83) 
L7 18.5 24.76 
6.26 
(76.63) 
L8 29.13 33.41 
4.28 
(19.42) 
L9 29.09 34.44 
5.35 
(40.78) 
L10 29.09 34 
4.91 
(30.06) 
L11 23 25.75 
2.75 
(6.72) 
L12 22 24.78 
2.78 
(6.86) 
L13 30 27.23 
2.77 
(6.82) 
L14 30 35.67 
5.67 
(50.91) 
L15 29 40 
11 
(2048) 
L16 27 31.82 
4.82 
(28.24) 
L17 29.09 34.44 
5.35 
(40.78) 
L18 28.86 36 
7.14 
(141.04) 





L20 26 31.34 
5.34 
(40.50) 
L21 30 34.11 
4.11 
(17.26) 
L22 30 31.73 
1.73 
(3.31) 
L23 29 33.93 
4.93 
(30.48) 
L24 27 34.7 
7.7 
(207.93) 
*L. pneumophila qPCR assay described in 2.3.2 
 
3.3.2 Sequence based typing of L. pneumophila using clinical metagenomics data  
 
Following identification of L. pneumophila, we attempted to further characterize the pathogen 
using metagenomic data for genome assemblies. For this analysis, de novo genome assemblies 
were initially generated with Supernatant-extracted reads (i.e. L. pneumophila and L. 
longbeachae) using Canu (described in 2.8.4.1). In total, assemblies could only be generated for 
pathogens identified in 5/36 samples reported positive by metagenomics (L2, L7, L12, L25 and 
L29) using data after 24 hours of sequencing, from which three were assembled genomes of L. 
pneumophila and two of L. longbeachae. The L. longbeachae reads of L25 were assembled in 74 
contigs (longest contig=277 Kbp and n50 length=137 Kbp) and the genome assembly of L29 
consisted of 19 contigs (longest contig= 1272 Kbp and n50 length=537 Kbp). The L. 
pneumophila reads were assembled in 246 contigs (longest contig=12871bp and n50 
length=3579 bp) for L2, 180 contigs (longest contig= 80323 bp and n50 length=11551 bp) for L7 
and 239 contigs (longest contig=47582 bp and n50 length=10877 bp) for L12 (see Table 3.26A). 
Assemblies were used for sequence based typing by MLST (https://github.com/tseemann/mlst) 
for L. pneumophila-positive samples only (described in 2.8.4.3). According to routine sequence-
based typing (described in 2.3.2), the sequence type (ST) reported for L7 was 1, for L12 was 18 
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and no ST was reported for L2. Sequence-based typing (SBT) using the de novo genome 
assemblies generated from CMg data could not report a ST, hence comparison against routine 
SBT could not be done (Table 3.26B). 
Failure to identify a sequence type was most likely due to the low coverage observed in the 
majority of the samples after metagenomic sequencing (<10x genome coverage). Therefore, we 
attempted to generate assemblies through a reference-based approach, aiming to increase the 
genome coverage observed with the previous approach. Hence, L. pneumophila samples with 
>1000  L. pneumophila classified reads (n=5) after 24 hrs of sequencing were mapped against a 
concatenated reference containing all complete genomes of L. pneumophila available in NCBI 
using minimap2 (246) (described in 2.8.4.1). Reference-based assemblies were produced from 
four samples (Table 3.26A), including the three samples, that de novo assemblies were generated 
(L2, L7, L12) and L10 (no ST was reported for L10 by the clinical lab). An improvement was 
observed in the L. pneumophila reference-based assemblies for L2 and L12 when compared to de 
novo assemblies, i.e. L2 consisted of 239 contigs (de novo assembly consisted of 246) and 
longest contig for L12 was 144 kb versus 47 kb with the de novo assembly. However, for L7, the 
number of contigs increased from 180 to 209 for the reference-based assembly and for L10 the 
reference-based assembly had 61 contigs (longest contig=32362 bp and n50 length=7663 bp) - 
see Table 3.26A. 
SBT was still not possible using the reference-based assemblies and the correct sequencing type 
or allele ID could not be identified. Only two correct allele IDs were reported for mompS (2) and 





Table 3.26A: Comparison of L. pneumophila de novo and reference-based assemblies.  
 
 De novo assemblies Reference-based assemblies 
Sample   
ID 
L2 L7 L12 L2 L7 L10 L12 
Number 
of contigs 
246 180 239 239 209 61 208 
Longest 
contig    
(bp) 
12871 80323 47582 12874 80592 32362 144460 
n50 length 
(bp) 
3579 11551 10877 3666 14709 7663 24138 
 
After failing to identify STs by using genome assemblies (either de novo or reference-based) we 
attempted to perform SBT using unassembled reads. We used Krocus (249), a tool which uses 
basecalled FASTQ reads for multi-locus-sequence based-typing and is specifically designed to 
tolerate the high single read error-rate of nanopore reads. Krocus was initially tested using 
mapped-reads from different timepoints (5, 20 and 40 min) of sequencing data of sample S1 (an 
E. coli-positive sample previously processed with the optimised CMg pipeline in the proof of 
concept study - described in 3.1.13) to identify the minimum genome coverage required by the 
tool to provide an ST. Krocus reported the correct E. coli ST (ST131) using the data after 40 min 
of sequencing from S1. This suggested that the minimum coverage needed to provide a ST with 
Krocus is ≥13X from metagenomic data (13.48x genome was recovered in S1 and 414,241 E. 
coli reads were reported after 40 min of sequencing for S1 - see Figure 3.2E).  
L12 was the only Legionella sample that produced the minimum coverage required (16x 
coverage after 24 hrs of sequencing) and was the only sample used for this analysis. The correct 
allele IDs for 5/7 housekeeping genes (pilE, asd, mip, proA, neuA) were identified using Krocus 
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when compared with results reported by the clinical laboratory (Table 3.26B) However, as the 
correct allele IDs for 2/7 housekeeping genes (flaA and mompS) were not identified, an ST 
identification was still not possible.  Failure to identify a ST using data generated by the CMg 
pipeline was due to the low genome coverage obtained – this was directly related to the use of 






Table 3.26B: Sequence based typing (SBT) compared against routine testing of L. pneumophila 
samples. 




flaA 2 1 1 2 
pilE 0 4 4 10 
asd 17 3 3 9 
mip 1 1 0 13 
mompS 9 1 0 2 
proA 4 1 0 5 
neuA 1 1 1 6 
Sequence 
type 



































No ST No St 
Not 
found 




flaA N/A N/A N/A 32 
pilE N/A N/A N/A 10 
asd N/A N/A N/A 9 
mip N/A N/A N/A 13 
mompS N/A N/A N/A 63 
proA N/A N/A N/A 5 
neuA N/A N/A N/A 6 
Sequence 
type 
N/A N/A N/A No ST 
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4.  Discussion 
 
LRTIs are considered as the deadliest communicable disease. Current diagnostic methods used 
for LRTIs are too slow (48-72hours), hence contribute to the overuse of empiric antibiotics in 
respiratory infections, which increases the emergence of antibiotic resistance in respiratory 
pathogens (10, 62). Delayed targeted antibiotic treatment, prolongs hospital stays, significantly 
increasing hospital costs (80, 253). The need for rapid diagnostics to guide appropriate antibiotic 
therapy, thereby reducing patient morbidity and mortality and the emergence of antimicrobial 
resistance has been emphasized by the UK government in the 5-year AMR action plan and the 
O’Neil report  (82, 83). Although current FDA/CE-IVD-approved molecular-based tests (such as 
PCR-based tests) provide results in hours, they are not comprehensive enough to replace current 
diagnostics (254). 
Clinical metagenomics (CMg)-based tests have demonstrated the potential to revolutionise 
clinical microbiology and overcome challenges of current diagnostic tests (102). The main aim 
of my PhD was to develop a CMg pipeline that could replace current diagnostics tests and detect 
pathogens and relevant resistance genes in a rapid turnaround time. The metagenomics pipeline 
developed in this study was mainly focused on the diagnosis and characterization of LRTIs. We 
considered, LRTIs as a good starting point for the application of CMg, for two reasons: i) the 
importance of respiratory infections on the public and economic sector (previously discussed) 
and ii) pathogen levels present in respiratory samples (>100-1000 cells). Lower levels of 
pathogens are challenging to detect and discriminate from contamination and requires the use of 
additional steps in the pipeline prior to sequencing, such as a sensitive whole genome 
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amplification, to amplify low amounts of pathogen DNA (femtogram range) remaining after host 
depletion. 
One of the main shortcomings of CMg-based assays is turnaround time. An example, is the 
service for the diagnosis of encephalitis/meningitis offered by the UCSF Clinical Microbiology 
Laboratory (https://nextgendiagnostics.ucsf.edu/our-diagnostic-lab/). With this pipeline, 
pathogens are detected via very deep sequencing (no host depletion) where only a small fraction 
of the genome is recovered, meaning results are provided in a slow turnaround (>48 hrs, 
excluding sample transportation) (136). This CMg pipeline, is not able to replace culture as it can 
only be used as a last-resort diagnostic for cases where commonly used tests failed to identify the 
cause of infection. The goal of this study, and of the O’Grady group in general, is for CMg to be 
used as the primary test for the diagnosis of infectious diseases, replacing culture-based 
diagnostics. 
The pipeline developed in this study, consists of human DNA depletion, microbial DNA 
extraction, sequencing of low-biomass samples and data analysis. Pathogen and resistance genes 
can be rapidly detected (~6 hrs), which will enable clinicians to choose the appropriated targeted 
antimicrobial therapy avoiding a second dose of broad-spectrum antibiotics. The rapid 
turnaround time achieved with our pipeline was achieved by developing a rapid and inexpensive 






4.1 Optimisation of the Clinical metagenomics pipeline 
   
4.1.1 Host depletion 
 
As previously discussed, in clinical samples the ratio of human:microbial DNA is high and 
therefore, rapid pathogen detection in clinical samples with metagenomic sequencing would not 
be possible without efficient removal of host nucleic acid or enrichment of pathogen DNA prior 
to sequencing (122). The O’Grady lab has significant expertise in the development of host 
depletion methods, including differential cell-lysis approaches, and have applied them in urine 
(129) and blood samples (255). However, for this study we aimed to develop a pipeline that 
would be cheaper and faster, which would make it easier to implement in a clinical microbiology 
laboratory setting.  
A review of the literature suggested that saponin was a good candidate for depleting human 
DNA (174) and at the beginning of this PhD study, we found a saponin-based method optimised 
in whole blood (177, 178, 256). Based on the methods described in these studies, we adjusted 
and optimised the saponin-based method described in this study, for use in respiratory samples 
(described in 3.1.1 and 3.1.2) which resulted in a host depletion method capable of removing 
>99.99% human DNA in respiratory samples (104-fold enrichment).  
It should be noted that prior to optimising the host depletion method we also observed a high 
number of depletion failures mainly in sputum samples. Purulent sputum is a complex matrix 
mainly consisting of mucus and WBCs, making it viscous and hard-to-work with. However, 
sputum samples and ETAs that were previously treated with sputasol had better depletion rates. 
This was probably due to sputasol breaking down the mucus and making WBCs more accessible 
to saponin. We recommend that our saponin-depletion method be coupled with a sputasol-
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treatment step to avoid depletion failures in respiratory samples (if the sputum remains viscous, a 
second treatment should be performed). In our method we use a higher saponin concentration 
and extended duration of the treatment than what was used in previous studies (177, 178) to 
improve performance in sputum samples. We also knew from previous experience within the 
O’Grady research lab, with blood samples (257), that the HL-SAN nuclease does not lose 
efficiency in clinical samples when used with very high salt buffer (>5M) unlike other 
commonly-used nucleases (such as the Turbo DNase) that lose activity in complex clinical 
samples such as sputum (in our hands). The high salt concentration is also, likely important for 
efficient depletion of human DNA, because histones (proteins associated with chromatins) 
undergo certain rearrangements making the DNA more accessible in stress conditions such as 
high salt (258). The addition of the 5.5M salt HL-SAN buffer, results in such rearrangements, 
making the human DNA more accessible for digestion with the nuclease. Therefore, the highly 
salt-tolerant HL-SAN nuclease is better suited for this application than other nucleases which 
cannot withstand high salt concentrations. 
The optimised version of our pipeline provided more robust depletion rates in comparison to 
reported results in the literature of the commercially-available host depletion kits or microbial 
enrichment kits. The MolYsis Kit, that also utilises a differential-lysis approach with chaotropic 
agents, has been reported to provide 104-fold in PJI samples and oral samples (259) but was 
reported to lyse Gram-ve bacteria such as Pseudomonas spp. (166). The NEBnext microbiome 
kit that promises an efficient microbial enrichment has been reported to lose efficiency in clinical 
samples such as sputa (165). This kit is part of the pipeline used by the UCSF Clinical 
Microbiology Laboratory and has been reported to enrich microbes only by ~2.5-fold in CSF 
samples (136) or <100-fold in other sample types (165).  
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We did not report any significant bacterial loss with the optimised version of the saponin-based 
host depletion (average 2.63-fold loss (see 3.1.9) according to the 16S rRNA qPCR assay 
performed on depleted samples and undepleted controls). On average 86.65% of classified reads 
were microbial according to MinION sequencing and up to 104 of human DNA was depleted 
according to qPCR results for any of the pathogens tested, with the exception of S. pneumoniae 
(discussed later in this section). 
Qiagen also has a saponin-based patent for the differential lysis of human/animal cells (260). In 
this protocol, 500 µL of 7.73 wt-% of saponin is used and samples are incubated for 30 min 
followed by nuclease treatment and centrifugation steps to remove lysed cells and digested 
nucleic acid. Although the depletion rate in depleted samples and undepleted controls was not 
reported, Ct values of human DNA target in depleted samples were close to the detection limit of 
the rt-PCR used (reported CT= 31->35) (260). Reported human DNA levels of this patent were 
similar with human DNA levels reported in samples processed with the optimised method 
(average Cq=32.5 of human DNA tested with probe-based qPCR assay post-depletion). Our 
saponin treatment however, is faster (10 min vs 30min) and also it is unclear how the Qiagen 
method would perform in a complex sample type like sputum (Qiagen method tested on whole 
blood and swab samples).    
Other in-house developed pipelines, such as the one reported by Hasan et al. (167), also use a 
saponin-based depletion method. Their pipeline was consisted of a saponin-based host cell 
depletion (0.025% final concentration) followed by digestion of nucleic acid with Turbo DNAse 
and microbial DNA extraction. Satisfactory depletion rates were reported (1.9%-2.1% of relative 
human DNA quantity in depleted samples compared to 100% quantity in undepleted controls) 
with a minimal effect in spiked organisms in CSF and nasopharyngeal aspirates (NPA) (167). 
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However, it is likely that the depletion efficiency of their method would decrease in sputum 
samples due to the DNase used – in our hands the Turbo DNase lost efficiency in mucoid 
respiratory samples (discussed earlier).  
Rapid, inexpensive host depletion coupled with real-time sequencing should be considered as a 
key factor in the application of CMg-based assays for the rapid diagnosis of not only LRTIs but 
other infectious diseases. Our method has been successfully applied in other samples types (such 
as blood and PJIs) by other members of the O’Grady group (during and after this PhD study) and 
by or in collaboration with other groups e.g. in urine samples where it enabled the recovery of ≥ 
92.8x of the N. gonorrhoea genome (261, 262). 
 
4.1.2 Microbial DNA extraction 
 
Approaches for microbial DNA extraction have been extensively investigated in microbiome 
studies as a non-efficient or biased extraction would lead to a false representation of the 
microbiome (263). Studies investigating the extraction efficiency of different approaches, like 
chemical, enzymatic and bead-beating have concluded that the most accurate representation of 
the microbiome is retrieved when bead-beating is incorporated (263, 264). In a recent study, 
where chemical and bead-beading based lysis were compared in saliva, the bead-beating 
extraction provided greater yield of microbial DNA when Gram +ve bacteria were present in the 
samples (265). We also demonstrated that the best approach for efficient unbiased DNA 
extraction was to include a bead-beating step combined with a chemical based-extraction.   
At the early stages of the study we were satisfied with the results provided by utilising a 
chemical-based extraction but after evaluating the performance of the pilot method metagenomic 
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sequencing missed an S. aureus culture-positive sample. This was resolved with the addition of 
bead-beating as all S. aureus culture-positive samples were correctly identified by 
metagenomics. Although we mainly focused on the identification of bacterial LRTIs in this 
study, the addition of the bead-beating step makes this pipeline suitable for the detection of 
fungal pathogens. While diagnosis of fungal pathogens was not investigated in depth in this 
study, fungi were identified in a high proportion of samples tested in a study performed by 
collaborators at Pittsburgh Medical School using our optimised pipeline (185).  
For microbial DNA purification, we used an automated system (MagNA Pure Compact 2.0) but 
we did not test any other automated systems or manual extraction kits. The MagNA Pure was 
chosen as it is used by clinical microbiology laboratories (e.g. PHE), has a rapid turnaround (25 
mins) and automated/standardises the purification step of the pipeline. It is possible that other 
manual or automated extraction/purification methods may have yielded more or higher quality 
DNA from sputum samples. Other methods have been tested in the O’Grady lab – typically the 
automated magnetic bead based methods were better than manual methods and MagNA Pure 
performed well in comparison. The lab has recently moved to the Promega Maxwell (with the 
Maxwell® Pure Food Pathogen kit) as it can process more samples and produces a higher yield 
from sputum, although it takes about 10 minutes longer to run.  
 
4.1.3 Nanopore Sequencing of low-biomass samples 
 
Nanopore sequencing (MinION) was exclusively used for this study. Nanopore sequencing 
overcomes the main limitations of other sequencing platforms related to implementation in 
clinical microbiology settings. These are: i) real-time data acquisition and analysis, ii) reduced 
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cost for low-throughput sequencing and iii) small footprint (122). The long reads generated using 
nanopore sequencing also have some advantages over short reads such as AMR-gene host 
identification and genome/plasmid assembly. However, nanopore sequencing was still under 
development and at the beginning of this PhD study we observed poor flowcells and 
inconsistency in library preparation kit performance. Despite these early difficulties, rapid 
development of nanopore technology over the course of my PhD resulted in robust products 
suitable for clinical application. R9.4.1 flow cells have proven to be highly reliable, providing 
sequencing quality and data yields comparable to other sequencing platforms (120).  
At the beginning of this study, all nanopore sequencing kits required at least 1µg of input DNA. 
As discussed earlier, respiratory samples are low biomass samples after host depletion, hence 
have low DNA quantities often not detectable with fluorescent-based assays (122). This 
limitation was overcome when ONT released a rapid PCR-based library preparation (SQK-
RLI001) that only required 10ng of input DNA (described in 3.1.3). Another advantage of this 
workflow was that it allowed amplification and preparation of samples in a simple and fast 
manner, which makes it easier to implement in a clinical lab. This workflow follows a similar 
approach used by Illumina’s Nextera XT DNA Library Prep Kit (136) which is used in the CMg 
diagnostic assays implemented in the UCSF Clinical Microbiology Laboratory. We used this 
original kit on a small number of depleted respiratory samples and it provided satisfactory results 
in terms of yield and turnaround.  
Shortly after, ONT released the multiplexed version of this kit (SQK-RLB001 and later SQK-
RPB004). At the beginning of the study however, performance in respiratory samples wasn’t as 
good as with the original kit. We worked together with ONT to optimize this (described in 3.1.3). 
Washing the MagNA Pure extracted DNA, increasing the amount of transposase (FRM) and 
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increasing the PCR reaction volume from 50ul to 100ul improved performance. These steps were 
introduced to overcome the inhibitory effect of the sputum matrix on these enzymatic reactions. 
‘Cleaner’ DNA extracts would mean that the extra washing step would not be necessary. 
Removal of this step would reduce method complexity and turnaround time. Also, increased 
reagent volumes might not be necessary if the DNA was cleaner, reducing costs. New extraction 
methods are constantly evaluated in the O’Grady lab to find a method that produces suitably 
clean DNA in a short turnaround (discussed earlier).  
We sequenced six samples and a negative control per flowcell throughout the study and didn’t 
investigate increased or decreased multiplex sample numbers. We estimated that sequencing six 
samples per flow cell would provide a good balance in terms of cost, turnaround time and 
genome coverage and this worked well in our hands. Samples could be run at a cost of US$130 
per sample (122) and allowed enough genome coverage to be recovered for pathogen and 
resistance gene detection with using only 2 hrs of sequencing data. Cost could be reduced by 
multiplexing more samples, but this may have an impact on turnaround time. Also, when testing 
patients for HAP/VAP for example, only a few patients per day might need to be tested, and if 
you wait for 11 or 12 samples before you test, patients will be waiting days for their results, 
negating the use of a rapid test. Towards the end of the study, Flongle was made available by 
ONT. Flongle flowcells costs $90, hence are suitable for testing 1-2 samples at a time. This 





4.1.4 Data analysis for bacterial identification and resistance gene detection 
 
Bioinformatics pipelines used for the analysis of metagenomics data have the difficult task of 
accurately classifying microbes from a massive database of microbial sequences along with 
detecting antimicrobial resistance genes. Additionally, in order for the metagenomics pipeline to 
be implementable in clinical microbiology, the pipeline needs to present the results in an easy-to-
interpret format (203). This would allow the biomedical scientist to interpret and report results 
just as easy if it would be to ‘read’ a plate. An example of a clinically implemented CMg 
pipeline is SURPI (266), which was developed and implemented by the Chiu lab at UCSF. The 
pipeline identifies microbes in a rapid turnaround (11 min to 5 hrs depending on read count 
analysed) and results are presented in an easy-to-interpret summary (136). In this study we used 
ONT’s EPI2ME Antimicrobial Resistance pipeline for pathogen identification and resistance 
gene detection, which analyses metagenomic data rapidly and presents results in an easy-to-
interpret format. This pipeline combines ‘Centrifuge’ kmer based tool for read identification 
using the RefSeq database with ‘Minimap2’ mapping of reads to the CARD database to identify 
resistance genes (described in 2.8.2 and 2.8.3). 
The quality of the chosen microbial and resistance gene databases has a direct impact on the 
accuracy of microbial classification and resistance gene detection. Comprehensive databases are 
usually overpopulated with model organisms such as E. coli genomes, which can skew the 
analysis of closely related species towards the overrepresented species in the database used. This 
is a particular problem with S. pneumoniae and related species in respiratory samples. Databases 
used for the analysis of metagenomic data should be curated, where incomplete genomes would 
be removed and representation/addition of all the relevant taxa of pathogens and commensals 
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should be evaluated (266). Curation of databases should be done by experts in the field to 
remove unrelated sequences that are beyond the scope of the study. Analysis would then be more 
reliable and faster as unnecessary ‘matching’ against not-relevant targets will not be possible 
(102). In this study, a similar approach was used for AMR prediction, where a knowledge-based 
parameter was used to only report ‘clinically relevant’ genes in the CARD database (used by 
ARMA). This eliminated reporting of irrelevant resistance genes and simplified the analysis. For 
microbial identification however, this was not possible as curating/adapting the RefSeq database 
was not possible in this study.  
It should also be noted that the O’Grady lab is focused on the development and evaluation of 
wet-lab method development rather than data analysis, hence in this study we did not 
develop/tested alternative pipelines. We are unsure whether ONT validated the FASTQ 
Antimicrobial Resistance Pipeline appropriately before release by, for example, using specimens 
spiked with known organisms or simulated data, to test classification accuracy (267). We 
validated the pipeline by testing clinical samples with known pathogen and AMR profiles. While 
the EPI2ME agent performed well in this study, it is very difficult to accurately validate its 
performance for either pathogen or AMR gene identification in these types of samples due to 
their complexity. For example, AMR genes in a metagenomic sample can come from any of the 
bacteria in the sample (pathogen or commensal) whereas the AMR profile provided by the lab is 
only for the isolated pathogen. Similarly, culture reports pathogens and not commensals, so it is 
hard to know whether all bacteria identified by the pipeline were truly present in the sample. 
However, our analysis of additional detections (pathogens reported by metagenomics and not 
culture) by PCR in the pilot study, showed that all additional detections were truly present in the 
sample with two exceptions, a K. oxytoca reported by culture had K. oxytoca and K. pneumoniae 
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incorrectly reported by metagenomics (most likely bioinformatics misclassification of reads) and 
an E. coli reported in a mixed-infection sample (likely a laboratory/kit contaminant) – discussed 
later in this section. 
Thresholds for CMg studies or NGS studies are valuable as they help identify false-positive 
results and increases confidence of reporting accurate results. CMg tests always apply thresholds 
to their bioinformatics pipeline to remove low-quality reads, barcode cross-talk, reagent and kit 
contaminants and misalignments occurring from metagenomic classifiers. For example, Miller et 
al., applied thresholds to their bioinformatics pipeline when validating their CMg test. Firstly, 
only reads with a high stringency (203) were analyzed and any identified pathogen would only 
be reported as ‘detected’ when the RPM-r (reads per million (RPM) ratio) was ≥10 (where the 
RPM-r was calculated by the reads corresponding to the pathogen in the clinical sample divided 
by the reads in the negative control (136)). Thresholds are also often applied during routine 
culture i.e. the sputum sample is diluted with water prior to plating (described in 2.3.1) such that 
only bacteria present in high concentrations (>105/ml) grow – this step is incorporated in some 
labs to reduce false positives as concentrations of pathogen below this threshold are considered 
clinically irrelevant. In a similar manner, we also use thresholds to eliminate any reads with a 
low-quality alignment score (>19 qscore) and only pathogens reads above the chosen threshold 





4.2 Evaluation of the pilot and optimised Clinical metagenomics pipeline 
 
4.2.1 Testing of the pilot pipeline 
 
Initial testing of the pilot version of pipeline was carried out using excess respiratory samples 
collected from the NNUH clinical microbiology lab from community and hospital patients 
(described in 3.1.4). Forty samples were collected and used to evaluate the performance of the 
pipeline. Numbers were limited to this number as we considered this was sufficient to determine 
the initial performance of the pipeline before any required optimisation. The pipeline was 91.2% 
sensitive and 100% specific. Only six culture-negative samples were tested, which, in hindsight, 
should have been increased to get a more accurate representation of the specificity. Additionally, 
the primary sample type used was sputum and the pipeline should have been tested on more 
BALs, as this sample type is ‘cleaner’ (fewer upper respiratory tract commensals) and it has a 
lower microbial load. However, collecting BALs was challenging, as sputum is the primary 
sample collected from patients with a suspected LRTI in the community and at NNUH and 
BALs are typically only collected from some ventilated patients (268). 
The pilot version of the pipeline had a turnaround time of ~8hrs and was reduced to ~6hrs after 
optimisation (described in 3.1.5). This rapid turnaround is currently superior to the turnaround 
time reported for other published CMg pipelines which are able to report results within 12-48 hrs 
or longer (128, 136, 269, 270). As previously discussed, rapid turnaround time is extremely 
important for patient outcomes and antibiotic stewardship. Ideally, results should be available 
before antibiotics are prescribed and administered (<1 hour turnaround). However, as it stands 
now our pipeline can only be used to guide treatment decisions after they have received one dose 
of empiric therapy, typically 8 hours after first treatment (62). Although there is potential to 
215 
 
further reduce turnaround time for this pipeline, this was not further pursued due to time 
limitations (discussed further in future work).   
 
4.2.2 Limit of Detection  
 
The LoD of the pipeline is sample-dependent as the commensal and pathogen loads are variable 
in each sample and the ratio of pathogen:commensal DNA is directly related to the LoD of the 
test. Variability in the efficiency of the host depletion step can also impact on LoD. To test LoD, 
we used one sputum with a ‘high’ amount commensal background and one with a ‘low’ amount 
as representatives of the variability we observe in respiratory samples (described in 3.1.6). The 
analytical LoD of the streamline version of the CMg pipeline was determined to be at 103-105 
cfu/ml. The determined LoD is similar to the LoD applied for culture in NNUH (described in 
2.3.1) (271). However, the clinical microbiology lab has different guidelines for samples for ICU 
patients or for patients with risk factors (such as immunocompromised) - samples from these 
patients do not get diluted which makes culture more sensitive (estimated LoD of undiluted 
culture is102 cfu/ml – i.e. one colony on a plate streaked using a 10µl loopful of sample). Also, 
clinical microbiology labs from different NHS trusts have different guidelines. For example, the 
clinical lab at St Thomas’ does not dilute respiratory samples prior to plating. This variability in 
clinical microbiology lab testing makes measuring performance of any new diagnostic tests (not 
just CMg) against culture very challenging. 
The estimated LoD of our pipeline is in a similar range to the LoD reported by Zelenin et al., 
(104 cfu/ml in whole blood) but the pipeline used by Anscombe et al., was more sensitive (10 
cfu/ml in whole blood). Other pipelines used for the diagnosis of infections of the sterile sites 
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have also reported to have lower detection limits. For example, Miller et al., reported an LoD of 
8-10 cfu/ml for bacterial pathogens and 14-313 copies/ml for DNA and RNA viruses 
respectively in CSF (136). Blauwkamp et al., also reported an LoD of 39-103 molecules of 
cfDNA µl/plasma. Greninger et al., reported an LoD of 105 copies/ml for RNA viruses in whole 
blood samples (144). These studies use different approaches during library preparation (e.g. a 
more sensitive WGA (178)) or deep sequencing which is coupled with slow turnaround time 
(136, 269). Also, LoD of CMg tests in sterile site samples vs non-sterile site specimens are not 
comparable as commensals DNA competes with pathogen DNA for sequencing reads. 
A limitation of our current pipeline for respiratory infections is that it cannot be used for the 
diagnosis of viral infections. This is particularly important for CAP where a large proportion 
(>75% paediatric vs 25% adults cases) of disease is caused by viral pathogens rather than HAP 
or VAP where the pathogens are typically bacterial and fungal. A modification that would enable 
of our pipeline to be used for diagnosis of viral infections, would be the addition of SISPA 
(sequence-independent single-primer-amplification) for the amplification of unknown viral 
genomes (272, 273). During this process random k-mers tagged with a known sequence are used 
as primers for the PCR-based amplification of viral RNA. Recently, this approach has been used 
to diagnose SARS-CoV-2 directly from nasopharyngeal swabs within 8 hrs (154). Alternatively, 
multiple displacement amplification (MDA) WGA (including a reverse transcription step for 
viral RNA) can be used instead, to amplify microbial RNA/DNA prior to sequencing to improve 
detection limits. More sensitive WGA would also, be required for sterile sample site testing, such 





 4.2.3 Mock community and loss of S. pneumoniae 
 
Saponin has previously been reported to lyse some common pathogenic organisms (177, 178), 
therefore, we sought to investigate whether the saponin-based differential lysis step of the 
procedure would cause lysis of any common respiratory pathogens in the mock community 
experiments (described in 3.1.7). Saponin treatment didn’t have any negative effects on any of 
the mock community organism expect for S. pneumoniae (5.8-fold loss). Further investigation 
showed most of the loss occurred during the saponin incubation and from the addition of the HL-
SAN buffer (5.5M salt), but other parts of the process were also potentially involved (described 
in 3.1.8). 
The saponin-based step utilises Quillaja saponin and it is known to have lytic effects on  
cholesterol-containing cell membranes (171, 172). All bacteria have cell walls protecting their 
inner membrane and S. pneumoniae is a Gram-positive bacterium with a thick peptidoglycan 
wall, therefore saponin should not be capable of lysing this pathogen. A possible explanation for 
the loss is that when S. pneumoniae cells are under stress, the autolysin gene can be expressed, 
resulting in autolysis (274). Therefore, we hypothesize that the addition of saponin and/or of the 
HL-SAN buffer may trigger the production of autolysin, causing cell lysis and subsequent 
degradation of S. pneumoniae DNA. Alternatively or additionally, the autolysis may be related to 
stressed conditions experienced by S. pneumoniae when in pure culture or in sputum. In clinical 
samples, we saw varying loss of S. pneumoniae DNA ranging from ΔCq= 1.7-5.84 (see 3.1.8). 
This would suggest that the loss is not caused by the method itself, but potentially by the 
conditions the S. pneumoniae is stored in and whether this leads to autolysis before host 
depletion is performed. Hence, the time taken to go from sample collection to host depletion may 
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be very important to preserve S. pneumoniae in clinical samples. For the same reasons, S. 
pneumoniae is known to be a fastidious pathogen that is difficult to culture in the clinical 
microbiology lab. This may no longer be an issue if CMg is implemented in the clinical 
microbiology lab and fresh samples are tested rather than testing excess samples that are several 
days old. 
Looking at the literature, a similar effect was also reported by Anscombe et al. were S. 
pneumoniae loss was observed after human depletion (178). However, Hasan et al (167).,  
demonstrated no loss of S. pneumoniae during saponin depletion. The concentration of saponin 
used in this study was significantly lower (0.025% final concentration) than in our method and 
Anscombe’s method and may be an important factor.  
Street et al., which used our saponin-based host depletion method on Neisseria gonorrhoeae-
spiked and clinical samples reported similar results (261). The pathogen was reported to be more 
susceptible to lysis in clinical samples after host depletion, as no lysis was observed in spiked 
samples. The authors stated that pathogenic cells, may have already been damaged pre-depletion, 
due to the long storage/transferring times (261). Additionally, a limitation of the mock 
community used in this study is that we did not test the effect that saponin would have on 
pathogens with no cell wall such as Mycoplasma pneumoniae. This pathogen, is an important 
pathogen for CAP and would most likely lyse during the saponin process due to its physiology 





4.2.4 Evaluation of the optimised pipeline 
The performance of the optimised version of the pipeline was tested on a similar number of 
respiratory samples from community patients as the pilot pipeline so a direct comparison of the 
two versions was possible (122). The optimised pipeline had higher clinical sensitivity than the 
pilot pipeline (96.6% vs 91.2%) as only one sample was reported as a false negative versus three 
false negatives with the pilot pipeline. Increased sensitivity is attributed to the optimisation of the 
microbial extraction by mechanical lysis (discussed before). Additional PCR analysis confirmed 
the absence of the missed pathogen – suggesting a false positive result from the clinical lab. We 
used the undepleted control sample to test for the presence of the ‘missed’ pathogen in case the 
host depletion led to the loss of the pathogen in the sample. Possible explanations for the false 
positive culture result are lab contamination or misidentification of the isolate.  
The optimised pipeline was less specific than the pilot pipeline (41.7% vs 100%) but that was 
expected as a higher number of culture-negative sample was tested. Also, our optimised CMg 
pipeline is more sensitive than respiratory culture due to the sample dilution step applied by the 
clinical lab (discussed earlier). We investigated additional pathogen findings with confirmatory 
qPCR and gene specific analysis (described in 3.1.10) to determine whether these findings were 
‘real’. Indeed, analysis confirmed additional findings in 10/16 samples. Samples where CMg 
detection of additional pathogens could not be confirmed contained mostly pathobionts H. 
influenzae or S. pneumoniae. High false-positivity rates for pathobionts has also being reported 
in other similar studies (275). Also, as previously mentioned, in one K. oxytoca-positive sample, 
CMg also detected K. oxytoca and K. pneumoniae – this was a clear example of bioinformatic 
misclassification of K. pneumoniae reads. 
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The majority of metagenomics classifiers use a k-mer-based classification approach (186), which 
makes accurate calling of closely-related species from sequencing data challenging. There is also 
the problem of sequence databases being dominated by the pathogenic species in genera such as 
Streptococcus and Haemophilus as discussed earlier. This highlights the need for 
improving/developing bioinformatic tools and sequence databases that accurately call microbes 
to the species level directly from metagenomic data (275). Perhaps, when pathobionts are 
identified, their presence should be investigated in the context of the microbial community. For 
example, if S. pneumoniae is reported in a sample where the microbial community is dominated 
by other non-pathogenic Streptococci spp. then S. pneumoniae detection may be due to 
misclassification or may be present, but more likely be commensal rather than pathogenic. 
Additional analysis should be carried out (e.g. species-specific gene analysis) or more stringent 
thresholds should be considered (e.g. increasing alignment scores) in such cases.  
A diagnostics pipeline needs to report identified pathogens but could also be used for the 
detection of clinically relevant resistance genes in order to have the biggest impact on patient 
management. Our CMg pipeline was able to detect resistance genes in some samples that were 
concordant with clinical microbiology (e.g. mecA gene was identified in two MRSA samples) – 
see 3.1.11. However, this analysis highlighted how challenging it is to confidently report 
resistant genes from metagenomic data. Resistance genes were reported in samples with 
susceptible organisms identified or in culture-negative samples. Detected genes were most likely 
originated from commensal bacteria. A limitation of the EPI2ME analysis pipeline is that the 
host of the resistance gene cannot be determined. For chromosomal resistance genes, the 
flanking regions of the long nanopore reads (3kb average in our pipeline) beyond the resistance 
gene can be used to identify the origin of the gene. This approach was recently demonstrated by 
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Leggett et al., by using NanoOK-RT, the authors were able to identify a genes’ host in gut 
microbiome samples (123). A caveat of this approach is that it cannot be applied to plasmid-
borne resistance genes. We did not seek mutational resistance in this study as that is even more 
complex in metagenomic data than looking for acquired genes. A recent study by Sanderson et 
al., has demonstrated that this is possible for Neisseria gonorrhoeae in urine using nanopore data 
(276), however, urine doesn’t typically contain commensals (it is much less complex than 
sputum) and their approach was designed for a single pathogen. Additionally, the new ONT pore 
chemistry, R10, reduces the single-read error rate of nanopore sequencing down to as low as 
<1% (119) and this will help improve SNP calling from nanopore metagenomic data. 
An alternative approach that can be applied for both acquired and mutational resistance would be 
to identify the lineage of the pathogen in question (277). In fact, we collaborated with Brinda et 
al., for the development and evaluation of RASE, a tool that can predict pathogen 
resistance/susceptibility by identifying the lineage of the pathogen’s closest relatives (277). 
Brinda et al., was able to accurately predict resistance from 5/6 of our S. pneumoniae positive 
metagenomic samples within minutes (277). A limitation of this approach is that it has only been 
optimised for 2 pathogens (N. gonorrhoeae and S. pneumoniae) and it is unlikely to work well 
for certain pathogens i.e. those where the correlation between lineage and AMR isn’t strong and 
good local pathogen genome databases are required for good accuracy (e.g resistance in  P. 
aeruginosa). Another approach would be to use a tool based on a knowledge-based algorithm i.e. 
an analysis tool that only lists the resistance genes that can be found in the pathogen/s that has 
been identified by metagenomic sequencing. Such a tool tool would be able to exclude irrelevant 
resistances (typically from commensals) and provide a summary of relevant resistances based on 
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the pathogen identified (202). The O’Grady lab has recently developed such a tool in 
collaboration with Dr. Andrew Page at Quadram Institute Biosciences (QIB). 
The pipeline presented in this study was one of the first to demonstrate a feasible, rapid, cost-
effective clinical metagenomics pipeline that could be translated into the clinical microbiology 
laboratory. Our pipeline is superior to other CMg pipelines primarily due to its rapid turnaround 
time and low cost, which are related to efficient host depletion. For example, Votintseva et al., 
report a turnaround time of 7.5 hrs but reproducibility of the fast version of this pipeline was 
poor (128). Thoendel et al., used CMg for the diagnosis of PJI, but reported bacterial loss when 
using the MolYsis kit for host depletion (166).  In a more recent study, Miller et al., developed 
and validated a CMg pipeline for the diagnosis of meningitis but is has a slow turnaround as no 
host depletion is used (136). Langeliel et al.,(275) also developed a diagnostics pipeline for the 
diagnosis of LRTIs, which included metagenomic sequencing of respiratory samples coupled 
with a novel bioinformatics approach that could separate infectious from non-infectious 
respiratory illnesses and differentiate pathogens from respiratory commensals. Although good 
performance of this test was reported (receiver-operating curve (AUC) of 0.80-0.96% for their 
three bioinformatics models), turnaround time was not reported for their protocol (275). 
Blauwkamp et al., also developed and validated a CMg pipeline, called the Karius test, that uses 
cell-free DNA in plasma samples to identify pathogens (269). Although this pipeline is very 
comprehensive, it has a slow turnaround time (53 hrs), is expensive and has low specificity (63% 
for the diagnosis of blood stream infection) as it detects cfDNA from any microbe in the body 
including commensals, gut microbes and pathogens causing unrelated infections (e.g. sore throat) 
(270). Although, in the pilot study we originally reported low specificity using our pipeline 
223 
 
compared to culture, PCR analysis demonstrated additional detections were real (122), raising 
our specificity to 100%.  
As previously mentioned, a limitation of our pipeline is that it was not applied for the detection 
of viral pathogens. There is potential to modify it for viral diagnostics. Currently, any viruses are 
lost as centrifugation is used to pellet bacterial cells at several points in the procedure and the 
supernatant containing viruses is discarded. A second arm of the pipeline could be introduced, 
during which a second aliquot of the sample (or the supernatant after the first centrifugation step) 
would processed without centrifugation (122), followed by nuclease treatment of the sample to 
remove cell free human nucleic acid, viral nucleic acid extraction, cDNA synthesis and pooling 
with the bacterial DNA before sequencing. This approach is currently being tested and optimized 




4.3 Implementation in the INHALE trial 
 
 
4.3.1 NNUH INHALE sample testing  
 
The optimised CMg pipeline was implemented in the INHALE trial as a third molecular-based 
test (alongside 2 PCR based pneumonia panels, Filmarray and Unyvero) for the diagnosis of 
HAP and VAP in ICU respiratory samples (described in 3.2). Initial analysis of the INHALE 
samples revealed an increased number of sequencing ‘failures’ and we had to apply additional 
parameters to remove these samples. The majority of the ‘failures’ were culture-negative 
samples (NBG/NSG/NG) which produced very few reads. We hadn’t come across such samples 
during the development of the CMg pipeline as we hadn’t been focussed on the ICU, where no 
growth samples appear to be more common. These samples revealed the need for a process 
control to monitor performance of the pipeline. A suitable process control would be a non-
pathogenic difficult-to-lyse (probably Gram-positive) bacterium that is never found in the 
respiratory tract and can be spiked into the clinical sample at a concentration that should always 
produce sequencing reads in the absence of any respiratory bacteria (but also at a concentration 
that wouldn’t outcompete low levels of pathogen in a sample) (102). The process control would 
ensure all steps of the pipeline were successful and no inhibition or microbial loss occurred 
(267). Without this, it is impossible to tell the difference between the pipeline failing and ‘no 
growth’ samples. Time constraints meant that I couldn’t develop a process control during my 




Miller et al., validated a synthetic CSF matrix positive control for their CMg pipeline which 
consisted of seven representative pathogens (including bacteria, fungi, DNA and RNA viruses) 
in known quantities (136). This approach, however, doesn’t monitor for individual sample 
failures, only issues that result in the failure of the entire run. This type of a positive control 
would be hard to design and validate for respiratory metagenomics, as a synthetic sample 
mimicking the composition of a respiratory sample is hard to design (consistency and 
microbial+human load is very variable in respiratory samples).  
The sensitivity of the pipeline was decreased when tested on the INHALE sample set compared 
to the pilot study samples (80.77% versus 96.6%). As previously discussed, this was probably 
due to the discrepancy between the thresholds applied in ICU respiratory samples by the clinical 
laboratory and community samples (no dilution of samples prior to culture, making culture more 
sensitive). Also, in the INHALE sample set, more BALs were processed than the pilot study, 
which typically contain a lower microbial load (sample diluted in large volumes of saline). 
Increasing the library prep PCR cycle number to 30 or 35 may be necessary to increase the 
sensitivity of the pipeline so that BAL samples can be reliably tested.  
 The majority of missed pathogens in the INHALE sample set (4/5 false negative samples) were 
reported as bacterial mixed infections by culture. This was probably due to the difference in 
quantities of the pathogens present in the sample and possibly only a few colonies of the second 
pathogen were reported by culture, at a concentration below the limit of detection of the pipeline. 
During the library preparation PCR reaction, the organism present at higher concentration 
dominates the PCR reaction, leading to poor amplification of the pathogen/s at lower 
concentration. In fact, in 1/4 cases, sequence reads were detected for the ‘missed’ pathogen (S. 
aureus in YS053), but they were below the chosen thresholds for pathogen detection. The 
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difference in the concentration of the ‘missed’ pathogens was also reflected by the semi-
quantification of the two PCR tests (BIOFIRE and Curetis), as lower quantities of all ‘missed’ 
pathogens in the four false negative samples were reported.  
Additional analysis of the INHALE CMg false positives by the two PCR tests revealed that 6/15 
additional pathogens detected were due to contamination arising from common contaminants. 
Contamination is a major challenge for metagenomic and microbiome studies especially when 
low-biomass samples are sequenced (278). A study investigating contamination in sequencing 
and extraction kits reported that contaminant organisms are ubiquitous and were always present 
in PCR reagents, library preparation kits, water and other reagents (278). Also contamination 
composition varied amongst the different batches of same kits (278).  
We always included a negative process control and thresholds and even then, contamination 
could not be removed from the INHALE sample set. This highlights the importance of having 
additional parameter/s dealing with contamination, especially for ICU or sterile samples (where 
<1000 microbial reads were reported with metagenomic sequencing). A more stringent negative 
control rule (than the one applied in my analysis) would help remove reads from barcode cross-
talk and from real contaminants. For example, common contaminants of the skin microbiome 
and reagents should be defined at the beginning of the study and not reported when identified 
(136). However, it isn’t possible to rule out all common contaminants as some e.g. E. coli, are 
important pathogens and in different contexts, e.g. S. epidermidis a skin flora bacterium is an 
important PJI pathogen. For these organisms different parameters should be used.  
Also, as it stands now the depletion part of the pipeline consists of various steps which increases 
the likelihood of introducing contamination, especially in the hands of less-experienced handlers. 
Sample processing of INHALE samples was performed by different operators which is a likely 
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reason why there was an increase in contamination levels in comparison to the previous samples 
sets. In fact, it was clear from the data that more experienced (and meticulous) operators 
produced fewer failed and contaminated datasets. This lack of method robustness is clearly a 
weakness and further simplification of the pipeline is required to aid implementation (discussed 
further in future work).  
 
4.3.2 Comparison of metagenomics against BIOFIRE 
 
Comparison of the findings of the CMg pipeline against BIOFIRE (as it was the test progressing 
to the randomised controlled trial) revealed that CMg was less concordant with BIOFIRE and 
more concordant with culture (described in 3.2.4). The majority of discordant and partial 
concordant results were due to BIOFIRE identifying more pathogens than CMg. Our findings are 
not a surprise, as PCR-based tests are more sensitive than sequencing-based tests (8, 279). 
However, this raises the question of which organisms are clinically relevant and should be 
treated? PCR results should not be interpreted without considering other laboratory findings or 
clinical information. If treatment is only guided based on the PCR output, it may lead to over-
diagnosis and over-treatment of patients. 
These findings, highlight an advantage CMg has over PCR-based tests, which is its 
comprehensiveness – CMg would not only detect pathogens but also commensals, meaning the 
presence of the pathogen can be interpreted in the context of the rest of the microbial 
community. For example, in our experience a pathogen in a true-positive sample would be 
dominating the microbial community and will be listed as the most abundant organism in the 
WIMP report. Conversely, in an NRF sample the top hit is a commensal/s. Reports of 
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metagenomic data, resemble on how culture plates looks – a mix of non-pathogenic bacteria for a 
negative sample or heavy growth of a pathogen with a few commensal colonies for an infected 
sample. CMg, however, is more comprehensive than culture, as anaerobes, fastidious organisms, 
bacteria and fungi are all reported in one test.   
Additionally, as CMg does not rely on a pre-defined panel will also detect rare or even novel 
pathogens. This is particularly topical in relation to the current SARS-CoV-2 pandemic – if a 
comprehensive bacterial/viral CMg pipeline was in routine use in Wuhan in 2019, the novel 
virus would have been identified almost immediately after moving to humans and the outbreak 
may have been stopped before spreading globally. The diagnostic PCRs in the clinical virology 
labs couldn’t detect the new virus and metagenomics had to be employed to identify the cause of 




4.4 Characterisation of Legionella spp. using clinical metagenomics 
 
Previous CMg studies focused on pathogen identification only as insufficient genome sequence 
recovered could not reliably detect AMR genes or study the pathogen in more detail  (136, 166). 
Our CMg pipeline can generate whole pathogen genomes due to efficient host depletion using 
saponin, which can be used to further study the pathogen/s (described in 3.1.13). This capability 
means that our pipeline should be suitable for not only diagnostics but for public health 
applications. Public health microbiologists at PHE approached us with an interest in applying 
CMg to Legionella outbreak investigation. Rapid detection and simultaneous genotyping of 
Legionella in suspected outbreak samples would have a major impact in the field. Therefore, we 
applied our CMg pipeline for the diagnosis and molecular typing of Legionella pneumophila 
directly from respiratory samples (described in 3.3). The sensitivity of the pipeline these samples 
was lower compared to the proof-of-concept study (85.71% vs 96.6%) even after using less 
stringent thresholds. This discrepancy was potentially caused by: i) low microbial load of L. 
pneumophila observed in this sample set pre-depletion and ii) the condition of the samples 
(described in 3.3.1). The samples used in this sample set were frozen samples (some having gone 
through multiple freeze-thaw cycles) collected over 5 years ago. We previously demonstrated 
that frozen samples are not ideal for our pipeline (bacteria either lyse or are damaged and 
possibly lost during the host depletion step)- see 3.2.1. qPCR pre- and post-depletion 
demonstrated L. pneumophila DNA loss in the host depletion step (described in 3.3.1). Hence, 
we recommend our CMg pipeline only be used only on fresh samples, as this would be the case 
if implemented. Frozen samples are mainly used in research – clinical samples are never frozen 
before testing. If samples need to be frozen, they should be frozen with a stability agent so as not 
to damage microbes upon thawing (281). 
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Contamination in this sample set was also high and this was due to using a sequencing positive 
control at a too high concentration. This was extracted L. pneumophila DNA which was included 
as an external positive control at the beginning of the library preparation. The concentration for 
the control was high, producing many reads, leading to barcode-cross talk and potential cross-
contamination. As previously discussed, a process control should have been used – however, as 
this is not straight forward to develop, the positive control should have at least been something 
not ever found in the respiratory tract and been used at low concentrations. This study is still on-
going and the data and analysis presented in this thesis is preliminary. Therefore, in the future we 
plan to test fresh samples but also improve the positive control.  
Detecting the sequence type (ST) of the L. pneumophila positive-samples (described in 3.3.2) 
was not possible using our CMg pipeline due to low genome coverage. Different strategies were 
attempted using different inputs: de novo assemblies, reference-based assemblies and basecalled 
FASTQ reads, but none of these approaches were able to identify an ST. The O’Grady lab plans 
to further investigate if molecular typing of L. pneumophila is possible directly from respiratory 
samples using CMg by processing fresh samples and by applying appropriate thresholds and 





4.5 Conclusion  
 
   
Although application of the pipeline in INHALE and for Legionella typing was challenging, we 
have learned a great deal and know the reasons for reduction of performance compared to the 
pilot studies (changes in culture processing of ICU samples in INHALE and old frozen samples 
in the Legionella study). We have also learned that our pipeline is too laborious for clinical 
implementation further work is required to address this (see below). However, the pipeline and 
data presented in this study have demonstrated that clinical metagenomics has the potential to 
revolutionise clinical microbiology and replace current tests for the diagnosis of bacterial LRTIs. 
The CMg pipeline allowed identification of bacterial pathogens and resistance gene detection in 
~6hrs. Rapid accurate diagnostics will improve antibiotic stewardship and patient management, 





4.6 Future work 
 
• Develop and evaluate a positive process control, suitable for bacteria and DNA and RNA 
viruses.  
• Develop a viral metagenomics arm suitable for the diagnosis of CAP.  
• Improve the LoD of the method to make it more reliable for the diagnosis of ICU 
samples. This can be achieved by improving the sensitivity of the library preparation 
PCR.   
• Further simplify the depletion and shorten the pipeline to make it more robust and 
implementable. This would likely involve some automation of the process e.g. using a 
liquid-handler for depletion step and bead-based washing steps.  
• Develop and clinically validate a bioinformatics pipeline that will allow an accurate 
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AMR Antimicrobial Resistance  
AMS Antimicrobial Stewardship  
ARMA Antimicrobial Resistance Mapping Application 
BAL Bronchoalveolar lavage 
BCY-C Charcoal Yeast Extract with Cefamandole 
BCYE Buffered Charcoal Yeast Extract 
BHI  Brain Heart Infusion  
BLAST Basic Local Alignment Search tool 
BMPA Buffered Polymyxin Anisomycin 
CAP Community Acquired Pneumonia 
CARD Comprehensive Antibiotic Resistance Database 
CDC Centre for Disease Control and Prevention  
CLED Cysteine–lactose–electrolyte-deficient  
CMg  Clinical Metagenomics 
CMV Cytomegalovirus 
COPD Chronic Obstructive Pulmonary Disease 
CRP C-reactive Protein  
CSF Cerebrospinal Fluid  
DBG De Bruijn Graph 
DNTPs Dideoxy Nucleotides 
EMBL European Molecular Biology Laboratory 
ESBL Extended Spectrum Beta-lactamase 
ESCMID  European Society of Clinical Microbiology and Infectious Diseases 
ESKAPE 
Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterococcus faecium 
ESR  Erythrocyte Sedimentation Rate  
ETA Endotracheal Aspirates 
FDA US Food and Drug Administration  
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GOSH Great Ormond Street Hospital Children's Charity 
HAP Hospital Acquired Pneumonia 
HCAP  Health Care Associated Pneumonia 
HPIV3              Parainfluenza 3 Virus 
ICU Intensive Care Unit 
INSDC International Nucleotide Sequence Database Collaboration 
LB  Luria Broth 
LRTI Lower Respiratory Tract Infection  
MAG Metagenome-Assembled Genome 
MDR  Multi Drug Resistant 
MDR-GNEB Multi Drug Resistant- Gram Negative Enterobacteria  
MLST Multi-Locus-Sequence-Typing 
MNPs Magnetic Nanoparticles 
MRSA  Methicillin Resistant Staphylococcus aureus 
MSSA Methicillin Sensitive Staphylococcus aureus  
Mtb Mycobacterium tuberculosis 
NPA Nasopharyngeal aspirates  
NCBI  National Center for Biotechnology Information 
NFW Nuclease Free Water 
NG  No Growth  
NGS Next Generation Sequencing  
NICE National Institute of Health Excellence  
NNUH Norfolk and Norwich University Hospitals 
NRCCE Nextera Rapid Capture Custom Enrichment 
NRF  Normal Respiratory Flora  
NSG  No Significant Growth 
ONT Oxford Nanopore Technologies 
PacBio  Pacific Biosciences 
PCR  Polymerase Chain Reaction 
PHE Public Health England 
PI Pulmonary Infiltrate  
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PJI Prosthetic Joint Infection  
PSB  Protected Specimen Brush  
QC Quality Control 
RAD Rapid Adapter 
RASE Resistance-Associated Sequence Elements 
RBC Red Blood Cells  
RCT Randomized Controlled Trial  
RHF Royal Free Hospitals 
RPM Reads Per Million 
RSV  Respiratory Syncytial Virus 
RT  Room Temperature  
RVPBRU  Respiratory and Vaccine Preventable Bacteria Reference Unit 
SAD Sabouraud Dextrose 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 
SBT Sequence Based Typing 
sCAP  Severe Community Acquired Pneumonia 
SNP Single-Nucleotide Polymorphisms 
ST  Sequence Type 
STEC Shiga-Toxin producing E. coli 
TB Tuberculosis 
TSB  Tryptic Soy Broth  
UCLH  University College London Hospitals 
UEA University of East Anglia 
UHNM University Hospitals of North Midlands 
URT Upper Respiratory Tract  
UTIs Urinary Tract Infections 
VAP  Ventilator Associated Pneumonia 
WGA Whole Genome Amplification 
WGS Whole Genome Sequencing 
WHO  World Health Organisation  
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